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Positron emission tomography (PET), by using different radiopharmaceuti-
cals evaluating different metabolic pathways or receptor expression, is a 
functional imaging method widely available worldwide.
In particular, hybrid tomographs as positron emission tomography/com-
puted tomography (PET/CT) and positron emission tomography/magnetic 
resonance imaging (PET/MRI) combining morphological and functional 
information are currently used in the clinical practice.
Even if a large amount of literature is available about PET, the number of 
evidence-based articles on this imaging method, such as systematic reviews 
and meta-analyses, is relatively limited.
A meta-analysis is a statistical analysis that combines the results of mul-
tiple scientific studies. Meta-analysis can be performed when there are mul-
tiple scientific studies addressing the same question, with each individual 
study reporting measurements that are expected to have some degree of error. 
The aim then is to use approaches from statistics to derive a pooled estimate 
closest to the unknown common truth. Existing methods for meta-analysis 
yield a weighted average from the results of the individual studies. In addition 
to provide an estimate of the unknown common truth, meta-analysis has the 
capacity to identify sources of disagreement among the different study results, 
or other interesting relationships that may come to light in the context of 
multiple studies. A key benefit of this approach is the aggregation of informa-
tion leading to a higher statistical power and more robust point estimate than 
is possible from the measure derived from any individual study.
This unique evidence-based book summarizes the findings or recent meta- 
analyses on the use of PET for different clinical indications. These meta- 
analyses on PET have been selected by the editors after a systematic literature 
search performed by using PubMed databases (last search: January 2019). 
Meta-analytic articles published from 2012 to the date of the last literature 
search were selected.
About the structure of this book, after a section introducing PET and meta- 
analyses, respectively, several sections describe the results of meta-analyses 
on PET for different indications including the following medical fields: 
oncology, cardiology, neurology, infectious and inflammatory diseases.
The different chapters are written by researchers who are both expert in 
PET and familiar with meta-analytic methodology.
This book provides evidence-based information on PET, which can be 
very useful for clinicians of different specialties and for international 
Preface
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 scientific societies. In particular, the evidence-based information provided 
by this book could help international scientific societies and national regula-
tory bodies on healthcare in approving the use of PET for several emerging 
clinical indications.
Furthermore, the updated information provided by this book could help 
worldwide clinicians of different specialties in prescribing PET with several 
radiotracers for different clinical indications.
Bellinzona and Lugano, Switzerland Giorgio Treglia 
Zurich, Switzerland  Luca Giovanella 
Preface
vii
Part I  Introduction
 1  Introduction to Different PET Radiopharmaceuticals  
and Hybrid Modalities (PET/CT and PET/MRI)  . . . . . . . . . . . .   3
Luca Giovanella, Lisa Milan, and Arnoldo Piccardo
 2  A Practical Guideline on Diagnostic and Prognostic  
Meta-Analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
Ramin Sadeghi and Giorgio Treglia
Part II  Evidence-Based PET in Oncology
 3  Evidence-Based PET for Brain Tumours . . . . . . . . . . . . . . . . . . .  25
Giorgio Treglia and Barbara Muoio
 4  Evidence-Based PET for Head and Neck Tumours . . . . . . . . . . .  35
Gaetano Paone
 5  Evidence-Based PET for Thoracic Tumours  . . . . . . . . . . . . . . . .  41
Filippo Lococo, Alfredo Cesario, Stefano Margaritora,  
and Giorgio Treglia
 6  Evidence-Based PET for Breast Cancer . . . . . . . . . . . . . . . . . . . .  53
Giorgio Treglia
 7  Evidence-Based PET for Abdominal and Pelvic Tumours  . . . . .  59
Salvatore Annunziata, Daniele Antonio Pizzuto,  
and Federica Galiandro
 8  Evidence-Based PET for Cutaneous, Musculoskeletal  
and Unknown Primary Tumours . . . . . . . . . . . . . . . . . . . . . . . . . .  73
Luisa Knappe and Gaetano Paone
 9  Evidence-Based PET for Haematological Tumours . . . . . . . . . . .  79
Francesco Bertagna, Raffaele Giubbini,  
and Domenico Albano
 10  Evidence-Based PET for Endocrine Tumours  
and Disorders  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  89
Alexander Stephan Kroiss and Giorgio Treglia
Contents
viii
Part III  Evidence-Based PET in Cardiology
 11  Evidence-Based PET for Cardiac Diseases . . . . . . . . . . . . . . . . . .  99
Christel H. Kamani, Marie-Madeleine Meyer,  
Sarah Boughdad, Nathalie Testart, Marie Nicod Lalonde,  
Gilles Allenbach, Mario Jreige, Niklaus Schaefer,  
Giorgio Treglia, and John O. Prior
Part IV  Evidence-Based PET in Infection and Inflammation
 12  Evidence-Based PET for Infectious  
and Inflammatory Diseases  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
Giorgio Treglia and Barbara Muoio
Part V  Evidence-Based PET in Neurology
 13  Evidence-Based PET for Neurological Diseases . . . . . . . . . . . . . . 125
Alberto Miceli, Selene Capitanio, Maria Isabella Donegani, 
Stefano Raffa, Anna Borra, Matteo Bauckneht,  
and Silvia Morbelli
Part VI  Miscellaneous





3© The Author(s) 2020 
G. Treglia, L. Giovanella (eds.), Evidence-based Positron Emission Tomography, 
https://doi.org/10.1007/978-3-030-47701-1_1








Positron Emission Tomography (PET) is an 
imaging technique performed by using positron 
emitting radiotracers. Positron decay occurs with 
neutron-poor radionuclides and consists in the 
conversion of a proton into a neutron with the 
simultaneous emission of a positron (β+) and a 
neutrino (ν). The positron has a very short life-
time, and after the annihilation with an electron 
simultaneously produces two high-energy pho-
tons (E  =  511  keV) in approximately opposite 
directions that are detected by an imaging cam-
era. The PET scanning is based on the so-called 
annihilation coincidence detection (ACD) of the 
511  keV γ-rays after the annihilation. 
Tomographic images are formed collecting data 
from many angles around the patient by scintil-
lating crystals optically coupled to a photon 
detectors used to localize the position of the 
interaction and the amount of absorbed energy in 
the crystals (Table 1.1) [1].
L. Giovanella (*) 
Clinic of Nuclear Medicine and Molecular Imaging, 
Imaging Institute of Southern Switzerland,  
Ente Ospedaliero Cantonale, Bellinzona, Switzerland 
Laboratory of Radiomics and Predictive Imaging, 
Imaging Institute of Southern Switzerland,  
Ente Ospedaliero Cantonale, Bellinzona, Switzerland 
Clinic of Nuclear Medicine, University Hospital  
and University of Zurich, Zurich, Switzerland
e-mail: luca.giovanella@eoc.ch 
L. Milan 
Clinic of Nuclear Medicine and Molecular Imaging, 
Imaging Institute of Southern Switzerland,  
Ente Ospedaliero Cantonale, Bellinzona, Switzerland 
Laboratory of Radiomics and Predictive Imaging, 
Imaging Institute of Southern Switzerland,  
Ente Ospedaliero Cantonale, Bellinzona, Switzerland 
A. Piccardo 
Division of Nuclear Medicine, Ente Ospedaliero 
“Ospedali Galliera”, Genoa, Italy
1
Table 1.1 Properties of PET scintillator crystals
NaI(Tl) BGO LSO GSO LYSO
Effective atomic 
number (Z)
50 73 66 59 60
μ (cm−1) 0.34 0.95 0.87 0.70 0.86
Index of 
refraction
1.85 2.15 1.82 1.85 1.81
Density (g/cm3) 3.67 7.13 7.40 6.71 7.30
Photon yield 
(per kVp)






410 480 420 430 420
Decay time 
constant (ns)
230 300 40 65 41
Energy 
resolution (% at 
511 keV)
7.8% 20% 10.1% 9.5% 20%
Hygroscopic Yes No No No No
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The key properties that characterize the PET 
scanner performances are the spatial resolution, 
the sensitivity, the Noise-Equivalent Count 
Rate (NECR) and the contrast [2]. The projec-
tion data acquired in the form of sinograms are 
affected by a number of factors that contribute 
to the degradation of the final images and hence 
to the PET scanner performances, as reported in 
Table 1.2.
Two classes of reconstruction techniques exist: 
the analytical and the iterative methods [3]. The 
most used analytical method is the backprojec-
tion. To compensate the blurring, a filter is applied 
to the projections before they are back- projected 
onto the image [i.e. filtered backprojection 
(FBP)]. In modern scanners, the image recon-
struction algorithms are based on iterative meth-
ods, which approach the true image by means of 
successive estimations, in order to  converge to an 
image that best represents the original object. 
These algorithms are known as expectation maxi-
mization (EM) and Ordered Subset Expectation 
Maximization (OSEM) algorithm [4].
1.2  Hybrid Scanners: PET/CT 
and PET/MRI
Combined PET/CT systems were commercially 
available from 2001 and in a very short time the 
dedicated PET scanner was completely replaced 
by hybrid PET/CT. The ability of hybrid PET/CT 
systems to accurately identify the anatomic loca-
tion of diseases and to provide attenuation- 
corrected images are the main causes of their 
rapid success and diffusion [5]. Modern clinical 
PET/CT consists in a high-performance PET 
scanner in-line with a high-performance CT scan-
ner arranged in sequential gantries. The scanner 
table moves along the gantry axis in order to sub-
sequently acquire CT and then PET data. A soft-
ware integrated in the system has to check if the 
patient bed undergoes some deflections during the 
translation [6]. Images of tissue attenuation from 
the CT scan are used to derive the PET attenua-
tion correction factors. The latter depends on the 
energy of the photons: since CT X-rays and PET 
γ-rays have an energy of 70  keV and 511  keV, 




The minimum distance 
between two points in an 
image that can be 
detected by a scanner
Positron range: Error occurs in the localization of the true position of the 
positron emission resulting in the degradation of the spatial resolution
Non-collinearity: The two 511 keV photons are not emitted at exactly 
opposite directions: This deviation can reach a value of ±0.25° at maximum
detector size and its intrinsic resolution: resolution is better in the centre of 
the FOV than at the edge
Sensitivity Number of counts per 
unit time detected by the 
system for a unitary 
activity
Geometric efficiency: the fraction of emitted radiation that hits the detector 
and it depends on the source to detector distance, on the diameter of the ring 
and on the number of detectors in each ring
Intrinsic efficiency: the fraction of radiation that reaches the detector and is 





Parameter used to define 
the noise and to compare 
the PET performance
Takes into account the effects introduced by scatter and random 
coincidences
Contrast Difference in counts 
between an area of 
interest and its 
surroundings
Scatter, random and out-of-FOV radiation
L. Giovanella et al.
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respectively, the attenuation correction factor 
obtained from CT must be scaled to the 511 keV 
photons applying a scaling factor defined by the 
ratio of the μ of the 511 keV photons to that of the 
70 keV X-rays in a given tissue [1].
PET/MRI is a multi-modality technology 
combining the functional information of PET 
with the soft-tissue contrast of MRI.  Actually, 
two approaches are implemented in the commer-
cial PET/MRI scanners: sequential PET/MRI 
[7–9]. The characteristics of the three commer-
cial PET/MRI scanners are summarized in 
Table 1.3.
1.3  Positron Emission 
Tomography 
Radiopharmaceuticals
Radiopharmaceuticals are radiolabelled mole-
cules consisting in a molecular structure and a 
radioactive nuclide. The first one defines the 
pharmacokinetics and dynamics within the 
organism, while the latter is responsible for a 
detectable signal and for the consequent image 
visualization [10]. To maintain the stability of 
these two components, a linker may be necessary. 
The most important PET nuclides and their phys-
ical characteristics are summarized below:
 – Carbon-11 (11C) has a physical half-life of 
about 20  min and decays by β+ emission 
(99.75%) and by electron capture (0.25%) to 
the ground state of the stable nuclide Boron- 11 
(11B). β+ average energy is 386  keV, corre-
sponding to a mean range in water of 1.3 mm. 
11C can be produced by different nuclear reac-
tions; however, the main production mode is 
targeting Nitrogen-14 (14N) with cyclotron 
accelerated protons: 14N(p,α)14C.
 – Fluorine-18 (18F) has a physical half-life of 
about 110  min and decays by β+ emission 
(96.86%) and electron capture (3.14%) 
directly to the ground state of the stable 
Table 1.3 The characteristics of the three commercially available PET/MRI scanners
Siemens biograph 
mMR Philips ingenuity GE Signa
PET/MR technology Integrated Sequential Integrated
PET
Scintillator LSO LYSO LBS
Crystal size (mm) 4 × 4 × 20 4 × 4 × 22 4 × 5.3 × 25
Crystal number 28,672 28,336 20,160
Photodetector APD PMT SiPM
TOF No Yes Yes
Energy resolution (%) 14.5 12 10.5
Energy window (keV) 430–610 460–665 425–650
Time resolution (ns) 2.93 0.53 0.39
Coincidence window (ns) 5.86 6.00 4.57
Transaxial FOV (cm) 59.4 cm // 60 cm
Axial FOV 25.8 cm 18 25 cm
Sensitivity (kcps/MBq) 15.0 7.0 22.2
Scatter fraction (%) 37.9 26.0 43.4
Peak NECR (kcps @ kBq/mL) 184@ 23.1 88.5@13.7 218@17.7
MR
Field strength (T) 3 3 3
Bore (cm) 60 60 60
FOV (cm3) 50 × 50 × 50 50 × 50 × 45 50 × 50 × 50
Gradient mT/m 45 40 44
Slew rate (T/m)/s 200 100 200
1 Introduction to Different PET Radiopharmaceuticals and Hybrid Modalities (PET/CT and PET/MRI)
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nuclide Oxygen-18 (18O). β+ average energy 
is 250 keV, corresponding to a mean range in 
water of 0.6 mm. 18F can be produced by dif-
ferent nuclear reactions; however, the main 
production mode is targeting Oxygen-18 
with cyclotron accelerated protons: 
18O(p,n)18F.
 – Gallium-68 (68Ga) has a physical half-life of 
about 67.8  min and decays by β+ emission 
(88.88%) and by electron capture (11.11%) 
into 68Zn. β+ average energy is 830 keV, cor-
responding to a mean range in water of 
3.6  mm. 18Ga can be produced by different 
nuclear reactions; however, the main produc-
tion mode is using a Germanium-68 (68Ge)- 
68Ga generator.
 – Iodine-124 (124I) has a physical half-life of 
about 4.2  days and decays by β+ emission 
(23%) and by electron capture (77%) to the 
excited level and the ground state of 
Tellurium- 124 (124Te). β+ average energy is 
836 keV, corresponding to a mean range in 
water of 3.4  mm. 124I can be produced by 
different nuclear reactions; however, 
124Te(p,n) reaction gives the purest form of 
124I.
 – Copper-64 (64Cu) has a physical half-life of 
about 12.7 h and decays by β− emission (38%) 
to Zinc-64 (64Zn) and by β+ emission (17.4%) 
or electron capture (44.6%) to the excited 
level and the ground state of Nickel-64 (64Ni). 
β+ average energy is 278 keV, corresponding 
to a mean range in water of 0.7 mm. The main 
64Cu production modes are the following: 
63Cu(n,γ)64Cu, 65Cu(n,2n)64Cu, 64Zn(n,p)64Cu, 
64Zn (d,2p)64Cu.
The wide and feasible availability of positron 
emitters radionuclides is a prerequisite for suc-
cessful application on a routine basis. Fluorine-18 
and Gallium-68 are the most used in a clinical 
setting, so far. Due to its versatility, 
18F-Fluorodeoxyglucose (FDG), namely a radio-
labelled analogue of glucose, is the by far most 
widely used PET radiopharmaceutical world-
wide. FDG is very useful to detect malignant 
tumours characterized by increased glucose 
metabolism. However, FDG remains a non- 
specific tracer and its uptake is also been observed 
in many benign conditions, such as infective and 
inflammatory processes. Therefore, over the last 
decade, there is a growing interest in researching 
and using new radiopharmaceuticals, such as 
radiolabelled amino acids, nucleoside deriva-
tives, choline derivatives, nitroimidazole deriva-
tives and peptides, able to carefully target specific 
biomarkers. These new generation radiopharma-
ceuticals allow the analysis of several molecular 
pathways in tumour biology including metabo-
lism, proliferation, oxygen delivery and protein 
synthesis as well as receptor and gene expression 
(Tables 1.4, 1.5 and 1.6). Some examples of PET 
images with different radiopharmaceuticals are 
showed in Figs. 1.1 and 1.2.
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Evidence based medicine is defined as using the 
best available evidence for everyday clinical prac-
tice [1–3]. Synthetic literature including system-
atic reviews and meta-analyses plays an important 
role in evidence based medicine. Essentially sys-
tematic reviews and meta- analyses are the corner-
stone of evidence based practice. The main 
difference between a systematic review and a nar-
rative review is the clear method of the former 
including a clear search and predefined inclusion 
criteria. The methodology of systematic reviews 
makes them reproducible which is not the case in 
narrative reviews [1–3]. The number of systematic 
reviews and meta-analyses on nuclear medicine 
diagnostic and prognostic studies is increasing [4, 
5]. In the current chapter, a practical guideline has 
been prepared for the researchers who intend to 
perform a systematic review or meta-analysis of 
diagnostic and prognostic studies.
2.2  A Clear Topic for Systematic 
Review: Formulating 
the Question
The single most important step in preparing a 
systematic review is to have a clear topic. The 
topic is usually divided into several aspects 
including: patients (the population of the study), 
intervention (the diagnostic test under study or a 
prognostic factor which is being evaluated), com-
parison (the procedures comparative to the index 
test), outcome (the outcome which is going to be 
evaluated which are usually sensitivity and speci-
ficity for diagnostic studies and overall survival 
(OR) and progression free survival (PFS) in 
prognostic ones).
The abovementioned method is called 
patients-intervention-comparison-outcome 
(PICO) [6, 7]. The search strategy for systematic 
reviews is based on the PICO question.
Here are two examples:
 1. How does positron emission tomography 
(PET) [Intervention] work for detection of 
recurrence [Outcome] in endometrial carci-
noma [Patients]?
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 2. What is the prognostic significance of PET 
[Intervention] for predicting survival 
[Outcome] in renal cell carcinoma [Patients]?




Search strategy is based on our PICO question. 
The keywords and databases which are used for 
searching should minimize the chance of miss-
ing any relevant article. Using Boolean opera-
tors (i.e., AND, OR, NOT) is highly 
recommended. This makes your search as sensi-
tive as possible.
For example for the abovementioned PICO 
questions the following keywords seem to be 
optimal:
 1. (PET OR “Positron Emission Tomography”) 
AND (endometrial OR endometrium OR uter-
ine) AND recurrence.
 2. (PET OR “Positron Emission Tomography”) 
AND (RCC OR “renal cell carcinoma” OR 
kidney).
At least two databases should be included 
in the search strategy. PubMed/Medline and 
SCOPUS (or EMBASE) are two main sources 
for any systematic review.
The inclusion and exclusion criteria should 
be as clear as possible too. The following fac-
tors should be considered to set useful inclu-
sion criteria:
(a)  Standard of reference: Included studies 
should describe the reference or gold 
standard with which the diagnostic test is 
compared.
(b)  Outcome data: Enough information 
should be available to reconstruct a 2 × 2 
diagnostic table or prognostic factors 
(such as hazard ratio (HR)) of each 
study.
(c)  Language and time limit: Preferably no 
language or time limit should be 
imposed.
For example for the abovementioned PICO 
questions, the following inclusion criteria can 
be set:
 1. All studies which compared PET with con-
ventional imaging for detection of recurrence 
in endometrial cancer.
 2. All studies which evaluated the prognostic 
significance of PET factors (SUVmax, 
SUVmean, etc.) in survival (OS or PFS) of 
renal cell carcinoma patients.
Full texts of all relevant studies should be 
retrieved. The reference of primary studies and 
all relevant reviews should be checked to search 
for additional primary studies that could have 
been missed (backward searching of the cita-
tions). In addition, articles citing the relevant 
included articles can be used to find any other 
missing articles (forward searching of the cita-
tions). The citing articles can be found easily 
using Google Scholar (https://scholar.google.
com/), SCOPUS, or Dimensions (a free newly 
launched application with many useful options: 
https://app.dimensions.ai/discover/publication).
Remember to keep the records of all the 
searches, as well as included and excluded 
studies.
2.4  Quality Assessment 
of the Included Studies
Not all included studies are of same quality. 
Quality of each study should be checked and 
reported. Several checklists are available for 
diagnostic studies [8, 9].
Two of the most commonly used checklists 
are:
 1. Oxford Center for Evidence Based Medicine 
worksheet for diagnostic studies (available at 
https://www.cebm.net/wp-content/uploads/ 
2018/11/Diagnostic-Accuracy-Studies.pdf).
 2. Quality Assessment of Diagnostic Accuracy 
Studies-2 (QUADAS-2) [10]. QUADAS-2 is 
the revised, 2011 version of the 2003 
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QUADAS and consists of four dimensions 
(patient selection, index test, reference stan-
dard, and finally, flow and timing), the first 
three of which require an answer among the 
three available responses (yes/high, no/low, 
and unclear).
Several checklists are also available for prog-
nostic studies [11].
Two of the most commonly used checklists 
are:
 1. Oxford Center for Evidence Based Medicine 
worksheet for prognostic studies (available at 
https://www.cebm.net/wp-content/uploads/ 
2018/11/Prognosis.pdf).
 2. QUIPS tool (quality in prognostic factor stud-
ies) [12]. QUIPS has several domains (study 
participation, study attrition, prognostic factor 
measurement, outcome measurement, adjust-
ment for other prognostic factors, and statisti-
cal analysis). Risk of bias in each domain 
should be rated as high or low.
Checklists are usually equivalent to each 
other; however, each domain or dimension for all 
included studies should be explained in detail to 
give the reader of systematic reviews a clue 
regarding the quality of the included studies. 
Reporting only based on numbers (quality scores) 
should be discouraged.
2.5  Data Extraction
All relevant data should be extracted from the 
included studies. Detailed information regard-
ing the study population, method of the diag-
nostic or prognostic test, gold standard test, 
follow-up times, methods of ascertaining out-
comes, outcome variables such as false and true 
negative (FN, TN), false and true positive (FP, 
TP) cases for diagnostic studies, and hazard 
ratios (HR) for OS and PFS for prognostic stud-
ies should be extracted. Extraction of data 
should be as complete as possible to allow 
reconstruction of 2 × 2 diagnostic tables or HR 
of prognostic factors as well as sub-group anal-
yses [11, 13, 14].
Extraction of data in prognostic studies can be 
very tricky: not all studies reported HR, and only 
Kaplan Meier (KM) curves and associated log 
rank tests are usually reported. HR can be 
extracted from KM curves. Usually the survival 
data can be extracted manually from KM curves 
using special software such as getdata graph digi-
tizer (available at http://getdata-graph-digitizer.
com/download.php). Finally the extracted sur-
vival data can be converted to HR by Parmar 
method using a special Excel file provided by 
Parmar et al. [15].
Another important aspect of extraction data in 
prognostic systematic reviews is type of prognos-
tic factor (quantitative vs. qualitative factors) and 
evaluation of other prognostic factors (multivari-
ate vs. univariate analysis). HR of quantitative 
variables (such as SUVmax) can be provided in 
two ways: first, the prognostic factor can be used 
as a quantitative variable and a HR using Cox 
regression is provided. The second type of HR 
can be calculated by categorizing a quantitative 
variable into two ranks (for example, SUVmax 
>7 and ≤7). These two types of HR cannot be 
pooled with each other even for a same prognos-
tic factor. In addition, only univariate or multi-
variate HR should be used for pooling data across 
studies. Pooling univariate HR with a multivari-
ate HR is discouraged as the latter (but not the 
former) takes into account other potential prog-
nostic factors.




In this final step, the numerical results of the 
included studies would be pooled together. First 
of all, diagnostic or prognostic indices of each 
included study should be presented.




 – Positive likelihood ratio (LR+) =  sensitivity/
(1 − specificity)
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 – Negative likelihood ratio (LR−) = (1 − sensi-
tivity)/specificity
 – Diagnostic odds ratio (DOR) = LR−/LR+
The following prognostic indices should be 
reported:
 – Log rank test and p-value of each prognostic 
factor (only available for categorical 
variables).
 – Hazard ratios (HR) for prognostic factors.
 – Univariate and multivariate HR (if available) 
should be reported. In addition, for quantita-
tive variables HR for the quantitative variable 
as well as HR for categorized variable (if 
available) should be reported (see the previous 
section for more information).
Meta-analysis is a special statistical method 
for pooling data across different studies and giv-
ing pooled diagnostic indices. For this purpose, a 
weight is attributed to each study and the 
weighted diagnostic indices are pooled together. 
Special software are available for this purpose, 
including SAS, R, and STATA.
For diagnostic studies, two free software are 
available:
 1. OpenMeta [Analyst] is a free software for 
meta-analysis of diagnostic studies. This soft-
ware is available online at http://www.cebm.
brown.edu/openmeta/downloads/OpenMeta-
analyst_Windows.zip [16].
 2. Meta-Disc is another free software which has 
been specially designed for diagnostic studies. 
This soft’ware is available online at https://
download. f reedownloadmanager.org/
Windows-PC/Meta-DiSc/FREE-1.4.html [17].
For prognostic studies, usually hazard ratios 
should be pooled across included studies. Several 
software are available in this regard, such as R, 
SAS, and Comprehensive Meta-Analysis (CMA).
The least required data to be provided in a 
meta-analysis are:
 1. Pooled indices: They can be perfectly reported 
by forest plots which give all included studies 
as well as the pooled data in one view.
 2. Pooling method: We recommend random 
effects model for pooling studies as fixed 
model would not account for heterogeneity 
among included studies [18].
 3. Heterogeneity: Included studies of a system-
atic review are different from each other on 
several accounts such as studied population, 
methodology of the diagnostic tests or prog-
nostic factors, etc. Several factors contribute 
to the heterogeneity among studies: sampling 
error of the individual studies including true 
differences between included studies and 
finally the threshold effect [19, 20]. Methods 
for undertaking analyses which account for 
both sensitivity and specificity, the relation-
ship between them, and the heterogeneity in 
test accuracy, require fitting hierarchical ran-
dom effects models [21]. To report heteroge-
neity for each meta-analysis, at least 
Cochrane Q value and its associated p-value 
and I squared should be reported. Several 
methods are available in order to address the 
heterogeneity across included studies such as 
sub- group analysis, meta-regression, and 
sensitivity analysis. The authors should use 
these methods to explain the underlying rea-
sons of heterogeneity across included 
studies.
 4. Threshold effect: A unique source of hetero-
geneity in meta-analysis of diagnostic studies 
is the threshold effect. Not all studies use the 
same cut-off value for a positive result. This 
can be due to an explicit cut-off point value or 
explicit human or instrumental factors. This 
should be addressed in all diagnostic meta- 
analyses. Although the summary receiver 
operating characteristic curve (SROC) method 
and reporting Q∗ have been used traditionally 
for evaluating the threshold effect in diagnos-
tic studies, the best way to report the possible 
effect of threshold effect is bivariate meta- 
analyses [22, 23]. In this method, correlation 
between specificity and sensitivity is used as a 
variable to correct the results of the meta- 
analyses for possible threshold effect. This 
method has been incorporated in the last ver-
sion of OpenMeta [Analyst] and can be easily 
reported. The traditional SROC method is no 
longer recommended.
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 5. Publication bias: Although there is substantial 
literature relating to publication bias in sys-
tematic reviews and meta-analyses of ran-
domized controlled trials, little research has 
been done in the context of systematic reviews 
and meta-analyses of diagnostic studies. 
However, publication bias can be visually pre-
sented by funnel plots and can be quantified 
by several methods such as Egger’s regression 
intercept or trim and fill method [24, 25].
2.7  Discussion and Conclusion 
of Systematic Reviews
The discussion and final conclusion of a system-
atic review and meta-analysis should be as objec-
tive as possible. The authors should discuss the 
main results of the systematic review and meta- 
analysis. Final conclusion should be based on the 
main results of the systematic review. Any het-
erogeneity of the included studies should be 
explained and the possible reasons should be 
discussed.
Standard method of reporting systematic 
reviews and meta-analyses Preferred Reporting 
Items for Systematic Reviews and Meta-
Analyses (PRISMA) provides a minimum 
requirement for reporting systematic reviews 
and meta-analyses [21, 26]. Although it is origi-
nally prepared for systematic reviews of ran-
domized clinical trials, systematic reviews of 
diagnostic accuracy studies can be reported 
using PRISMA too. PRISMA statement and 
checklist can be found in the following link: 
http://www.prisma-statement.org/.
2.8  Final Comment
To publish a high quality systematic review or 
meta-analysis of diagnostic test accuracy or 
prognostic studies, certain methodology should 
be followed. Only methodologically sound sys-
tematic reviews and meta-analyses are worth 
publication and can change or support clinical 
use of a diagnostic test or a prognostic factor. 
Hopefully, the abovementioned methodology 
could help the researchers through the process of 
systematic review and meta-analysis 
preparation.
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Positron emission tomography (PET) using dif-
ferent radiotracers evaluating different metabolic 
patterns is able to early detect pathophysiological 
changes in oncological patients, including those 
with brain tumours. These functional changes 
usually occur before the development of morpho-
logical changes detected by conventional radio-
logical imaging techniques such as computed 
tomography (CT) and magnetic resonance imag-
ing (MRI) [1]. MRI is the standard neuroimaging 
method used for diagnosis of brain tumours, for 
performing stereotactic biopsy and surgical plan-
ning in neuro-oncology [2]. Currently, hybrid 
imaging techniques as PET/CT and PET/MRI, 
providing a combination of both functional and 
morphological information, may be useful meth-
ods for early diagnosis of brain tumours [1, 2].
Different PET radiotracers have been used to 
evaluate brain tumours including fluorine-18 flu-
orodeoxyglucose (18F-FDG), carbon-11 methio-
nine (11C-methionine), fluorine-18 
fluoroethyltyrosine (18F-FET), fluorine-18 fluoro-
dihydroxyphenylalanine (18F-FDOPA), fluorine-
 18 fluorothymidine (18F-FLT) and radiolabelled 
choline (11C-choline or 18F-choline).
Enough literature data already exist about the 
diagnostic performance and prognostic value of 
PET with different tracers in brain tumours. In 
particular, 24 meta-analyses on the use of PET or 
PET/CT with different tracers in brain tumours, 
published from 2012, were selected through a 
comprehensive computer literature search [3–26]. 
The findings of the selected meta-analyses on the 
diagnostic performance are presented in Table 3.1. 
Here below we have summarized the main find-
ings of meta-analytic studies based on the differ-
ent clinical indications of PET or  PET/CT.
3.2  Evaluation of Suspicious 
Primary Brain Tumour
Four meta-analyses have assessed the diagnostic 
performance of PET or PET/CT with different 
tracers in patients for whom primary brain 
tumours are suspected [3, 20, 23, 26].
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Table 3.1 Characteristics and main findings of included meta-analyses on the diagnostic performance of PET or PET/
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Yang et al. [18] NR NR NR NR NR
LR+ positive likelihood ratio; LR− negative likelihood ratio; DOR diagnostic odds ratio; 95%CI 95% confidence inter-
val; AA∗ radiolabelled amino acid PET including radiolabelled methionine, fluoroethyltyrosine and fluorodihydroxy-
phenylalanine; NR not reported; HGG high- grade gliomas only; PCNSL primary central nervous system lymphoma; 
mean TBR mean tumour-to- background uptake ratio; max TBR maximum tumour-to- background uptake ratio
Table 3.1 (continued)
3.2.1  18F-FDG
A meta-analysis including patients with suspi-
cious primary brain tumours showed that 18F- 
FDG PET or PET/CT has a moderate sensitivity 
and specificity for differentiating brain tumours 
from non-tumour lesions. False-positive findings 
were often due to inflammatory lesions or other 
non-tumour tissues; on the other hand, reduced 
18F-FDG uptake in brain tumours is usually influ-
enced by the high physiological glucose metabo-
lism in surrounding normal brain tissue, leading 
to a decreased sensitivity [23]. Another meta- 
analysis also demonstrated that 18F-FDG PET or 
PET/CT has a moderate diagnostic performance 
in distinguishing between tumour and non- 
tumour lesions in the brain, lower than amino 
acid PET [20].
3.2.2  11C-Methionine
A meta-analysis by Zhao et  al. demonstrated a 
good diagnostic performance of 11C-methionine 
PET or PET/CT in detecting brain tumours 
(pooled sensitivity and specificity were of 95% 
and 83%, respectively) with higher diagnostic 
accuracy values compared to 18F-FDG PET or 
PET/CT, likely due to the higher 11C-methionine 
uptake in brain tumours and lower accumulation 
in normal brain tissue [23].
3.2.3  18F-FET
For initial assessment of patients with a newly 
diagnosed brain lesion, 18F-FET PET or PET/CT 
demonstrated a good performance in the diagno-
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sis of a brain tumour with a pooled sensitivity and 
specificity of 82% and 76%, respectively. A mean 
tumour-to-background uptake ratio (TBR) 
threshold of at least 1.6 and a maximum TBR of 
at least 2.1 had the best diagnostic value for dif-
ferentiating brain tumours from non-tumour 
brain lesions. For the diagnosis of glioma versus 
non-glioma brain lesions, 18F-FET PET or PET/
CT demonstrated a good sensitivity (84%) but a 
not adequate specificity (62%) [26]. In a head-to- 
head comparative meta-analysis, the diagnostic 
performance of 18F-FET PET or PET/CT in dis-
tinguishing between tumour and non-tumour 
lesions in the brain was found significantly higher 
compared to that of 18F-FDG PET or PET/CT 
performed in the same patients [20].
3.2.4  18F-FDOPA
18F-FDOPA PET or PET/CT revealed a moderate 
sensitivity (71%) and a good specificity (86%) in 
detecting newly diagnosed gliomas [3].
3.3  Glioma Grading
Gliomas are the most frequent primary brain 
tumours. High-grade gliomas like glioblastomas 
are the most common gliomas in adults, with a 
poor prognosis with any current therapy. 
Conversely, low-grade gliomas, the second most 
common type of gliomas, are potentially curable 
with appropriate treatment. Several meta- 
analyses have evaluated the role of PET or PET/
CT with different tracers in differentiating 
between high-grade and low-grade gliomas [3, 6, 
14, 20].
3.3.1  18F-FDG
18F-FDG uptake is significantly higher in high- 
grade gliomas compared with low-grade glio-
mas. According to the meta-analysis of Dunet 
et al., a mean TBR of at least 1.4 and a maxi-
mum TBR of at least 1.8 at 18F-FDG PET had 
the best value to distinguish between low- and 
high-grade gliomas, with a sensitivity, specific-
ity and accuracy of 60%, 91% and 74%, respec-
tively, for mean TBR and 72%, 73% and 72%, 
respectively, for maximum TBR [20]. A recent 
meta-analysis demonstrated a lower sensitivity 
of 18F-FDG PET or PET/CT in differentiating 
between high-grade and low-grade gliomas 
compared to radiolabelled amino acid PET 
(11C-methionine and 18F-FET) but with higher 
specificity [6].
3.3.2  11C-Methionine
11C-methionine PET or PET/CT had a moderate 
diagnostic accuracy in differentiating between 
high-grade and low-grade gliomas, according to 
data provided by a recent meta-analysis (pooled 
sensitivity and specificity of 80% and 72%, 
respectively) [14]. Another meta-analysis dem-
onstrated that 11C-methionine PET or PET/CT 
has a higher sensitivity compared to 18F-FDG 
PET or PET/CT in differentiating between high- 
grade and low-grade gliomas but with lower 
specificity; diagnostic performance values were 
similar to those of 18F-FET PET or PET/CT in 
this setting [6].
3.3.3  18F-FET
18F-FET uptake is significantly higher in high- 
grade gliomas compared with low-grade gliomas. 
Dunet et al. reported that a mean TBR of at least 
2.0 and a maximum TBR of at least 3.0 at 18F- 
FET PET reached a sensitivity, specificity and 
accuracy of 88%, 73% and 81%, respectively, for 
mean TBR, and 80%, 82% and 81%, respec-
tively, for maximum TBR [20]. A recent meta- 
analysis demonstrated that 18F-FET PET or PET/
CT has a higher sensitivity compared to 18F-FDG 
PET or PET/CT in differentiating between high- 
grade and low-grade gliomas but with lower 
specificity; diagnostic performance values were 
similar to those of 11C-methionine PET or PET/
CT in this setting [6].
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3.3.4  18F-FDOPA
For differentiating high-grade from low-grade 
gliomas, 18F-FDOPA PET or PET/CT showed a 
pooled sensitivity of 88% and a pooled specific-
ity of 73% [3].
3.4  Delineation of Gliomas
For surgical and radiation therapy planning in 
patients with glioma, a correct delineation of the 
target volume is needed. A recent evidence-based 
article suggested that radiolabelled amino acid 
PET may ameliorate the delineation of high- 
grade gliomas compared to standard MRI [16].
3.5  Diagnosis of Recurrent Brain 
Tumours
Distinguishing recurrent brain tumours from 
non-tumour lesions after radiation therapy and/or 
chemotherapy is a crucial clinical issue, because 
the different diagnosis will lead to divergent 
treatments. Several meta-analyses have assessed 
the diagnostic performance of PET with different 
tracers in this setting [3, 4, 7, 9, 11, 13, 21–25].
3.5.1  18F-FDG
A meta-analysis of Zhao et  al. demonstrated a 
moderate diagnostic accuracy of 18F-FDG PET or 
PET/CT in detecting brain tumour recurrence 
[23]. This finding was confirmed by another 
meta-analysis which showed a pooled sensitivity 
and specificity of 78% and 77%, respectively 
[21]. Furuse et al. showed that the diagnostic per-
formance of 18F-FDG PET or PET/CT in detect-
ing recurrent brain tumours was lower compared 
to that of radiolabelled amino acid PET or PET/
CT [7]. Nihashi et al. showed that, when consid-
ering both low- and high-grade gliomas, pooled 
sensitivity and specificity of 18F-FDG PET or 
PET/CT in detecting glioma recurrence were 
77% and 78%, respectively. In subgroup analyses 
limited to high-grade gliomas, pooled sensitivity 
and specificity were 79% and 70%, respectively 
[25]. Wang et al. reported a moderate sensitivity 
(70%) but a good specificity (88%) of 18F-FDG 
PET or PET/CT in detecting recurrent glioma; 
however, the diagnostic accuracy was lower com-
pared to that of 11C-methionine PET or PET/CT 
and magnetic resonance spectroscopy in this set-
ting [22]. Another meta-analysis demonstrated 
that the diagnostic performance of 18F-FDG PET 
or PET/CT in detecting recurrent glioma is not 
optimal, in particular if compared with other 
available neuroimaging methods [7].
3.5.2  11C-Methionine
11C-methionine PET or PET/CT demonstrated 
good diagnostic performance in detecting brain 
tumour recurrence (pooled sensitivity and speci-
ficity of 92% and 87%, respectively), with higher 
values compared to 18F-FDG PET or PET/CT 
[23]. For high-grade gliomas, pooled sensitivity 
and specificity of 11C-methionine PET or PET/
CT in detecting glioma recurrence were 70% and 
93%, respectively [25]. Compared to dynamic 
susceptibility contrast-enhanced MRI, 
11C-methionine PET or PET/CT demonstrated 
comparable pooled sensitivity and specificity in 
detecting glioma recurrence, with pooled values 
of 87% and 81.3%, respectively [24]. Similar val-
ues of sensitivity and specificity (85% and 83%, 
respectively) were described by Wang et  al., 
which demonstrated that the diagnostic perfor-
mance of 11C-methionine PET or PET/CT in 
detecting glioma recurrence was similar to that of 
magnetic resonance spectroscopy [22]. A large 
meta-analysis including 29 studies confirmed the 
good diagnostic performance of 11C-methionine 
PET or PET/CT in this setting with a pooled sen-
sitivity and specificity of 88% and 85%, respec-
tively [13].
3.5.3  18F-FET
A recent meta-analysis demonstrated that 18F- 
FET PET or PET/CT has a good diagnostic accu-
racy in differentiating between brain tumour 
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recurrence and radiation necrosis after treatment, 
with pooled sensitivity and specificity values of 
82% and 80%, respectively. In the subgroup of 
patients with suspicious glioma recurrence, sen-
sitivity and specificity of 18F-FET PET or PET/
CT were 83% and 81%, respectively [11]. The 
good diagnostic performance of 18F-FET PET or 
PET/CT in this setting was also confirmed by 
Furuse et  al. who reported increased diagnostic 
performance of 18F-FET PET or PET/CT com-
pared to 18F-FDG and 11C-methionine PET or 
PET/CT [7]. Kim et  al. found that amino acid 
PET or PET/CT, including 18F-FET PET, has a 
good diagnostic performance in differentiating 
residual or recurrent brain tumour from treatment- 
related changes (pseudoprogression) in patients 
with high-grade gliomas [4].
3.5.4  18F-FDOPA
A recent meta-analysis indicated that 18F-FDOPA 
PET or PET/CT has a good diagnostic accuracy 
in differentiating between brain tumour recur-
rence and radiation necrosis after treatment, with 
pooled sensitivity and specificity values of 85% 
and 77%, respectively. In the subgroup of patients 
with suspicious glioma recurrence, sensitivity 
and specificity of 18F-FDOPA PET or PET/CT 
were 94% and 89%, respectively [11]. Xiao et al. 
reported a good sensitivity of 18F-FDOPA PET 
and PET/CT in detecting recurrent glioma (92%) 
and a moderate specificity (76%) [3].
3.5.5  18F-FLT
18F-FLT PET or PET/CT demonstrated a similar 
diagnostic performance in detecting brain tumour 
recurrence compared to 18F-FDG PET or PET/
CT with pooled sensitivity and specificity of 82% 
and 76%, respectively [21].
3.5.6  18C-Choline
A recent meta-analysis indicated that 11C-choline 
PET or PET/CT has a good diagnostic accuracy 
for differentiating glioma recurrence from radia-
tion induced necrosis after treatment, with a 
pooled sensitivity and specificity of 87% and 
82%, respectively [9].
3.6  Diagnosis of Brain 
Metastases
The reliability of PET or PET/CT with different 
tracers in detecting brain metastases has been 
evaluated to a less extent compared to primary 
brain tumours. A meta-analysis demonstrated 
that the pooled sensitivity and specificity of 18F- 
FDG PET or PET/CT in detecting brain metasta-
ses in patients with lung cancer were 21% and 
100%, respectively. In particular, the sensitivity 
of this method is lower compared to that of 
contrast- enhanced MRI [19].
3.7  Diagnosis of Recurrent Brain 
Metastases
The meta-analysis of Li et al., focused on the use 
of PET or PET/CT with different tracers in dif-
ferentiating recurrent brain metastasis from 
radionecrosis after radiation therapy, demon-
strated a good diagnostic accuracy of PET or 
PET/CT with both 18F-FDG and radiolabelled 
amino acid tracers (11C-methionine, 18F-FET, 
18F-FDOPA) in this setting [12]. MRI and PET 
with different tracers showed similar diagnostic 
performance for the detection of recurrent brain 
metastasis after stereotactic radiosurgery; never-
theless, advanced MRI methods showed a signifi-
cantly higher diagnostic performance in this 
setting compared to PET [8].
3.8  Diagnosis of Primary Central 
Nervous System Lymphoma 
(PCNSL)
18F-FDG PET and PET/CT showed considerable 
accuracy in identifying PCNSL among various 
brain lesions in immunocompetent patients 
(pooled sensitivity and specificity of 88% and 
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86%, respectively), therefore, 18F-FDG PET/CT 
could be a valuable diagnostic imaging method in 
this setting [17]. High diagnostic accuracy of 18F- 
FDG PET and PET/CT has also been demon-
strated in identifying PCNSL among various 
brain lesions in patients with human immunode-
ficiency virus (HIV) infection [18].
3.9  Prognostic Value in Patients 
with Glioma
Beyond the diagnostic accuracy, PET/CT param-
eters, and particularly the TBR, may be signifi-
cant prognostic factors in patients with glioma. A 
recent meta-analysis demonstrated that increased 
TBR at 18F-FDG PET, 11C-methionine PET and 
18F-FET PET could indicate poor overall survival 
(pooled hazard ratios were 3.05 for 18F-FDG 
PET, 1.59 for 11C-methionine PET and 1.15 for 
18F-FET PET) [5]. Another meta-analysis showed 
that the TBR and metabolic tumour volume at 
11C-methionine PET are significant prognostic 
parameters for patients with gliomas. Patients 
with a high TBR have a higher risk of death, and 
patients with a high metabolic tumour volume 
have a higher risk of adverse events or death [10].
3.10  Conclusions
Evidence-based data demonstrated good diag-
nostic performance of PET with different tracers 
in detecting brain tumours, in particular radiola-
belled amino acid tracers showed the highest 
diagnostic performance values. All the PET trac-
ers evaluated had significant prognostic value in 
patients with glioma [27].
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Head and neck cancer (HNC) accounts for 
approximately 5% of all malignant tumours with 
a continuous growing incidence. Head and neck 
squamous cell carcinoma (HNSCC) represents 
the majority of HNC [1, 2]. Nodal involvement is 
frequent in HNC patients, whereas distant metas-
tases are rather uncommon at the time of initial 
diagnosis and are found approximately in 10% of 
patients. There is a clear association with life-
style and factors as alcoholism, smoking, alimen-
tary factors and viruses for the etiological role, 
while increasing T and N stages remain the most 
important adverse prognostic factor [3, 4]. 
Diagnosis of HNC is usually achieved clinically 
with endoscopy to obtain direct tissue biopsies. 
Conventional Imaging (CI), including ultrasound 
(US), computed tomography (CT) and magnetic 
resonance imaging (MRI) is important for the 
evaluation of local extension and to provide 
information about infiltration, involvement of 
surrounding structures and regional nodal 
involvement. There is growing evidence, how-
ever, that these modalities have limitations for the 
diagnostic accuracy of nodal involvement and 
distant metastases. 18F-FDG PET/CT, allowing 
the analysis of both metabolic and anatomic fea-
tures, is a very useful imaging tool in HNC, in 
particular for disease staging, detection of carci-
noma of unknown primary (CUP), treatment 
monitoring, evaluation of residual or recurrent 
disease and for prognostic information [5–7].
4.2  Staging
Accurate staging of disease extension at the time 
of diagnosis is the most important factor for treat-
ment planning and patients prognosis. 
Furthermore, providing information in early 
stage of disease is extremely useful for selecting 
high-risk patients with impact on specific- 
treatment selection.
4.2.1  T Staging
18F-FDG PET/CT has high accuracy in detecting 
the primary tumour but a moderate diagnostic 
performance than CI to identify the real tumour 
extension and infiltration of surrounding tissue 
and structures. These data are necessary for ade-
quate therapeutic strategy and patient prognosis. 
False-negative results occur on 18F-FDG PET/CT 
when the primary tumour is superficial or small, 
but also in areas of high physiologic activity such 
as in pharyngeal lymphoid tissue. False-positive 
results of 18F-FDG PET/CT may be due to 
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 inflammatory processes. In literature, we found 
conflicting data; preliminary studies have shown 
divergent results of 18F-FDG PET/CT in diagno-
sis and staging of HNSCC.  Rohde et  al. com-
pared the diagnostic accuracy of 18F-FDG PET/
CT for diagnosing HNSCC in comparison with 
standard CI showing a pooled sensitivity of 
89.3% and specificity of 89.5% for 18F-FDG 
PET/CT and a pooled sensitivity and specificity 
of 71.6% and 78.0%, respectively, for CI. The 
authors concluded that 18F-FDG PET/CT is 
highly accurate in diagnosing patients suffering 
from HNSCC [8]. Chen et  al. compared MRI, 
CT and 18F-FDG PET/CT in the diagnosis of 
local and metastatic nasopharyngeal carcino-
mas. Their analysis suggested that MRI has 
good accuracy in diagnosis of T stage, whereas 
CT has a good performance in diagnosis of N 
stage and 18F-FDG PET/CT shows a good accu-
racy in diagnosis of M stage [9]. Similarly for 
evaluation of extracapsular spread (ECS), CT 
and MRI may be similarly effective, whereas 
evidence was lacking for 18F-FDG PET/CT and 
US [10]. 18F-FDG PET/CT can provide, instead, 
more useful clinical information and higher sen-
sitivity and specificity (pooled sensitivities and 
specificity 90% and 89%, respectively) to delin-
eate the presence and extent of mandibular 
involvement in patients with oral cavity cancer, 
especially in cases of contextual dental artefacts 
[11, 12]. For evaluation of precancerous and 
tumour lesions of larynx, Mannelli et  al. 
expressed the need to integrate different imag-
ing methods, proposing a flow chart that allows 
to stratify patients and select the most appropri-
ate procedure [13].
Overall, the current practice is not in favour of 
18F-FDG PET/CT as gold standard for T staging 
in HNC in exception of cases with suspect man-
dibular involvement in oral cavity cancer. The 
preliminary data about 18F-FDG PET/MRI dem-
onstrated high sensitivity and moderate specific-
ity of this technique in the diagnosis of HNC 
lesions, showing also a better tumour delineation. 
Further investigations are needed to define the 
real impact of 18F-FDG PET/MRI in HNC and 
whether the technique can improve the detection 
rate of occult primary HNC [14].
4.2.2  Nodal and Distant Metastases 
Detection
Lymph nodal involvement is the most important 
prognostic factor in patients with HNSCC with a 
significant impact on outcome in terms of dis-
ease free survival and overall survival. Lymph 
nodal (N) metastases occur in approximately 
50% of HNC patients at the time of diagnosis 
with a consequent survival decrease. An accurate 
N staging is therefore a fundamental step. 
Similarly, the detection of distant metastases at 
initial staging influences the prognosis avoiding 
unnecessary radical treatments. Metastases (M) 
are frequently found in the lungs, followed by 
the liver and bone.
Several data in the literature confirm an excel-
lent diagnostic accuracy of 18F-FDG PET/CT in 
N and M staging. A meta-analysis of Vellayappan 
et  al. assessed the diagnostic accuracy of 18F- 
FDG PET/CT for staging nasopharyngeal carci-
noma (NPC), showing good accuracy of 18F-FDG 
PET/CT for N staging (pooled sensitivity and 
specificity were 84% and 90%, respectively) and 
for M staging (pooled sensitivity and specificity 
were 87% and 98%, respectively), but not for T 
classification [15]. Similarly, Shen et  al. con-
firmed in their meta-analysis an excellent diag-
nostic performance of 18F-FDG PET/CT for 
detecting lymph node and distant metastases in 
patients with NPC with a pooled sensitivity and 
specificity of 89% and 96%, respectively [16]. 
Considering only the detection accuracy for 
regional nodal metastases in HNC before treat-
ment, 18F-FDG PET/CT showed good diagnostic 
performance [17, 18]. Moreover, compared with 
CI, 18F-FDG PET/CT may have higher per-neck- 
level sensitivity [19]. These values are even more 
significant excluding clinically N0 patients with 
greater accuracy values for 18F-FDG PET/
CT. Several data showed moderate sensitivity of 
18F-FDG PET/CT for detection of cervical lymph 
nodal metastases in clinical N0 HNSCC patients 
with absence of significant better diagnostic 
accuracy compared to CI; conversely, 18F-FDG 
PET/CT has a higher specificity and negative pre-
dictive value for the detection of cervical meta-
static lymph nodes compared to the other imaging 
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modalities in clinical N0 HNSCC [20–22]. 
Avoiding elective neck dissection is a fundamen-
tal step in the diagnostic-therapeutic flow chart of 
these patients in order to minimize morbidity and 
health costs. At present elective neck dissection 
in patients with clinical N0 should not be based 
upon cross-sectional imaging. A combination of 
CI and sentinel node biopsy seems to be the pre-
ferred staging strategy to reduce the risk of occult 
metastases in clinical N0 HNSCC [23].
On the other hand, the excellent diagnostic 
performance of 18F-FDG PET/CT for detecting 
distant metastases is clearly underlined in the lit-
erature [24–29]. Xu et al. showed a pooled sensi-
tivity and specificity of 85.7% and 98.1%, 
respectively, for 18F-FDG PET/CT, resulting in a 
significantly better M staging than CI [26]. This 
was mainly due to the superior diagnostic perfor-
mance of 18F-FDG PET/CT compared to CI in 
detecting bone metastases [27]. In this setting, 
18F-FDG PET/CT has higher sensitivity com-
pared to bone scintigraphy [28]. On the other 
hand, for detection of liver metastases 18F-FDG 
PET/CT requires further optimization and inte-
gration with CI, especially contrast-enhanced CT 
and MRI [25]. About lung metastases, a meta- 
analysis demonstrated that 18F-FDG PET/CT is a 
valuable diagnostic tool for diagnosing lung 
malignancies in patients with HNSCC [29].
4.3  Prognostic Value
The prognostic value of 18F-FDG PET/CT has 
been widely discussed with controversial results. 
Relevant limiting factors are the variability and 
reproducibility of each individual parameter. 
Overall, maximum standardized uptake value 
(SUVmax), metabolic tumour volume (MTV) 
and total lesion glycolysis (TLG) were signifi-
cant prognostic predictors in patients with HNC 
[30–36].
No significant correlation was found between 
metabolic parameters of 18F-FDG PET/CT in 
HNC and human papillomavirus (HPV) status 
[37]. Furthermore, the semi-quantitative PET/CT 
parameters were not related to histopathological 
parameters in HNSCC, as Ki67 and p53 [38].
4.4  Post-treatment Evaluation
Relevant applications of 18F-FDG PET/CT in 
HNC are delineation of the tumour volume for 
radiation treatment planning, discrimination of 
post-treatment changes, evaluation of response to 
multimodality therapy and detection of 
recurrence.
About radiation therapy planning, Jeong et al. 
found that 18F-FDG-avid HNC apparently require 
10–30% more radiation dose than FDG-non-avid 
tumours, supporting radiotherapy boosts for 
18F-FDG-avid tumours; prospective studies are 
still required in this field [39].
The role of intra-therapy and post-therapy 18F- 
FDG PET/CT in predicting long-term survival 
outcomes in patients treated for HNC has been 
widely studied. Sheikhbahaei et al. reported that 
positive results of intra-therapy or post-therapy 
18F-FDG PET/CT could significantly predict the 
2- and 5-year risk of death or disease progression 
[40]. The same group confirmed the high diag-
nostic performance of 18F-FDG PET/CT in 
detecting local, regional and distant recurrences 
in curatively treated patients with HNC.  The 
pooled sensitivity and specificity of follow-up 
18F-FDG PET/CT for detection of recurrence 
were 92% and 87%, respectively [41]. These data 
support its use in clinical practice as confirmed 
also by other studies that highlight the high accu-
racy of 18F-FDG PET/CT performed after the 
completion of therapy both in NPC and HNSCC 
before salvage treatment [42–44]. 18F-FDG PET/
CT is also superior to MRI in distinguishing 
recurrent NPC from fibrosis or scar tissue after 
radiotherapy in irradiated fields with distortion of 
normal architecture [45]. Treatment-to-time scan 
remains a debated aspect. Several works have 
indicated that early 18F-FDG PET/CT was less 
accurate than more delayed imaging after ther-
apy, particularly Cheung and coauthors supported 
the use of 18F-FDG PET/CT more than 12 weeks 
after radiotherapy with or without chemotherapy 
for the assessment of residual or recurrent HNC 
[46]. Recently, Helsen et al. confirmed that 18F- 
FDG PET/CT performed within 6 months after 
chemo-radiotherapy in HNSCC patients is the 
method of choice for ruling out residual/recurrent 
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nodal disease reducing the need for therapeutic 
intervention [47]. Finally, sensitivity and speci-
ficity of 18F-FDG PET/CT in identifying local 
failure following curative radiotherapy or surgery 
for HNSCC were significantly improved when 
imaging was performed 3  months after end of 
treatment [48].
4.5  Carcinoma of Unknown 
Origin and Incidental 
Findings
Several studies have investigated the accuracy of 
18F-FDG PET/CT to identify carcinoma of 
unknown origin (CUP) in patients with cervical 
lymph nodal metastases. Generally, the most com-
mon sites of detection include the palatine tonsils 
and the base of the tongue, with increase of false-
negative results when the primary tumour is small 
or adjacent to physiological uptake sites. Zhu et al. 
showed a high sensitivity (97%) and a moderate 
specificity (68%) for the detection of CUP in 
patients with cervical nodal metastases [49].
Finally, Treglia et  al. calculated the pooled 
prevalence and risk of malignancy of incidental 
focal 18F-FDG uptake in the parotid glands. The 
pooled prevalence of this finding is about 1% of 
all 18F-FDG PET/CT. Although these incidental 
findings are benign in most of the cases, comple-
mentary evaluation is needed to exclude malig-
nant lesions or with possible malignant 
degeneration [50].
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Fluorine-18 fluorodeoxyglucose positron emis-
sion tomography/computed tomography (18F- 
FDG PET/CT) is a robust imaging tool that is 
currently used in daily clinical practice for the 
evaluation of thoracic malignancies. This chapter 
provides an overview of the current evidence- 
based data on the usefulness of PET/CT for the 
evaluation of patients with thoracic tumours 
including lung cancer, pleural and thymic 
tumours, and esophageal cancer.
5.2  Evidence-Based Data on PET 
in Primary Lung Tumours
Herein we reviewed recent evidence-based data 
on the usefulness of 18F-FDG PET/CT for: (1) 
characterization of solitary pulmonary nodules 
(SPNs), (2) non-small cell lung cancer (NSCLC) 
staging, (3) restaging after induction therapy and 
systemic therapy response assessment in NSCLC, 
(4) radiation therapy planning, (5) diagnosis of 
lung cancer recurrence in NSCLC, (6) prognostic 
evaluation, (7) management of small cell lung 
cancer (SCLC).
5.2.1  Characterization of Solitary 
Pulmonary Nodules (SPNs)
Characterizing a SPN detected incidentally or, as 
is the case more recently, on CT screening for 
lung cancer is a major public health issue. 18F- 
FDG PET/CT is not indicated for characteriza-
tion of SPNs of less than 8  mm in diameter 
according to current guidelines [1]. This thresh-
old was set to take into account the spatial resolu-
tion of PET systems, due to the significant risk of 
false-negative findings for small lesions. 
However, over the last decade, the spatial resolu-
tion of 18F-FDG PET/CT has significantly 
increased and future analysis could verify if this 
threshold will be modified accordingly.
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5.2.1.1  Single-Time-Point 18F-FDG PET 
or PET/CT
In the last decade, a robust evidence has been 
produced on the potential use of 18F-FDG PET/
CT in early diagnosis of lung cancer (Table 5.1). 
Chien and colleagues [2] in 2013 conducted a 
systematic review on this topic reporting evi-
dence of lung cancer screening programmes with 
18F-FDG PET, in which the estimated pooled sen-
sitivity and specificity were 83% and 91%, 
respectively. At that moment, despite PET 
appeared to have high sensitivity and specificity 
as a selective screening modality, the role of pri-
mary PET screening for lung cancer remained 
unknown and still undefined.
Subsequently, a further systemic analysis [3] 
reported a very high (98.7%) pooled sensitivity 
of 18F-FDG PET/CT in this setting while specific-
ity was suboptimal (58.2%).
In 2016, the research team headed by Madsen 
[4] suggested that 18F-FDG PET/CT can rule out 
malignancy in most SPNs due to high sensitivity 
(recommendation level A) but at the same time 
the sensitivity of 18F-FDG PET/CT in general is 
insufficient to rule out mediastinal lymph node 
metastasis (recommendation level A). Therefore, 
with few exceptions (lesions <1 cm and non-solid 
lesions), they concluded that SPNs could be pre-
sumptively considered benign if 18F-FDG PET is 
negative. In addition, lymph node metastasis in 
the mediastinum cannot be ruled out on the basis 
of a negative 18F-FDG PET/CT, and confirmative 
(mini)invasive staging should be performed in 
most patients.
More recently, a further meta-analysis [5] 
showed that the pooled sensitivity and specificity 
of 18F-FDG PET/CT in characterizing SPNs were 
82% and 81%, respectively, demonstrating mod-
erate accuracy for 18F-FDG PET/CT in differenti-
ating malignant from benign SPNs.
A further meta-analysis exploring the value of 
18F-FDG PET/CT in the diagnosis of SPNs was 
reported in 2018 [6]. Pooled results indicated a 
sensitivity of 89% and a specificity of 70%. 
Table 5.1 Main findings of included meta-analyses on the diagnostic performance of PET or PET/CT with different 
tracers in patients with solitary pulmonary nodules
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Considering the unsatisfactory results, especially 
in terms of specificity, the authors stated that 18F- 
FDG PET/CT cannot replace the “gold standard” 
pathology by resection or biopsy.
Not dissimilar results have been reported in a 
further recent meta-analysis performed by Divisi 
and co-workers [7]. The authors concluded that 
despite 18F-FDG PET/CT presents a fairly good 
diagnostic accuracy in SPNs evaluation, it should 
not be considered as a discriminatory test rather 
than a method to be included in a clinical and 
diagnostic pathway.
Interestingly, Deppen and co-workers [8] 
evaluated the accuracy of 18F-FDG PET in 
 diagnosing lung cancer comparing populations 
with or without a risk for endemic infectious lung 
disease. They observed a 16% lower average 
adjusted specificity in regions with endemic 
infectious lung disease (61%) compared with 
non-endemic regions (77%). On the other hand, 
the sensitivity did not change appreciably by 
endemic infection status, even after adjusting for 
relevant factors. On the light of these results, the 
authors did not suggest the use of 18F-FDG PET 
to diagnose lung cancer in regions with endemic 
pulmonary infections unless an institution 
achieves test performance accuracy similar to 
that found in non-endemic regions.
Lastly, a meta-analysis investigates the diag-
nostic performance of 18F-FDG PET/CT com-
pared with diffusion-weighted magnetic 
resonance imaging (DW-MRI) for distinguishing 
malignant versus benign SPNs [9]. DW-MRI had 
a pooled sensitivity and specificity of 83% and 
91%, respectively, compared with 78% and 81%, 
respectively, for PET/CT. The authors concluded 
that the diagnostic performance of DW-MRI is 
comparable or superior to that of 18F-FDG PET/
CT in the differentiation of malignant and benign 
pulmonary lesions.
5.2.1.2  Dual-Time-Point (DTP) PET
Several authors have also explored the potential 
use of a DTP 18F-FDG PET in differentiating 
malignant from benign SPNs (Table  5.1). In 
2012, a meta-analysis was performed by Lin and 
co-workers [10] exploring the diagnostic perfor-
mance of both single-time-point (STP) and DTP 
18F-FDG PET techniques. Sensitivity was higher 
with DTP imaging at moderate levels of specific-
ity. This potential advantage of DTP over initial 
STP scanning was diminished at higher levels of 
specificity. Although there was no clear evidence 
to support the routine use of DTP imaging with 
18F-FDG PET in the differential diagnosis of pul-
monary nodules, the authors suggested as such 
technique may provide additional information in 
selected cases with equivocal results from initial 
scanning. Other meta-analyses [11–13] reported 
similar diagnostic accuracy among DTP and STP 
18F-FDG PET or PET/CT in the diagnosis of 
SPNs. According to these results, the additional 
value of DTP compared to STP 18F-FDG-PET/
CT resulted to be questionable.
5.2.1.3  18F-FLT PET for Evaluation 
of Pulmonary Lesions
The potential use of fluorine-18 fluorothymidine 
(18F-FLT) PET in patients with pulmonary lesions 
was evaluated by two meta-analyses [14, 15] 
(Table 5.1), which showed that 18F-FLT PET had 
a higher specificity but lower sensitivity com-
pared to 18F-FDG PET in the evaluation of SPNs. 
Therefore, the authors assumed that 18F-FLT and 
18F-FDG together could add diagnostic confi-
dence for pulmonary lesions.
5.2.2  NSCLC Staging
Nodal (N) and distant metastases (M) staging is 
one of the major prognostic factors of survival in 
NSCLC patients. Accurate staging of distant 
metastases is crucial, as the treatment strategy is 
directly dependent on tumour stage. Although 
many studies have been reported in the last 
decades evaluating the performance of 18F-FDG 
PET/CT in lung cancer staging, the results among 
studies are still almost controversial.
5.2.2.1  N Staging
Zhao and associates [16] performed a meta- 
analysis about 18F-FDG PET/CT for detecting 
mediastinal nodal metastases in patients with 
NSCLC.  The pooled sensitivity and specificity 
with 95% confidence interval values (95%CI) on 
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a per-patient analysis were 71.9% (95%CI: 68.3–
75.3%) and 89.8% (95%CI: 88.2–91.2%), 
respectively.
A second meta-analysis on the same issue [17] 
showed a pooled sensitivity of 62% for 18F-FDG 
PET/CT (95%CI: 54–70%) and a pooled speci-
ficity of 92% (95%CI: 88–95%) on a node-based 
analysis. The pooled sensitivity and specificity 
were 67% (95%CI: 54–79%) and 87% (95%CI: 
82–91%), respectively, on a patient-based analy-
sis. Interestingly, those studies from tuberculosis 
endemic countries showed lower sensitivity and 
also lower specificity compared to non- 
tuberculosis endemic countries [17, 18].
Two meta-analyses were specifically limited 
to early-stage NSCLC cases. In detail, Wang and 
co-workers [19] found that the negative predic-
tive value (NPV) of 18F-FDG PET/CT for lymph 
nodal mediastinal metastases was 94% for T1 
disease and 89% for T2 disease. Including both 
T1 disease and T2 disease, the NPV was 93% for 
mediastinal metastases and 87% for overall nodal 
metastases. Interestingly, adenocarcinoma histol-
ogy type and high 18F-FDG uptake in the primary 
lesion were associated with greater risk of occult 
nodal metastases.
Similarly, a second meta-analysis [20] focused 
on patients with resectable NSCLC revealed that 
18F-FDG PET/CT had a pooled sensitivity and 
specificity for N staging of 81.3% (95%CI: 70.2–
88.9%) and 79.4% (95%CI: 70–86.5%), respec-
tively. The authors assumed that accuracy of 
18F-FDG PET/CT in N staging was insufficient to 
allow management and strategy of care based on 
18F-FDG PET/CT findings alone.
Shen et al. [21] also investigated the diagnos-
tic value of DTP 18F-FDG PET/CT versus STP 
imaging for detection of mediastinal nodal 
metastases in NSCLC patients. Pooled sensitivity 
and specificity for DTP PET/CT were 85% 
(95%CI: 78–91%) and 75% (95%CI: 68–82%), 
respectively, and for STP imaging the same val-
ues were 79% (95%CI: 70–85%) and 73% 
(95%CI: 65–79%), respectively. The authors 
were very cautious in supporting the implemen-
tation of DTP imaging in routine PET protocols 
for mediastinal lymph node staging of NSCLC.
Lastly, two meta-analyses compared 18F-FDG 
PET/CT and DW-MRI for detection of mediasti-
nal nodal metastases in NSCLC [22, 23] report-
ing similar results in terms of diagnostic accuracy 
among these two imaging methods.
5.2.2.2  M Staging
A meta-analysis by Li and co-workers [24] 
showed the excellent diagnostic performance of 
18F-FDG PET/CT for diagnosis of distant metas-
tases in patients with NSCLC with a pooled sen-
sitivity and specificity of 93% (95%CI: 88–96%) 
and 96% (95%CI: 95–96), respectively. Similar 
results were reported by Yu et al. [25] who found 
a pooled sensitivity of 81% (95%CI: 63–92%) 
and 96% (95%CI: 94–98%), respectively. A fur-
ther meta-analysis on the same topic [26] demon-
strated that concerning extra-thoracic metastases 
of NSCLC, the pooled sensitivities and specifici-
ties of 18F-FDG PET/CT were 77% (95%CI: 
47–93%) and 95% (95%CI: 92–97%) for all 
extra-thoracic metastases, whereas the same val-
ues were 91% (95%CI: 80–97%) and 98% 
(95%CI: 94–99%), respectively, for bone metas-
tases. Conversely, 18F-FDG PET/CT showed low 
sensitivity in detecting brain metastases.
Concerning the latter issue, a comparative 
meta-analysis MRI and 18F-FDG PET/CT for the 
diagnosis of brain metastases in NSCLC [27] 
revealed that MRI had higher sensitivity (77%) 
than 18F-FDG PET/CT (21%) for the diagnosis of 
brain metastases.
Chang et  al. [28] found a higher sensitivity 
and specificity of 18F-FDG PET/CT compared to 
bone scintigraphy (BS) in detecting bone metas-
tases from NSCLC. A further more robust meta- 
analysis [29] showed that 18F-FDG PET/CT is a 
better imaging method in terms of sensitivity 
and specificity compared to MRI and BS for 
detecting bone metastases from NSCLC, with a 
pooled sensitivity and specificity of 92% 
(95%CI: 88–95%) and 98% (95%CI: 97–98), 
respectively.
Finally, the diagnostic performance of 18F- 
FDG PET/CT in detecting adrenal metastases 
from NSCLC was recently evaluated by Wu and 
co-workers [30]. The pooled sensitivity and spec-
ificity of 18F-FDG PET/CT in this setting were 
88.7% (95%CI: 85.2–91.7%) and 90.8% (95%CI: 
87.5–93.4%), respectively, suggesting excellent 
performance.
F. Lococo et al.
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5.2.3  Restaging After Induction 
Therapy and Prediction 
of Treatment Response
The ability to identify potential responders to 
induction treatment may improve patient selec-
tion or surgery and may help in the development 
of response criteria suitable for routine monitor-
ing of response. By providing information on the 
metabolic activity of tumour cells, 18F-FDG  PET/
CT has become a powerful tool in assessing treat-
ment response. Zhang and colleagues [31] per-
formed a meta-analysis to evaluate the value of 
18F-FDG PET in predicting the pathological 
tumour response of lung cancer to induction ther-
apy. The authors found that 18F-FDG PET could 
play an important role in predicting non- 
responders to induction therapy in cases of lung 
cancer: indeed, the pooled sensitivity, specificity, 
positive predictive value, and negative predictive 
value for PET-predicted response were 83% 
(95%CI: 76–89%), 84% (95%CI: 79–88%), 74% 
(95%CI: 67–81%), and 91% (95%CI: 87–94%), 
respectively.
A recent evidence-based article assessed the 
use of 18F-FDG PET/CT for both assessing the 
efficacy of treatment response and performing 
post-treatment follow-up of lung cancer [32]. 
PET metabolic response (PERCIST criteria) has 
been shown to be a better predictor of histopatho-
logic response than anatomic response metrics 
(WHO and RECIST criteria). 18F-FDG PET/CT 
was indicated for treatment response assessment 
when it is performed within 6 months from treat-
ment completion, though evidence for its com-
parative effectiveness with chest CT is still 
evolving.
5.2.4  Radiation Therapy 
Pretreatment Planning 
in NSCLC
18F-FDG PET/CT may also increase the likeli-
hood of correctly delineating tumour tissue 
before radiotherapy dose planning. In 2017, 
Hallqvist and colleagues [33] reported the results 
of a meta-analysis on the use of 18F-FDG PET/
CT for radiotherapy dose planning. According to 
this meta-analysis, a change in target definition 
was 36% in patients with a former staging PET, 
and 43% and 26% in patients without a staging 
PET for NSCLC and SCLC, respectively. The 
corresponding summary estimates of a change in 
treatment intent from curative to palliative treat-
ment were 20% and 22% and 9%, respectively. 
Another recent meta-analysis demonstrated that 
functional lung imaging, including PET, may 
have potential utility in radiation therapy plan-
ning and delivery [34].
5.2.5  Diagnosis of Lung Cancer 
Recurrence
Although there are no conclusive data to support 
the survival benefits of early detection or early 
treatment for recurrence of lung cancer, an early 
and accurate diagnosis of recurrence is critical to 
optimize therapy. A meta-analysis [35] was per-
formed to assess the diagnostic value of 18F-FDG 
PET and PET/CT for cases of recurrent lung can-
cer. In the patient-based analysis performed, 18F- 
FDG PET and PET/CT were found to provide 
better detection of lung cancer recurrence com-
pared to CT.  Indeed, the pooled sensitivity for 
18F-FDG PET, PET/CT, and CT were 94% 
(95%CI: 91–97%), 90% (95%CI: 84–95), and 
78% (95%CI: 71–84%), respectively while the 
pooled specificity for 18F-FDG PET, PET/CT, 
and CT were 84% (95%CI: 77–89%), 90% 
(95%CI: 87–93%), and 80% (95%CI: 75–84%), 
respectively.
5.2.6  Prognostic Evaluation 
in NSCLC
In their meta-analysis, Paesmans et  al. [36] 
assessed the prognostic value of primary tumour 
maximum standardized uptake value (SUVmax) 
at 18F-FDG PET for overall survival (OS) of 
NSCLC patients. At multivariate analysis, 
SUVmax was found to be independently associ-
ated with survival. The hazard ratio (HR) for 
SUVmax was 1.58 (95%CI: 1.27–1.96).
Despite the SUVmax represents the most 
widely applied semi-quantitative PET parameter 
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in clinical practice, volumetric PET parameters, 
including metabolic tumour volume (MTV) and 
total lesion glycolysis (TLG), have been also 
used to reflect disease burden and tumour aggres-
siveness in NSCLC.  A first meta-analysis per-
formed by Liu et al. [37] explored the prognostic 
value of SUVmax, MTV, and TLG on disease- 
free survival (DFS) and OS in surgical NSCLC 
patients. The pooled HRs for OS were 1.52 for 
SUVmax, 1.91 for MTV, and 1.94 for TLG. On 
the basis of these results, the authors stated that 
high values of SUVmax, MTV, and TLG are able 
to predict a higher risk of recurrence or death in 
patients with surgical NSCLC, suggesting the use 
of 18F-FDG PET/CT to select patients who are at 
high risk of disease recurrence or death as the 
best candidates from aggressive treatments. 
Other authors [38] conducted a meta-analysis on 
the prognostic value of MTV and TLG in NSCLC 
patients. A worse prognosis was observed in 
patients with high MTV (HR: 2.31) and with 
high TLG (HR: 2.43).
Han and colleagues [39] performed a meta- 
analysis exploring prognostic value of texture 
parameters derived by 18F-FDG PET in patients 
with lung cancer. They concluded that there is 
insufficient evidence to support the prognostic 
value of texture analysis in 18F-FDG PET in lung 
cancer.
Another interesting application of 18F-FDG 
PET is the ability to predict long-term results 
after radiation therapy. Dong and co-workers 
[40] explored the prognostic relevance of 
SUVmax at 18F-FDG PET for early-stage NSCLC 
patients receiving stereotactic body radiation 
therapy (SBRT). The authors found that those 
NSCLC patients presenting with high levels of 
pre-SBRT SUVmax had poorer OS and local 
control and higher risk of distant metastases. 
These findings were confirmed by another meta- 
analysis [41] showing that both pre-radiotherapy 
and post-radiotherapy primary tumour SUVmax 
can predict the outcome of patients with NSCLC 
treated with radiotherapy.
Other authors [42] have summarized the prog-
nostic value of early response at 18F-FDG PET in 
NSCLC patients treated with tyrosine-kinase 
inhibitors (TKI). Early response of patients with 
NSCLC treated with TKIs identified on 18F-FDG 
PET was found to be associated with improved 
OS and progression-free survival (PFS).
5.2.7  Management of SCLC
The role of 18F-FDG PET in the management of 
SCLC has been largely investigated in the last 
decades. A systematic review and meta-analysis 
performed by Lu et al. [43] to evaluate the diag-
nostic accuracy of 18F-FDG PET/CT in the pre- 
therapeutic staging of patients with SCLC 
demonstrated a pooled sensitivity and specificity 
of 97.5% (95%CI: 94.2–99.2%) and 98.2% 
(95%CI: 94.9–99.6%), respectively, for the 
detection of extensive disease in SCLC patients. 
Therefore, evidence-based data suggest the role 
of 18F-FDG PET/CT for discriminating between 
limited and extensive disease in SCLC.
The prognostic value of the SUVmax of pri-
mary SCLC at 18F-FDG PET was recently inves-
tigated through a meta-analytic study [44]: the 
pooled HR for OS was 1.13 (95%CI: 1.05–1.22), 
thus indicating that SCLC patients with high 
SUVmax may have poorer prognosis.
5.3  Evidence-Based Data on PET 
in Pleural Tumours
Three meta-analyses assessed the role of 18F- 
FDG PET or PET/CT in the characterization of 
pleural lesions [45–47], whereas meta-analyses 
on the role of 18F-FDG PET/CT in staging, restag-
ing, prognostic or treatment response evaluation 
of pleural tumours are currently lacking.
18F-FDG-PET and PET/CT demonstrated to be 
accurate diagnostic imaging methods in the dif-
ferential diagnosis between malignant and benign 
pleural lesions in patients with or without known 
cancer; nevertheless, possible sources of false-
negative and false-positive results should be kept 
in mind [45, 46]. In patients without known can-
cer, sensitivity and specificity of 18F-FDG- PET 
and PET/CT were 95% (95%CI: 92–97%) and 
82% (95%CI: 76–88%), respectively [45]. In 
patients with known cancer, pooled sensitivity 
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was 86% (95%CI: 80–91%) and pooled specific-
ity was 80% (95%CI: 73–85%) [46]. Porcel et al. 
in their meta-analysis [47] demonstrated that 
semi-quantitative PET assessment had a signifi-
cantly lower sensitivity for diagnosing malignant 
pleural effusions than visual assessments. The 
pooled sensitivity and specificity of 18F-FDG 
PET/CT using semi-quantitative interpretation for 
identifying malignant pleural effusions were 81% 
and 74%, respectively. The moderate accuracy of 
semi-quantitative PET assessment precludes its 
routine recommendation for discriminating 
malignant from benign pleural effusions.
5.4  Evidence-Based Data on PET 
in Thymic Epithelial Tumours
One meta-analysis [48] showed that 18F-FDG 
PET may predict the WHO grade of malignancy 
in thymic epithelial tumours (TETs), reporting a 
statistically significant difference of SUVmax 
between the different TETs (low-grade thymo-
mas, high-grade thymomas, and thymic carcino-
mas). In detail, the pooled mean difference of 
SUVmax between high-risk and low-risk thymo-
mas was 1.2 (95%CI: 0.4–2.0), that between thy-
mic carcinomas and low-risk thymomas was 4.8 
(95%CI: 3.4–6.1), and that thymic carcinomas 
and high-risk thymomas was 3.5 (95%CI: 
2.7–4.3).
Notably, meta-analyses on the role of 18F-FDG 
PET/CT in staging, restaging, prognostic or treat-
ment response evaluation of TETs are currently 
lacking.
5.5  Evidence-Based Data on PET 
in Esophageal Tumours
5.5.1  Staging
The real and unquestionable additional diagnos-
tic value of 18F-FDG PET/CT in comparison to 
conventional imaging methods is in evaluating 
distant metastases (M staging) of esophageal 
cancer [49], whereas recent evidence-based arti-
cles have addressed the performance of 18F-FDG 
PET/CT for detecting lymph nodal metastases 
(N staging).
Jiang et al. [50] found that the pooled sensitiv-
ity and specificity estimates of 18F-FDG PET/CT 
for detecting regional lymph nodal metastases at 
staging were 66% (95%CI: 51–78%) and 96% 
(95%CI: 92–98%), respectively. The correspond-
ing values on a per-patient analysis were 65% 
(95% CI: 49–78%) and 81% (95%CI: 69–89%), 
respectively. Overall, 18F-FDG PET/CT has a 
moderate to low sensitivity and a high to moder-
ate specificity for detection of regional nodal 
metastases in esophageal cancer. Therefore, 
extending the extent of lymph node dissection or 
radiotherapy target volume is necessary after the 
diagnosis of regional nodal metastases by 18F- 
FDG PET/CT.
In another meta-analysis [51], Hu et al. evalu-
ated the diagnostic performance of 18F-FDG PET/
CT for the assessment of preoperative lymph 
node metastases in patients with esophageal can-
cer. In patients without neoadjuvant treatment, 
18F-FDG PET/CT had a pooled sensitivity and 
specificity of 57% (95%CI: 45–69%) and 91% 
(95%CI: 85–95), respectively. In patients who 
received neoadjuvant treatment, 18F- FDG PET/
CT had a pooled sensitivity and specificity of 53% 
(95%CI: 35–70%) and 96% (95%CI: 86–99%), 
respectively. Therefore, 18F- FDG PET/CT has a 
high specificity but a low sensitivity; thus, it can-
not accurately detect the lymph nodal involve-
ment in patients with esophageal cancer.
Shi et al. [52] also demonstrated that 18F-FDG 
PET/CT had lower sensitivity and accuracy for 
detection of regional nodal metastases in patients 
with esophageal cancer before surgery. The 
pooled sensitivity and specificity were 62% 
(95%CI: 40–79%) and 96% (95%CI: 93–98%), 
respectively, on a per-station analysis; the corre-
sponding values on a per-patient analysis were 
55% (95%CI: 34–74%) and 76% (95%CI: 
66–83%), respectively.
In this setting, cervical ultrasonography has 
very limited additional diagnostic value as sup-
plement to a negative 18F-FDG PET/CT in the 
detection of cervical lymph node metastases dur-
ing the initial staging of patients with esophageal 
cancer, as demonstrated by Goense et al. [53].
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5.5.2  Restaging
Restaging after neoadjuvant therapy aims to 
reduce the number of patients undergoing 
oesophagectomy in case of distant (interval) 
metastases. Kroese et al. [54] assessed the diag-
nostic performance of 18F-FDG PET or PET/CT 
for the detection of distant interval metastases 
after neoadjuvant therapy in patients with esoph-
ageal cancer. The pooled proportion of patients in 
whom true distant interval metastases were 
detected by 18F-FDG PET or PET/CT at restaging 
was 8% (95%CI: 5–13%). The pooled proportion 
of patients in whom false-positive distant find-
ings were detected by 18F-FDG PET or PET/CT 
at restaging was 5% (95%CI: 3–9%). In 
conclusion,18F-FDG PET or PET/CT at restaging 
after neoadjuvant therapy for esophageal cancer 
can considerably impact on treatment decision- 
making. However, pathological confirmation of 
suspected lesions is needed.
Cong et  al. [55] assessed the value of 18F-
FDG PET or PET/CT for response prediction of 
primary tumour in patients with esophageal 
cancer during (group A) or after (group B) neo-
adjuvant chemoradiotherapy. The pooled sensi-
tivity and specificity were 85% (95%CI: 
76–91%) and 59% (95%CI: 48–69%), respec-
tively, in group A. The equivalent values were 
67% (95%CI: 60–73%) and 69% (95%CI: 
63–74%), respectively, in group B. Interestingly, 
the pooled sensitivity was 90% in the studies 
that enrolled patients with esophageal squa-
mous cell carcinoma merely in group 
B. According to the present data, 18F-FDG PET/
CT should not be used routinely to guide treat-
ment strategy in esophageal cancer patients, but 
an additional value is expected in patients with 
esophageal squamous cell carcinoma treated 
with neoadjuvant chemoradiotherapy.
Goense et al. [56] assessed the diagnostic per-
formance of 18F-FDG PET or PET/CT for diag-
nosing recurrent esophageal cancer after initial 
treatment with curative intent. Pooled estimates 
of sensitivity and specificity for 18F-FDG PET 
and PET/CT in this setting were 96% (95%CI: 
93–97%) and 78% (95%CI: 66–86%), respec-
tively. Therefore, 18F-FDG PET and PET/CT are 
reliable imaging modalities with a high sensitiv-
ity and moderate specificity for detecting recur-
rent esophageal cancer after treatment with 
curative intent. However, histopathologic confir-
mation of PET/CT-suspected lesions is required, 
because a considerable false-positive rate is 
noticed.
5.5.3  Predictive and Prognostic 
Value
Han et al. [57] performed a meta-analysis on the 
prognostic value of volumetric parameters (MTV 
and TLG) derived from pretreatment 18F-FDG 
PET/CT in patients with esophageal cancer. The 
pooled HRs of MTV and TLG for OS were 2.26 
(95%CI: 1.73–2.96) and 2.23 (95%CI: 1.73–
2.87), respectively. Regarding event-free sur-
vival, the pooled HRs of MTV and TLG were 
2.03 (95%CI: 1.66–2.49) and 2.57 (95%CI: 
1.82–3.62), respectively. Therefore, in patients 
with esophageal cancer, MTV and TLG derived 
from pretreatment 18F-FDG PET are significant 
prognostic factors.
Schollaert et  al. [58] performed a meta- 
analysis on the predictive value of 18F-FDG PET 
for assessing DFS and OS in esophageal and 
oesophagogastric junction cancer after neoadju-
vant chemoradiation therapy. The pooled HRs for 
complete metabolic response versus no response 
were 0.51 for OS (95%CI: 0.4–0.64) and 0.47 for 
DFS (95%CI: 0.38–0.57), respectively. 
Therefore, metabolic response on 18F-FDG PET 
is a significant predictor of long-term survival.
Lastly, Zhu et  al. [59] performed a meta- 
analysis on the prognostic significance of 
SUVmax on 18F-FDG PET/CT in patients with 
localized oesophagogastric junction cancer 
receiving neoadjuvant chemotherapy/chemoradi-
ation therapy. Significant prognostic values of 
SUVmax before and during therapy in localized 
oesophagogastric junction cancer were not found. 
Conversely, relative changes in 18F-FDG-uptake 
after therapy are significant prognostic markers 
for OS and DFS.
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obtain permission directly from the copyright holder.
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Fluorine-18 fluorodeoxyglucose positron emis-
sion tomography/computed tomography (18F- 
FDG PET/CT) is currently used in daily clinical 
practice for the evaluation of breast cancer (BC) 
patients. This chapter provides an overview of 
the current evidence-based data on the useful-
ness of PET/CT (using 18F-FDG and other 
radiotracers) for different indications in patients 
with BC.
6.2  Staging
A recent network meta-analysis comparing 19 
different imaging methods demonstrated the rela-
tively higher specificity of 18F-FDG PET/CT 
compared to other imaging methods for the 
detection of BC lesions [1].
Liang et  al. [2] evaluated through a meta- 
analytic approach the accuracy of magnetic reso-
nance imaging (MRI) and 18F-FDG PET/CT for 
lymph nodal (N) staging of early BC. The pooled 
specificities of MRI and PET/CT for diagnosing 
regional lymph nodal status in BC patients were 
similar (93%); however, the pooled sensitivity of 
MRI was significantly greater than PET/CT (82% 
versus 64%), respectively.
Hong et al. [3] performed a meta-analysis to 
evaluate the value of 18F-FDG PET/CT for diag-
nosis of distant metastases of BC. Pooled sensi-
tivity and specificity of 18F-FDG PET/CT were 
96% (95%CI: 90–98%) and 95% (95%CI: 
92–97%), respectively. Compared with conven-
tional imaging, 18F-FDG PET/CT has higher sen-
sitivity for diagnosis of distant metastases in BC 
patients.
Similar findings were reported in another 
meta-analysis by Sun et al. [4]: pooled sensitivity 
and specificity of 18F-FDG PET or PET/CT were 
99% (95%CI: 88–100%) and 95% (95%CI: 
89–98%), respectively, confirming the excellent 
diagnostic performance of 18F-FDG PET/CT for 
distant metastasis staging in BC patients com-
pared to conventional imaging.
Rong et al. [5] found that the pooled sensitiv-
ity and specificity of 18F-FDG PET/CT for detect-
ing bone metastases of BC were 93% (95%CI: 
82–98%) and 99% (95%CI: 95–100%), respec-
tively. Compared with bone scintigraphy, 
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18F- FDG PET/CT has higher sensitivity and 
accuracy for detection of bone metastases in BC 
patients.
6.3  Restaging and Assessment 
of Response to Neoadjuvant 
Therapy
Evangelista et al. [6] performed a meta-analysis 
on the use of tumour markers in BC patients as a 
guide for 18F-FDG PET imaging. The meta- 
analysis provided the following results: pooled 
sensitivity 87.8% (95%CI: 83.8–90.9%) and 
pooled specificity 69.3% (95%CI: 55.3–80.5%), 
confirming the role of 18F-FDG PET/CT in 
detecting metastases in the presence of a progres-
sive increase of serum tumour markers in BC 
patients.
Xiao et al. [7] found that the pooled sensitivity 
and specificity of 18F-FDG PET or PET/CT in 
detecting BC recurrence were 90% (95%CI: 
88–90%) and 81% (95%CI: 78–84), respectively. 
Therefore, 18F-FDG PET/CT is a valuable imag-
ing method to detect relapse in suspected recur-
rent BC patients.
Several meta-analyses evaluated the useful-
ness of 18F-FDG PET/CT in predicting the 
response to neoadjuvant therapy in BC patients. 
According to Wang et al. [8], the pooled sensitiv-
ity, specificity, positive predictive value (PPV) 
and negative predictive value (NPV) of 18F-FDG 
PET/CT in this setting were 84% (95%CI: 
78–88%), 66% (95%CI: 62–70%), 50% (95%CI: 
44–55%) and 91% (95%CI: 87–94%), respec-
tively. For regional lymph nodes, sensitivity and 
NPV of 18F-FDG PET/CT were 92% (95%CI: 
83–97%) and 88% (95%CI: 76–95%), respec-
tively. Overall, 18F-FDG PET/CT is useful to pre-
dict neoadjuvant therapy response in BC patients, 
but the relatively low specificity and PPV still 
call for caution. Cheng et  al. [9] found similar 
results of 18F-FDG PET/CT in this setting report-
ing a pooled sensitivity and specificity of 84.7% 
(95%CI: 79.3–89.2%) and 66.1% (95%CI: 59.8–
72.0%), respectively, indicating that 18F-FDG 
PET/CT has reasonable sensitivity in evaluating 
response to neoadjuvant chemotherapy in BC, 
but the specificity is relatively low. Mghanga 
et  al. [10] found that 18F-FDG PET has moder-
ately high sensitivity (80.5%; 95%CI: 75.9–
84.5%) and specificity (78.8%; 95%CI: 
74.1–83.0%) in early detection of responders 
from nonresponders, and it can be used for the 
evaluation of response to neoadjuvant chemo-
therapy in BC patients. Another meta-analysis 
[11] reported that the pooled sensitivity and spec-
ificity of 18F-FDG PET/CT in this setting were 
81.9% (95%CI: 76.0–86.6%) and 79.3% (95%CI: 
72.1–85.1%), respectively, confirming the mod-
erate accuracy of 18F-FDG PET/CT in predicting 
neoadjuvant therapy response in BC patients.
Several meta-analyses compared 18F-FDG 
PET/CT and MRI for evaluation of treatment 
response to neoadjuvant chemotherapy (NAC) in 
BC patients. Liu et al. [12] reported that 18F-FDG 
PET/CT has a higher sensitivity and MRI has a 
higher specificity in assessing pathological com-
plete response (pCR) after NAC in BC patients. 
The pooled sensitivity and specificity of 18F-FDG 
PET/CT were 86% (95%CI: 76–93%) and 72% 
(95%CI: 49–87%), respectively. Therefore, the 
combined use of these two imaging modalities 
may have great potential to improve the diagnostic 
performance in assessing pCR after NAC. Another 
meta-analysis [13] indicates that the timing of 
imaging for NAC-response assessment exerts a 
major influence on the estimates of diagnostic 
accuracy: 18F-FDG PET/CT outperformed MRI in 
intra-NAC assessment, whereas the overall perfor-
mance of MRI was higher after completion of 
NAC, before surgery. The pooled estimates of sen-
sitivity and specificity were 71% and 77% for 18F-
FDG PET/CT and 88% and 55% for MRI, 
respectively. Chen et al. [14] found that the diag-
nostic performance of MRI is similar to that of 18F-
FDG PET/CT for the assessment of BC response 
to NAC. For 18F-FDG PET/CT, the pooled sensi-
tivity was 87% (95%CI: 71–95%) and pooled 
specificity was 85% (95%CI: 70–93%). For MRI, 
the pooled sensitivity was 79% (95%CI: 68–87%) 
and the pooled specificity was 82% (95%CI: 
72–89%). However, 18F- FDG PET/CT is more 
sensitive than conventional contrast-enhanced 
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MRI and more specific if the second imaging scan 
is performed before three cycles of NAC. Lastly, 
Li et al. [15] found that MRI had a higher sensitiv-
ity and 18F-FDG PET/CT had a higher specificity 
in predicting the pathologic response after NAC in 
patients with BC, with similar accuracy among the 
two methods. The pooled sensitivity and specific-
ity of MRI were 88% (95%CI: 78–94%), and 69% 
(95%CI: 51–83%), respectively. The correspond-
ing values for 18F-FDG PET/CT were 77% 
(95%CI: 58–90%) and 78% (95%CI: 63–88%), 
respectively.
6.4  Prognostic Value
Diao et al. [16] evaluated the prognostic value of 
maximum standardized uptake values (SUVmax) 
measured in the primary lesion and axillary 
lymph nodes (ALN) by pretreatment 18F-FDG 
PET or PET/CT in patients with BC. For event- 
free survival (EFS), patients with higher SUVmax 
in primary tumour and ALN showed a poorer 
prognosis with pooled hazard ratio (HR) of 1.96 
(95%CI: 1.40–2.73) and 1.89 (95%CI: 0.70–
5.07), respectively. In analysing invasive ductal 
carcinoma (IDC) patients, the pooled HR was 
1.91 (95%CI: 1.40–2.64). For overall survival 
(OS), the pooled HR of SUVmax in primary 
lesion and ALN were 0.64 (95%CI: 0.23–1.84) 
and 1.09 (95%CI 0.07–16.53), respectively. 
Therefore, patients with BC and higher SUVmax 
in primary lesion or ALN may experience a 
higher risk for recurrence or a poor progression.
6.5  Incidental 18F-FDG Uptake
A meta-analysis calculated the prevalence and 
clinical significance of breast incidental 18F-FDG 
uptake (BIU) detected by PET or PET/CT in 
patients performing PET for other reasons than 
BC evaluation [17]. The pooled prevalence of 
BIU on all PET scans was 0.4% (95%CI: 0.23–
0.61%), the pooled prevalence on PET scans on 
female patients only was 0.82% (95%CI: 0.51–
1.2%), the pooled risk of malignancy of BIU 
when further evaluated was 48% (95%CI: 
38–58%) and the pooled risk of malignancy of 
BIU with histological examination was 60% 
(95%CI: 53–66%). Despite being uncommon, 
the identification of BIU frequently signals the 
presence of an unsuspected subclinical lesion and 
the risk of malignancy is very high.
6.6  18F-FDG Positron Emission 
Mammography
The diagnostic performance of dedicated 18F- 
FDG positron emission mammography (PEM) in 
evaluating suspicious BC has been investigated 
by a meta-analytic study [18]: pooled sensitivity 
and specificity of 18F-FDG PEM in women with 
suspected breast malignancy were 85% (95%CI: 
83–88%) and 79% (95%CI: 74–83%), respec-
tively, on a per-lesion-based analysis. The detec-
tion of additional breast lesions and extensive 
intraductal involvement is improved by PEM, 
with comparable accuracy over that of MRI in the 
depiction of invasive BC.
6.7  PET/MRI
Lin et  al. [19] performed a meta-analysis to 
assess the staging/restaging performance of 
hybrid 18F-FDG PET/MRI in BC patients. The 
pooled sensitivity and specificity of 18F-FDG 
PET/MRI for staging/restaging BC were 98% 
(95%CI: 95–99%) and 87% (95%CI: 76–95%), 
respectively, on a per-patient analysis and 91% 
(95%CI: 88–94%) and 95% (95%CI: 92–97%), 
respectively, on a per-lesion analysis. Overall, 
18F-FDG PET/MRI has excellent diagnostic per-
formance in staging/restaging BC patients.
6.8  Other PET Tracers Beyond 
18F-FDG
Evangelista et  al. [20] assessed the role of 
18F-fluoroestradiol (18F-FES) PET in patients 
with BC. A pooled sensitivity of 82% (95%CI: 
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74–88%) and a pooled specificity of 95% 
(95%CI: 86–99%) for the evaluation of oestrogen 
receptor status in BC by 18F-FES PET were 
found, demonstrating a good accuracy of this 
method in this setting. Conversely, the pooled 
sensitivity and specificity of 18F-FES PET in pre-
dicting the response to hormonal therapy in 
patients with locally advanced or metastatic BC 
were unsatisfactory.
Deng et  al. [21] evaluated the diagnostic 
performance of 18F-fluorothymidine (18F-FLT) 
PET and PET/CT for evaluating the response 
to chemotherapy in patients with BC.  The 
pooled sensitivity and specificity of 18F-FLT 
PET in this setting were 77.3% (95%CI: 59.4–
90%) and 68.5% (95%CI: 47.9–84.9%), 
respectively, with a moderate diagnostic 
accuracy.
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Evidence-based data about the usefulness of pos-
itron emission tomography (PET) and hybrid 
imaging methods (PET/CT and PET/MRI) in 
abdominal and pelvic tumours have been col-
lected and discussed in this chapter. These data 
were divided in three sections: (1) gastrointesti-
nal tumours, (2) uro-genital tumours, (3) gynae-
cological tumours. Several pooled data 
(diagnostic and prognostic data), clinical settings 
(e.g. staging, restaging, treatment evaluation) and 
radiotracers as fluorine-18 fluorodeoxyglucose 
(18F-FDG), radiolabelled choline and prostate- 
specific membrane antigen (PSMA) were 
considered.
7.2  PET in Gastrointestinal 
Tumours
Fifty-two meta-analyses on the role of PET imag-
ing in gastrointestinal tumours have been selected 
[1–52]. Pooled data about PET/CT in colorectal 
cancer, gastric cancer, anal cancer, stromal 
tumours, hepato-biliary tumours, liver metastases 
and pancreatic cancer have been reported in 
Table 7.1.
7.2.1  Colorectal Cancer
Fourteen meta-analyses about 18F-FDG PET/CT 
in colorectal cancer have been found [1–14]. 
Two meta-analyses evaluated the role of this 
imaging method in a staging setting, showing 
good specificity but low sensitivity [4, 13]. 
Similarly, two studies showed high accuracy in a 
restaging setting [7, 12]. Some meta-analyses 
assessed sub- optimal accuracy in treatment eval-
uation [3, 6, 8, 10, 14]. Recent meta-analyses 
found that focal colorectal incidental uptake at 
18F-FDG PET/CT is observed in a not negligible 
number of patients who undergo this imaging 
method with a high risk of malignant or prema-
lignant lesions [2, 9]. Finally, poor predictive or 
prognostic role of 18F- FDG PET/CT in colorec-
tal cancer emerged [1, 5, 11].
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specificity PFS HR OS HR
Colorectal cancer Kim et al. [1] Prediction 0.66 0.67 – –
Son et al. [2] Characterization 0.87 0.83 – –
Rymer et al. [3] Treatment 
evaluation
– – – –
Ye et al. [4] T staging 0.73 0.99 – –
Xia et al. [5] Prognosis – – 0.45 0.36
Maffione et al. [6] Treatment 
evaluation
0.73 0.77 – –
Yu et al. [7] Restaging 0.94 0.94 – –
Li et al. [8] Treatment 
evaluation
0.81 – – –
Treglia et al. [9] Characterization – – – –
Li et al. [10] Treatment 
evaluation
0.78 0.81 – –
Krug et al. [11] Prognosis – – 0.70 0.39
Lu et al. [12] Restaging 0.90 0.80 – –
Lu et al. [13] N staging 0.43 0.88 – –
Zhang et al. [14] Treatment 
evaluation
0.78 0.66 – –
Gastric cancer Luo et al. [15] N staging 0.52 0.88 – –
Wu et al. [16] Prognosis – – 1.70 1.72
Li et al. [17] Restaging 0.85 0.78 – –
Zou et al. [18] Restaging 0.86 0.88 – –
Cui et al. [19] Staging 0.92 0.89 – –
Wu et al. [20] Restaging 0.78 0.82 – –
Seevaratnam et al. 
[21]
N staging 0.40 0.98 – –
Anal cancer Sadeghi et al. [22] Prognosis – – 5.36 5.87
Albertsson et al. 
[23]
RT planning – – – –
Mahmud et al. [24] N staging 0.93 0.76 – –
Jones et al. [25] Staging 0.99 – – –
Caldarella et al. 
[26]
N staging 0.56 0.90 – –
Stromal tumours 
(GIST)





0.90 0.62 – –
Hepato-biliary 
tumours
Liao et al. [29] Restaging 0.64 0.95 – –
Hu et al. [30] Staging 0.80 0.70 – –
Sun et al. [31] Prognosis – – 7.2 2.1
Annunziata et al. 
[32]
Staging 0.87 0.78 – –
Zhang et al. [33] Staging 0.91 0.81 – –
Bertagna et al. [34] Staging – – – –
Chou et al. [35] M staging 0.82 – – –
Annunziata et al. 
[36]
Staging 0.81 0.82 – –
Lin et al. [37] M staging 0.77 0.98 – –
S. Annunziata et al.
61
7.2.2  Gastric Cancer
Seven meta-analyses analysed the role of 18F- 
FDG PET/CT in gastric cancer [15–21]. Three 
meta-analyses found a good accuracy in a staging 
setting, but with low sensitivity in detecting 
lymph nodal (N) involvement [15, 19, 21]. 
Conversely, other meta-analyses showed a good 
accuracy in a restaging setting [17, 18, 20]. Only 
one evidence-based article demonstrated a sub- 
optimal prognostic value of 18F-FDG PET/CT in 
gastric cancer [16].
7.2.3  Anal Cancer
Five meta-analyses about 18F-FDG PET/CT in 
anal cancer have been included [22–26]. Some 
meta-analyses evaluated the role in a staging set-
ting, with discordant accuracy values [24–26]. 
One meta-analysis found a strong prognostic 
power of 18F-FDG PET parameters for progression 
free survival (PFS) and overall survival (OS) [22]. 
Finally, another meta-analysis assessed the role of 
18F-FDG PET/CT in radiotherapy planning [23].
7.2.4  Stromal Tumours (GIST)
Two meta-analyses about the role of 18F-FDG 
PET/CT in treatment evaluation and prediction 
of malignant potential in patients with GIST 
have been found and included [27, 28], suggest-
ing a role of this imaging method in these 
settings.
7.2.5  Hepato-biliary Tumours
Nine meta-analyses about 18F-FDG PET/CT in 
hepatic and biliary tumours have been included 
[29–37]. Some meta-analyses found a role of 18F- 
FDG PET/CT in a staging setting, in particular 
about detection of distant metastases (M) [30, 32, 
33, 35–37]. One meta-analysis found low sensi-
tivity in a restaging setting [29]. Conversely, 
another meta-analysis showed high prognostic 
power for PFS by 18F-FDG PET/CT in hepato- 
biliary tumours [31]. Beyond 18F-FDG, radiola-
belled choline PET/CT showed a good detection 






specificity PFS HR OS HR
Liver metastases Choi et al. [38] Staging 0.74 0.94 – –
Samim et al. [39] Treatment 
evaluation
0.84 0.92 – –
Maffione et al. [40] Staging 0.93 0.93 – –
Deng et al. [41] Staging 0.84 0.99 – –
Zheng et al. [42] Treatment 
evaluation
0.79 0.84 – –
Poulu et al. [43] Restaging 0.73 0.85 – –




0.54 n/a – –
Pancreatic cancer Daamen et al. [45] Restaging 0.88 0.89 – –
Wang et al. [46] M staging – – – –
Zhu et al. [47] Prognosis – – 1.90 1.70
Toft et al. [48] Staging 0.89 0.70 – –
Best et al. [49] Characterization 0.92 0.65 – –
Rijkers et al. [50] Characterization 0.90 0.76 – –
Wang et al. [51] Staging/prognosis 0.91 0.81 – 2.39
Wu et al. [52] Staging 0.87 0.83 – –
HR hazard ratio, PFS progression free survival, OS overall survival
Table 7.1 (continued)
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7.2.6  Liver Metastases
Seven meta-analyses about the role of 18F-FDG 
PET/CT in detecting liver metastases from differ-
ent primary tumours have been found [38–44]. 
Some studies showed high specificity in a staging 
setting [38, 40, 41]. One study found a sub- 
optimal sensitivity also in a restaging setting 
[43]. The role in treatment evaluation improved 
in a recent meta-analysis [42, 44].
7.2.7  Pancreatic Cancer
Eight meta-analyses about 18F-FDG PET/CT in 
pancreatic cancer have been published and 
included [45–52]. Interestingly, some papers 
showed good sensitivity in a staging setting [46, 
48, 51, 52]. Two studies demonstrated a good 
accuracy of this imaging method in characteriz-
ing pancreatic lesions [49, 50]. Finally, two 
 meta- analyses found a prognostic power for 18F-
FDG PET/CT in pancreatic cancer [47, 51].
7.3  PET in Gynaecological 
Tumours
Thirty-three meta-analyses on the role of 18F- 
FDG PET imaging in gynaecological tumours 
have been selected [53–82]. Pooled data about 
18F-FDG PET/CT in cervical cancer, endometrial 
cancer, ovarian cancer and peritoneal carcinoma-
tosis have been reported in Table 7.2.
7.3.1  Cervical Cancer
Twelve meta-analyses about the role of 18F-FDG 
PET/CT in cervical cancer have been included 
[53–64]. Some studies evaluated the role of 18F- 
FDG PET/CT in staging cervical cancer, showing 
low sensitivity and high specificity in N staging 
[53, 56, 64]. Several studies evaluated the role of 
18F-FDG PET/CT in a restaging setting, with 
high values of sensitivity and specificity [55, 58–
61, 63]. Some meta-analyses found a prognostic 
role of 18F-FDG PET/CT in cervical cancer [54, 
57, 62].
7.3.2  Endometrial Cancer
Seven meta-analyses about the role of 18F-FDG 
PET/CT in endometrial cancer have been 
included [65–71]. Some meta-analyses evaluated 
the role of 18F-FDG PET/CT in a staging or 
restaging setting, showing good values of sensi-
tivity and specificity [65, 68–71]. Conversely, 
one meta-analysis showed low sensitivity in N 
staging [71]. Finally, some meta-analyses showed 
a prognostic role of 18F-FDG PET/CT for PFS 
[66, 67].
7.3.3  Ovarian Cancer
Six meta-analyses about 18F-FDG PET/CT in 
ovarian cancer have been found [72–77]. Some 
meta-analyses showed high accuracy of this 
imaging method in a restaging setting [74–76]. 
Conversely, some meta-analyses showed 
 sub- optimal sensitivity in N and M staging [72, 
77]. Only one meta-analysis showed a good 
prognostic power of 18F-FDG PET/CT in ovarian 
cancer, with particular regard to OS [73].
7.3.4  Peritoneal Carcinomatosis
Three meta-analyses were focused on the role of 
18F-FDG PET/CT in peritoneal carcinomatosis, 
showing good values of sensitivity and specific-
ity of this method in this setting [78–80].
7.3.5  PET/MRI
Finally, recent studies evaluated the role of 18F- 
FDG PET/MRI in gynaecological malignancies, 
showing optimal diagnostic accuracy values 
[81, 82].
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7.4  PET in Uro-genital Tumours
Thirty-five meta-analyses on the role of PET 
imaging in uro-genital tumours have been 
selected [83–117]. In particular, pooled data 
about radiolabelled choline, PSMA and fluciclo-
vine PET/CT in prostate cancer and 18F-FDG 
PET/CT in bladder cancer, renal cell carcinoma, 
testicular and penile cancer have been included 
(Table 7.3).
7.4.1  Prostate Cancer
7.4.1.1  Radiolabelled Choline PET 
for Prostate Cancer
Several meta-analyses described a very high 
specificity for detection of local lymph node 
involvement and for detection of distant metasta-
ses of prostate cancer by using radiolabelled cho-
line PET.  Radiolabelled choline PET is also 
widely used in patients with suspected biochemi-





specificity PFS HR OS HR
Cervical cancer Ruan [53] N staging 0.72 0.96 – –
Han [54] Prognosis – – 5.89 6.62
Zhou [55] Restaging 0.97 0.81 – –
Liu [56] N staging 0.66 0.96 – –
Sarker [57] Prognosis – – 2.66 2.45
Xiao [58] Restaging 0.94 0.92 – –
Ding [59] Restaging 0.92 0.94 – –
Meads [60] Restaging 0.95 0.87 – –
Chu [61] Restaging 0.87 0.97 – –
Zhao [62] Prognosis – – – 2.06
Meads [63] Restaging 0.92 0.88 – –
Gong [64] N staging 0.68 0.97 – –
Endometrial cancer Bollineni [65] Restaging 0.95 0.91 – –
Pan [66] Prognosis – – 3.33 1.31
Ghooshkhanei 
[67]
Prognosis – – 7.4 –
Kakhki [68] Staging 0.82 0.90 – –
Sadeghi [69] Restaging 0.92 0.96 – –
Kadkhodayan 
[70]
Restaging 0.96 0.92 – –
Chang [71] N staging 0.63 0.95 – –
Ovarian cancer Han [72] M staging 0.72 0.93 – –
Han [73] Prognosis – – 2.50 8.06
Suppiah [74] Restaging 0.90 0.90 – –
Xu [75] Restaging 0.92 0.91 – –
Limei [76] Restaging 0.87 0.90 – –
Yuan [77] N staging 0.73 0.97 – –
Peritoneal carcinomatosis Kim [78] Diagnosis 0.87 0.92 – –
Li [79] Diagnosis 0.84 0.98 – –
Chang [80] Diagnosis 0.72 0.97 – –
PET/MRI Zheng [81] Restaging 0.96 0.95 – –
Nie [82] Staging 0.95 0.95 – –
HR hazard ratio, PFS progression free survival, OS overall survival
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Table 7.3 Main findings of meta-analyses about the role of PET imaging in uro-genital tumours
Tumours Authors Tracers Topic Sensitivity Specificity
Prostate 
cancer
Evangelista et al. [83] Choline N staging 0.49 0.95
Evangelista et al. [85] Choline Restaging 0.85 –
Evangelista et al. [84] Choline Staging 0.86 0.93
Fanti et al. [86] Choline Restaging 0.89 0.89
Guo et al. [90] Choline M staging 0.89 0.98
Liu et al. [92] Several tracers Staging 0.83 (choline) 0.93 (choline)
Beheshti et al. [93] Acetate Staging 0.75 0.76
Ouyang et al. [94] Several tracers Staging 0.78 (choline) 0.90 (choline)
Ren et al. [115] Fluciclovine Restaging 0.87 0.66
Sathianathen et al. 
[116]








Shen et al. [91] Choline M staging 0.91 0.99
Treglia et al. [88] Choline Restaging – –
Umbehr et al. [87] Choline Staging 0.84 0.79
Von Eyben et al. [95] Choline M restaging – –
Wei et al. [89] Choline Staging 0.82 0.92
Bertagna et al. [117] FDG Prediction – –
Corfield et al. [96] PSMA Staging – –
Han et al. [98] PSMA Management n/a n/a
Kim et al. [99] PSMA Staging 0.71 0.95
Pereira et al. [102] PSMA Restaging – –
Perera et al. [100] PSMA Staging 0.86 0.86
von Eyben [101] PSMA Staging 0.70 0.84
Hope et al. [97] PSMA Restaging 0.74 0.96
Bladder 
cancer
Lu et al. [105] FDG Staging 0.90 1
Soubra et al. [106] FDG Prediction 0.56 0.95
Wang et al. [107] FDG Staging 0.80 0.84
Zhang et al. [108] FDG Staging 0.82 0.92
Ha et al. [104] FDG N staging 0.57 0.92
Crozier et al. [103] FDG Staging 0.56 0.92
Kim et al. [109] Choline and acetate N staging 0.66 0.89
Testicular 
cancer
Zhao et al. [112] FDG Staging 0.75 0.87





Wang et al. [111] FDG Staging 0.91 0.88
Ma et al. [110] FDG Restaging 0.86 0.88
Penile 
cancer
Sadeghi et al. [114] FDG N staging 0.81 0.92
FDG fluorodeoxyglucose, PSMA prostate-specific membrane antigen
cal relapse after initial treatments, even as a guide 
for salvage lymph node dissection [83–87]. 
Additionally, PSA kinetics was shown to be 
strongly related to the detection rate in patients 
undergoing radiolabelled choline PET [88]. 
Similarly, high PSA trigger was shown to be an 
important risk factor for positive findings of 
radiolabelled choline PET/CT [89]. PET with 
radiolabelled choline is a well-established imag-
ing tool in clinical practice for detection of bone 
metastases [90, 91]. Diagnostic accuracy of 
radiolabelled choline PET was proven to be supe-
rior than other radiotracers as 18F-FDG and 
11C-acetate [92], even if 11C-acetate PET could be 
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considered in patients with relapse [93]. 
18F-fluorocholine (FCH) PET showed higher 
specificity than 11C-choline PET [94]. Conversely, 
the choice of 18F-FCH or 11C-choline might not 
affect the detection of metastases in restaging 
patients after primary surgery and/or radiother-
apy [95].
7.4.1.2  Radiolabelled PSMA PET 
in Prostate Cancer
Radiolabelled PSMA PET showed higher detec-
tion rate than other imaging modalities in pros-
tate cancer [96, 97]. It was also proven to alter 
significantly the clinical management of these 
patients [98]. Diagnostic performance of PSMA 
PET was high for detection of node involvement 
in intermediate- and high-risk prostate cancer 
patients [99–101]. PSA kinetics may be predictor 
of radiolabelled PSMA PET positivity in patients 
with biochemical relapse [102]. PSMA detection 
rate ranged from 64% to 97% when PSA trigger 
was over 2 ng/ml at the time of scan [97].
7.4.1.3  Fluciclovine PET in Prostate 
Cancer
A meta-analysis demonstrated that fluciclovine 
(18F-FACBC) PET/CT had an 87% pooled sensi-
tivity and 66% pooled specificity in detecting 
prostate cancer recurrence, being a useful imag-
ing method in this setting [115].
7.4.1.4  Incidental 18F-FDG Uptake 
in the Prostate
A meta-analysis demonstrated that incidental 18F- 
FDG uptake in the prostate is observed in about 
2% of 18F-FDG PET/CT scans performed in male 
patients carrying a significant risk of malignancy. 
Therefore, whenever this finding is detected fur-
ther investigation is warranted to exclude malig-
nancy [117].
7.4.2  Bladder Cancer
Several evidence-based articles were focused on 
the clinical usefulness of 18F-FDG PET/CT in 
patients with bladder cancer [103–109]. An over-
all sensitivity and specificity of 82% and 92% 
was reported, respectively [108]. Sensitivity and 
specificity were 90% and 100%, respectively, for 
primary staging, and 82% and 89%, respectively, 
for restaging [105]. For detection of node metas-
tases, specificity was found high, whereas sensi-
tivity was poor [103, 104, 106]. Additionally, 
detection of node involvement was assessed by 
other radiopharmaceuticals such as 11C-choline 
or 11C-acetate [109], showing low sensitivity and 
moderate specificity.
7.4.3  Renal Cell Carcinoma
Values of sensitivity and specificity of 18F-FDG 
PET/CT were 86% and 88%, respectively, for 
detection of recurrence [110]. If diagnostic per-
formance of 18F-FDG PET/CT for detection of 
recurrent renal and extra-renal lesions was 
assessed separately, sensitivity and specificity of 
extra-renal lesions was found superior than accu-
racy for renal lesions [111].
7.4.4  Testicular and Penile Cancer
18F-FDG-PET sensitivity was non-optimal in the 
evaluation of patients with testicular cancer 
[112]. Similar results were drawn if PET was per-
formed after chemotherapy treatment in patients 
with seminoma [113]. Clinical usefulness of 18F- 
FDG PET for detection of metastatic inguinal 
lymph nodes in patients with penile cancer is 
controversial [114].
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PET/CT is extremely useful method in cutaneous 
and musculoskeletal tumours. In this chapter, the 
evidence from the literature concerning PET or 
PET/CT in melanoma, sarcomas, bone metasta-
ses, cancer of unknown primary (CUP) and para-
neoplastic syndromes were analysed.
8.2  PET in Malignant Melanoma
8.2.1  Introduction
Melanoma is a highly malignant tumour hav-
ing its origin in melanocytes from the epider-
mal skin layer. As prognosis is highly 
dependent on lymph node involvement and 
presence of distant metastases at the time of 
diagnosis, a precise staging is important for 
determining prognosis and choosing the fittest 
therapy for the patient [1–4].
8.2.2  Staging
18F-FDG PET/CT in staging melanoma has to be 
performed as a whole body protocol from head to 
toe to visualize the whole skin. Nonetheless, the 
usefulness of 18F-FDG PET/CT is limited in stag-
ing of tumour expansion and detection of satellite 
metastases. For the recognition of lymph nodal 
metastases, ultrasound and histological examina-
tion of the sentinel lymph node have a higher sen-
sitivity and specificity than 18F-FDG PET/CT [5, 
6]. Vural Topuz et al. showed that 18F-FDG PET/
CT is probably negative in the first year post- 
surgery if the sentinel lymph node biopsy was 
negative. Hence, performance of 18F-FDG PET/
CT is not recommended in early stage melanoma 
for not providing any significant clinical contri-
bution [7].
In contrast, 18F-FDG PET/CT is well estab-
lished for imaging of distant metastases. In a 
meta-analysis of nine studies, Rodriguez Rivera 
et al. found out usefulness of 18F-FDG PET/CT in 
staging of stage III melanoma having a high sen-
sitivity (89.4%) and specificity (88.8%) [8]. Also 
Xing et al. valued 18F-FDG PET/CT as the most 
sensitive and specific method for detecting dis-
tant metastases [6]. 18F-FDG PET/CT is even 
superior to morphologic imaging and has 
replaced CT and magnetic resonance imaging 
(MRI) almost completely [1].
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8.2.3  Restaging and Treatment 
Monitoring
The early detection of disease progression or 
recurrence has a huge impact on prognosis of 
melanoma. The usefulness of 18F-FDG PET/CT 
has been proven not only for the staging of 
advanced melanoma but also for the detection of 
recurrences showing a sensitivity of 96% and a 
specificity of 92% [7]. Accordingly, 18F-FDG 
PET/CT frequently leads to a change of treat-
ment plan [6]. Due to a scarce number of pro-
spective studies regarding use of 18F-FDG PET/
CT in melanoma, more studies are needed to find 
the most effective and cost-effective intervals in 
follow-up.
8.3  PET in Sarcomas
8.3.1  Introduction
Sarcomas are malignant tumours originating 
from mesenchymal cells. They are a relatively 
rare cancer and represent only 1% of all malig-
nant tumours but extremely frequent in children. 
They can be divided in soft tissue, osseous and 
chondral sarcomas. Soft tissue sarcomas are a 
group of heterogeneous tumours as rhabdomyo-
sarcoma, leiomyosarcoma, fibrosarcoma, lipo-
sarcoma, angiosarcoma, etc. and they are the 
fourth most common solid tumours in children. 
The bone sarcomas are the osteosarcoma and the 
Ewing sarcoma. Classical imaging methods for 
sarcomas are X-ray, CT for control of stability 
and MRI for the illustration of the expansion in 
soft tissues. Biopsy and histopathological exami-
nation ensure diagnosis [9, 10].
8.3.2  Staging
PET/CT offers the possibility of simultaneous 
acquisition of bone lesions and their expansion in 
soft tissue and is very useful for the staging of 
sarcomas due to its high sensitivity, specificity 
and accuracy. The performance of 18F-FDG PET/
CT in the initial staging provides information of 
the initial metabolism activity of the tumour. This 
is important for the follow-up and the evaluation 
of the therapy response [11]. About 18F-FDG 
PET/CT in sarcomas, according to evidence- 
based data, the values vary between 86 and 96% 
for sensitivity and from 80 to 96% for specificity 
[12–15]. In particular, this hybrid imaging 
method is very useful for detecting distant metas-
tases, as osseous and lung metastases [12, 15]. 
Furthermore, 18F-FDG PET/CT might have a rel-
evant impact on the development of treatment 
strategy plan [15]. Additional to the high diag-
nostic quality, 18F-FDG PET/CT has also a prog-
nostic value in sarcomas. Chen et al. found out 
that semi-quantitative PET parameters showed a 
significant prognostic value for overall survival 
and thus are useful tools in identifying high-risk 
patients [16]. These findings were confirmed by 
other authors reporting that a high maximum 
standardized uptake value (SUVmax) may pre-
dict a significantly shorter overall survival period 
[17].
8.3.3  Restaging and Treatment 
Monitoring
18F-FDG PET/CT is a valuable method for detect-
ing post-surgery recurrence in patients with sar-
comas [12]. Liu et al. found a sensitivity of 92% 
and a specificity of 93% for the detection of 
recurrence in sarcoma [14]. Hongtao et  al. 
reported that 18F-FDG PET/CT is valuable for 
predicting the histological response to chemo-
therapy as they found a response to neoadjuvant 
chemotherapy in osteosarcomas with a sensitiv-
ity of 73% and a specificity of 86% [18]. 
Muheremu et al. showed that 18F-FDG PET/CT 
assesses the efficacy of neoadjuvant therapy with 
a sensitivity and specificity of 79% and thus is a 
reliable imaging method not only in diagnosis but 
also in treatment control of osseous and soft tis-
sue tumours [13]. Also Chen et al. valued post- 
treatment SUVmax as useful in monitoring 
therapy response [16]. Li et al. had similar results 
confirming that SUVmax before and after che-
motherapy has effective prognostic significance 
for survival outcomes [19].
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8.4  PET for Bone Metastases
8.4.1  Introduction
Bone metastases originate most frequently from 
breast cancer in women and from prostate carci-
noma in men (each 60%) followed by lung carci-
noma (25%), renal cell and thyroid carcinoma. 
Bone metastases can be differentiated in osteo-
blastic metastases which are typical for the pros-
tate carcinoma, osteolytic metastases which 
occur in renal cell, thyroid or colon carcinomas 
and mixed osteoblastic and osteolytic metasta-
ses for example from breast or lung cancer. 
They are localized often in the spine (60%) but 
also in the pelvis, proximal femur and skull, 
rarely in distal bones. Symptoms are mainly 
pain, radicular symptoms if a spine metastasis 
causes nerve root compression and functional 
impairment. Furthermore, metastases can cause 
instability of the bone with the consequent risk 
of fracture [20].
8.4.2  Detection of Bone Metastases
The probably most frequently performed imag-
ing method for osseous staging is the bone scin-
tigraphy (BS). In the actual development, this 
method is being replaced by PET/CT with differ-
ent tracers as 18F-FDG (which has the advantage 
to represent nearly all body districts) and 
18F-Fluoride which is more osseous specific. In a 
meta-analysis, Liu et  al. found a sensitivity of 
93% and a specificity of 95% for 18F-fluoride 
PET/CT in the detection of bone metastases. This 
method showed significantly higher sensitivity 
and specificity compared to BS and thus a supe-
rior diagnostic performance in bone metastases 
detection and higher accuracy [21]. Shen et  al. 
achieved similar results showing a sensitivity of 
92% and a specificity of 93% for 18F-fluoride 
PET/CT.  Compared with BS, it showed both 
higher sensitivity and specificity, whereas com-
pared with 18F-FDG PET/CT it showed only a 
higher sensitivity but no significant difference in 
specificity. Consequently, the authors describe an 
excellent diagnostic capacity for the detection of 
bone metastases and advantages compared with 
BS and 18F-FDG PET/CT [22].
Duo et al. analysed the performance of PET/
CT with different tracers in comparison with 
gadolinium- enhanced MRI for detecting bone 
metastases: similar sensitivity and specificity val-
ues for each method were found and conse-
quently an excellent diagnostic performance for 
the detection of bone metastases for both meth-
ods [23]. On the contrary, regarding only verte-
bral metastases, MRI showed a better performance 
than PET/CT both in sensitivity and specificity. 
This procedure outranged also all other imaging 
methods as CT or BS with tomographic acquisi-
tion (SPECT) [24].
Concerning the prognostic value of 18F-FDG 
PET/CT, Jeong et al. showed that patients with 
solid tumours and a lower level of 18F-FDG 
uptake in the bone marrow have a better event 
free and overall survival than patients with 
higher bone marrow 18F-FDG uptake and there-
fore propose to use the 18F-FDG uptake in the 
bone marrow for risk stratification of tumour 
progression [25].





Cancer of unknown primary (CUP) is a syndrome 
defined by the presence of a metastatic disease 
without identified primary tumour. In 2–5% of all 
malignant tumours, the localization of the pri-
mary tumour is unknown. CUP occurs in a het-
erogeneous group of cancers most frequently in 
malignant melanoma, neuroendocrine tumours, 
carcinoids, small cell lung carcinoma and head 
and neck cancer. Despite of modern imaging 
methods, CUP remains a challenge in clinical 
routine. As prognosis is rather poor, the identifi-
cation of the primary tumour can be important to 
adjust therapy and improve survival [26].
Paraneoplastic syndromes arise from tumour 
secretion of hormones, peptides or cytokines or 
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from immune cross-reactivity between malignant 
and normal tissues. Paraneoplastic syndromes 
may affect diverse organ systems, most notably 
the endocrine, neurologic, dermatologic, rheu-
matologic and hematologic systems. The most 
commonly associated malignancies include small 
cell lung cancer, breast cancer, gynaecologic 
tumours and hematologic malignancies. In some 
instances, the timely diagnosis of these condi-
tions may lead to detection of an otherwise clini-
cally occult tumour at an early and highly 
treatable stage [27].
8.5.2  Impact of PET in Patients 
with CUP
Since patients with CUP syndrome usually 
underwent a vast diagnostic procedure with nega-
tive results, the patients setting in which 18F-FDG 
PET/CT is performed with this question is highly 
selected. Consequently, the search for a primary 
tumour in CUP syndrome is more difficult than in 
other diseases. Nevertheless, Burglin et al. found 
a detection rate of unknown primary tumours in 
41% of cases by using 18F-FDG PET/CT and they 
recommended an early use of 18F-FDG PET/CT 
to obviate too much useless diagnostic proce-
dures [28].
8.5.3  Impact of PET in Patients 
with Paraneoplastic 
Syndromes
In patients with suspected paraneoplastic syn-
drome, 18F-FDG PET/CT showed a high accu-
racy for the detection of underlying 
malignancies with a sensitivity of 81% and a 
specificity of 88% [29]. Also in patients with 
paraneoplastic neurological syndrome, 18F-
FDG PET/CT showed a high diagnostic per-
formance with a detection rate of 15%, a 
sensitivity of 87% and specificity of 86% [30]. 
Generally, a heterogeneity in study design and 
diagnostic workup and the small number of 
patients in the available studies reduce inter-
pretability of the data [29, 30].
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Haematological malignancies include lympho-
mas such as Hodgkin lymphoma (HL) and non- 
Hodgkin lymphoma (NHL), leukaemia and 
multiple myeloma (MM). They can affect any 
organ system and positron emission tomography/
computed tomography (PET/CT) has been 
accepted as part of the routine management of 
most of them. In this chapter were only consid-
ered recent systematic reviews and meta-analyses 
concerning the use of PET or PET/CT with 18F- 
FDG in haematological malignancies dividing 
the results by the main areas of application.
9.2  18F-FDG PET or PET/CT 
in Staging or Detection
In staging HL and more aggressive NHL sub-
types, 18F-FDG PET/CT was shown to be clearly 
more accurate than conventional radiological 
imaging to detect nodal and extranodal involve-
ment. On the other hand, recent meta-analyses 
have addressed the diagnostic performance of 
this imaging method in some types of NHL, in 
MM and in the assessment of bone marrow 
involvement of HL and NHL [1–9].
9.2.1  Post-transplant 
Lymphoproliferative Disorder
Montes de Jesus et al. [1] evaluated the perfor-
mance of advanced imaging modalities at diag-
nosis for post-transplant lymphoproliferative 
disorder (PTLD) after solid organ and haemato-
poietic stem cell transplantation. 18F-FDG PET/
CT was the primary imaging modality investi-
gated. Subgroup analysis of imaging results for 
detection and staging in patients with PTLD 
indicated that 18F-FDG PET/CT identified addi-
tional lesions not detected by conventional imag-
ing in 27.8% of cases, from which extranodal 
sites in 23.6%. False negative results occurred in 
11.5% of cases, predominantly in physiological 
high background activity regions and in early 
PTLD lesions. False positive results occurred in 
4.8% of cases, predominantly due to inflamma-
tory conditions. They concluded that 18F-FDG 
PET/CT is currently the most frequently investi-
gated imaging modality in PTLD patients with 
promising results in detection and staging, but 
available studies suffer from methodological 
shortcomings.
9.2.2  Follicular Lymphoma
Adams et al. [2] studied the additional value of 
18F-FDG PET to CT for staging newly diagnosed 
follicular lymphoma (FL) in terms of Ann Arbor 
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staging and Follicular Lymphoma International 
Prognostic Index (FLIPI) risk stratification. The 
proportion of patients who were upstaged by 18F- 
FDG PET compared with CT ranged from 0 to 
45.2%, with a pooled summary proportion of 
18.7% (95% confidence interval (95%CI): 10.8–
30.4%). The single study that only included 
patients with CT-based limited non-bulky stage I 
to II disease reported 18F-FDG PET-induced 
upstaging in 40.5% of cases. No study reported 
data on the influence of 18F-FDG PET on FLIPI 
risk stratification. Although upstaging by 18F- 
FDG PET compared with CT occurs in a consid-
erable proportion of patients, the available studies 
on this topic had numerous methodological 
errors. The authors concluded that future well- 
designed studies are needed before 18F-FDG PET 
can be recommended for routine pre-treatment 
staging of FL.
9.2.3  Marginal Zone Lymphoma 
of the Mucosa-Associated 
Lymphoid Tissue
Treglia et  al. [3] analysed the detection rate 
(DR) of 18F-FDG PET and PET/CT for the eval-
uation of patients with marginal zone lym-
phoma of the mucosa-associated lymphoid 
tissue (MALT). The pooled DR of 18F-FDG 
PET or PET/CT was 71% (95%CI: 61–80%). A 
significant difference between the DR of PET/
CT (69%; 95%CI: 61–80%) and that of PET 
alone (73%; 95%CI: 60–84%) was not demon-
strated. A better DR of 18F-FDG PET or PET/
CT in bronchial (94%; 95%CI: 85–99%) and 
head-and-neck (90%; 95%CI: 78–98%) MALT 
lymphomas compared with gastric (62%; 
95%CI: 46–77%) and ocular (49%; 95%CI: 
36–63%) MALT lymphomas was found. This 
meta-analysis demonstrated that MALT lym-
phoma is an 18F-FDG-avid tumour in most of 
the cases, suggesting a potential clinical role in 
the initial evaluation of these patients. In par-
ticular, the DR of 18F-FDG PET or PET/CT is 
related to the primary site of the MALT 
lymphoma.
9.2.4  Bone Marrow Involvement 
in Lymphoma
Adams et al. [4] analysed the diagnostic perfor-
mance of 18F-FDG PET/CT in detecting bone 
marrow involvement (BMI) in patients with 
newly diagnosed diffuse large B-cell lymphoma 
(DLBCL). The pooled sensitivity and specificity 
of 18F-FDG PET/CT for detecting BMI were 
88.7% (95%CI: 82.5–93.3%) and 99.8% (95%CI: 
98.8–100%), respectively. The area under the 
summary ROC curve was 0.9983. They con-
cluded that 18F-FDG PET/CT is accurate and 
complementary to bone marrow biopsy (BMB) 
for detecting BMI in patients with newly diag-
nosed DLBCL.  A negative 18F-FDG PET/CT 
cannot rule out the presence of BMI, but positive 
18F-FDG PET/CT findings obviate the need for 
BMB for the detection of BMI in these patients.
The same group of authors systematically 
reviewed and meta-analysed published data on 
the diagnostic performance of 18F-FDG PET/CT 
in detecting BMI in newly diagnosed HL to 
assess whether 18F-FDG PET/CT can replace 
blind BMB in these patients [5]. The pooled sen-
sitivity and specificity of 18F-FDG PET/CT for 
the detection of BMI range were 96.9% (95%CI: 
93–99%) and 99.7% (95%CI: 98.9–100%), 
respectively. The area under the ROC curve was 
0.986. In conclusion, although the methodologi-
cal quality of studies that were included in this 
systematic review and meta-analysis was moder-
ate, the meta-analysis suggests that 18F-FDG 
PET/CT may be an appropriate method to replace 
BMB in newly diagnosed HL.
Cheng et  al. [6] also carried out a meta- 
analysis to evaluate the performance of 18F-FDG 
PET and PET/CT against BMB in the initial 
diagnosis of BMI in patients with HL. Both 18F- 
FDG PET and BMB had excellent specificity in 
detecting BMI.  However, 18F-FDG PET had 
excellent pooled sensitivity (94.5%; 95%CI: 
89.0–97.8%) in detecting BMI in the initial stag-
ing of HL patients, whereas the pooled sensitivity 
of iliac BMB was very poor (39.4%; 95%CI: 
30.8–48.4%). The authors concluded that 18F- 
FDG PET significantly outperforms iliac BMB in 
F. Bertagna et al.
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the detection of BMI in the initial staging of HL 
patients and therefore should be used as a first- 
line study.
9.2.5  Natural Killer/T-Cell 
Lymphoma
Ji et al. [7] evaluated the values of 18F-FDG PET/
CT and PET in diagnosing extranodal nasal type 
natural killer/T-cell lymphoma (ENKTL). Pooled 
sensitivity, specificity and area under the curve 
(AUC) of 18F-FDG PET/CT for diagnosing 
ENKTL were 97% (95%CI: 93–99%), 97% 
(95%CI: 88–99%) and 0.99 (95%CI: 0.98–1.00). 
The same parameters for 18F-FDG PET were 
81% (95%CI: 70–89%), 90% (95%CI: 66–98) 
and 0.86 (95%CI: 0.82–0.89), respectively. The 
authors concluded that in comparison with PET, 
18F-FDG PET/CT had excellent diagnostic value 
in detecting and staging ENKTL.
Zhou et al. [8] evaluated the role of 18F-FDG 
PET/CT in the diagnosis and staging of natural 
killer/T-cell lymphoma (NKTL). On a patient- 
based analysis, the pooled sensitivity and speci-
ficity of 18F-FDG PET/CT in the diagnosis of 
NKTL were 95% (95%CI: 89–98%) and 40% 
(95%CI: 9–78%), respectively. For lesion-based 
analysis, the pooled sensitivity and specificity of 
18F-FDG PET/CT in the staging of NKTL were 
98% (95%CI: 96–99%) and 99% (95%CI: 
99–100), respectively. The results indicated that 
18F-FDG PET/CT could be used as a valuable 
diagnostic and staging tool for NKTL.
9.2.6  Multiple Myeloma
Lu et al. [9] conducted a systematic review and 
meta-analysis to evaluate the diagnostic accuracy 
of 18F-FDG PET or PET/CT for intramedullary 
and extramedullary lesions in MM. The pooled 
sensitivity and specificity of 18F-FDG PET or 
PET/CT for the detection of extramedullary 
lesions in MM were 96.0% (95%CI: 79.6–99.9%) 
and 77.8% (95%CI: 40–97.2%), respectively. 
The pooled sensitivity and specificity of 18F-FDG 
PET or PET/CT for the detection of intramedul-
lary lesions in MM were 61.1% (95%CI: 43.5–
76.9%) and 94.1% (95%CI: 71.3–99.9%), 
respectively. They concluded that whole-body 
18F-FDG PET or PET/CT is a valuable imaging 
tool for the assessment of patients with MM, 
especially for the appraisal of extramedullary 
involvement.
9.3  18F-FDG PET or PET/CT 
in Treatment Response 
Evaluation (Interim and/or 
End of Therapy)
9.3.1  Post-transplant 
Lymphoproliferative Disorder
In the meta-analysis by Montes de Jesus et al. [1] 
on imaging modalities in PTLD, the subgroup 
analysis of imaging results at treatment response 
evaluation indicated that 18F-FDG PET/CT find-
ings altered or guided treatment in 29% of cases. 
False positive results during treatment response 
evaluation were reported in 20% of cases, pre-
dominantly due to inflammatory conditions. 
They concluded that 18F-FDG PET/CT may be 
promising in therapy evaluation but suffers from 
methodological shortcomings. Concerns remain 
with regard to occurrence of false negatives due 
to physiological high background activity and 
early PTLD lesions as well as false positives due 
to inflammatory conditions.
9.3.2  Hodgkin and Non-Hodgkin 
Lymphomas
Adams et  al. [10] systematically reviewed and 
meta-analysed the proportion of false positive 
lesions at interim and end-of-treatment 18F-FDG 
PET in lymphomas (both HL and NHL) using 
biopsy as reference standard. The pooled propor-
tion of false positive results among all biopsied 
18F-FDG-avid lesions at PET performed during or 
after completion of treatment was 55.7% (95%CI: 
32.6–76.6%). The pooled false positive propor-
tions were 83% (95%CI: 72–90.2%) for interim 
18F-FDG PET in NHL, 23.1% (95%CI: 4.7–64.5%) 
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for end-of-treatment 18F-FDG PET in HL and 
31.5% (95%CI: 3.9–83.9%) for end- of- treatment 
18F-FDG PET in NHL. The authors concluded that 
both interim and end-of-treatment 18F-FDG PET in 
patients with lymphoma suffer from a very high 
number of false positive findings.
Sun et  al. [11] conducted a meta-analysis to 
evaluate the predictive value of interim 18F-FDG 
PET/CT in patients with DLBCL treated with 
R-CHOP chemotherapy. The pooled sensitivity 
of interim 18F-FDG PET/CT was 52.4% and the 
pooled specificity was 67.8%. In conclusion, the 
sensitivity and specificity of interim 18F-FDG 
PET/CT in predicting the outcome of DLBCL 
patients treated with R-CHOP chemotherapy 
were not satisfactory. To improve this, some more 
work should be done to unify the response crite-
ria and some more research to assess the prog-
nostic value of interim 18F-FDG PET/CT with 
semi-quantitative analysis.
Ziakas et al. [12] assessed the diagnostic per-
formance of interim 18F-FDG PET with regard to 
the final outcome of adult patients with newly 
diagnosed HL. The pooled sensitivity was 67% 
(95%CI: 57–76%) and pooled specificity was 
89% (95%CI: 84–93%). The estimated negative 
predictive value was 93% (95%CI: 85–100%). 
The diagnostic performance was influenced by 
most covariates tested, including age, duration of 
follow-up, criteria used and time of interim 
PET.  In conclusion, the use of a PET-positive 
study as a surrogate marker was hampered by 
inconsistent interpretation criteria and study pop-
ulations. However, the high negative predictive 
value may permit treatment stratification based 
on a negative outcome.
9.4  18F-FDG PET or PET/CT 
in Prognosis/Outcome 
Evaluation
9.4.1  Hodgkin and Non-Hodgkin 
Lymphomas
Wang et  al. [13] carried out a meta-analysis to 
detect the prognostic power of 18F-FDG PET in 
the evaluation of pre-stem cell transplantation 
(SCT) and post-SCT in HL and NHL.  For the 
pre-SCT PET or PET/CT, the combined hazard 
ratios (HRs) of PET for progression-free survival 
(PFS) and overall survival (OS) were 2.32 and 
2.64, respectively. Subgroup analysis showed 
that the HRs of PFS for HL and NHL were 3.28 
and 2.0, respectively. For the post-SCT PET scan, 
the combined HR for PFS was 4.61. The authors 
found that 18F-FDG PET was especially effective 
in predicting pre-STC and post-STC prognosis. 
The patients with a negative PET scan had a bet-
ter prognosis compared with those with a positive 
scan for PFS and OS. In the subgroup analysis, 
18F-FDG PET had a higher value in predicting 
prognosis before SCT for HL patients.
Burggraaff et al. [14] aimed to assess the pre-
dictive value of visually assessed interim 18F- 
FDG PET on PFS or event-free survival (EFS) in 
DLBCL patients treated with first-line immuno-
chemotherapy regimens. The pooled HR was 
3.13 (95%CI 2.52–3.89) with a 95% prediction 
interval of 1.68–5.83. The negative predictive 
value for progression generally exceeded 80%, 
but sensitivity, specificity and positive predictive 
values ranged widely. These findings showed that 
interim 18F-FDG PET has predictive value in 
DLBCL patients. Some diagnostic test character-
istics were not satisfactory, especially the posi-
tive predictive value should be improved before a 
successful risk stratified treatment approach can 
be implemented in clinical practice.
Adams et al. [15] systematically reviewed and 
meta-analysed the prognostic value of complete 
remission status at end-of-treatment 18F-FDG- 
PET in DLBCL patients treated with 
R-CHOP.  The disease relapse rate among all 
patients with complete remission status accord-
ing to end-of-treatment 18F-FDG PET ranged 
from 7 to 20%, with a weighted summary propor-
tion of 13.7%. In conclusion, a non-negligible 
proportion of R-CHOP-treated DLBCL patients 
who achieve complete remission according to 
end-of-treatment 18F-FDG PET experiences dis-
ease relapse during follow-up.
Adams et  al. [16] analysed the prognostic 
value of interim 18F-FDG PET in DLBCL patients 
treated with R-CHOP. At multivariable analysis, 
two studies reported interim 18F-FDG PET to 
have independent prognostic value in addition to 
the International Prognostic Index (IPI) in pre-
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dicting treatment failure, whereas three studies 
reported that this was not the case. One study 
reported interim 18F-FDG PET to have indepen-
dent prognostic value in addition to the IPI in pre-
dicting death, whereas two studies reported that 
this was not the case. In conclusion, interim 
18F-FDG-PET in R-CHOP-treated DLBCL has 
some correlation with outcome, but its prognostic 
value is homogeneously sub-optimal across stud-
ies and it has not consistently proven to surpass 
the prognostic potential of the IPI. Therefore, at 
present there is no scientific base to support the 
clinical use of interim 18F-FDG-PET in R-CHOP- 
treated DLBCL.
Zhu et al. [17] analysed the prognostic value 
of interim 18F-FDG PET in DLBCL patients 
treated with rituximab-based immunochemother-
apy. The pooled HR comparing PFS between 
patients with positive and negative results was 
2.96 (95%CI  =  2.25–3.89). The patients in 
interim 18F-FDG PET-negative group had a 
higher complete response (CR) rates than those 
in interim 18F-FDG PET-positive group (relative 
risk  =  5.53, 95%CI  =  2.59–11.8). The authors 
concluded that consistent evidence favouring 
interim 18F-FDG PET-based treatment assess-
ment should be considered in the management of 
patients with DLBCL.
Pyo et  al. [18] evaluated post-chemotherapy 
response assessment in FL.  The pooled HR of 
end-therapy 18F-FDG PET and CT were 5.1 
(95%CI: 3.7–7.2) and 2.6 (95%CI: 1.2–5.8), 
respectively, which implies that PET is more pre-
dictive of PFS after chemotherapy than CT. The 
pooled CR rates of PET- and CT-based response 
criteria were 75% (95%CI: 70–79%) and 63% 
(95%CI: 53–73%), respectively, which implies 
that PET is more efficient in distinguishing CR 
from other states with residual disease. The 
authors concluded that PET-based treatment 
assessment should be considered in the manage-
ment of patients with FL.
Liao et al. [19] evaluated the prognostic value 
of 18F-FDG PET/CT visual interpretation in 
patients with aggressive NHL.  PFS and OS of 
PET/CT-positive patients were significantly 
lower when determined by the visual method. In 
subgroup analysis, International Harmonization 
Project (IHP), Deauville criteria, and having no 
standard interpretation groups were factors able 
to predict PFS; IHP and having no standard inter-
pretation group were able to predict OS.  With 
PET/CT, IHP and Deauville 5-point criteria, the 
PFS of patients receiving 2–4 cycles of chemo-
therapy before PET/CT was significantly lower 
than that of PET/CT-negative patients. No sig-
nificant difference in OS was observed when 
patients received 3 or fewer cycles of chemother-
apy before PET/CT, though OS was significantly 
lower in patients receiving more than 3 chemo-
therapy cycles. They concluded that interim PET/
CT analysis after 3–4 chemotherapy cycles is 
capable of predicting disease prognosis in aggres-
sive NHL.
Adams et al. [20] aimed to analyse the value 
of pretransplant 18F-FDG PET in predicting out-
come after autologous stem cell transplantation 
in aggressive NHL. Pooled sensitivity and speci-
ficity of 18F-FDG PET were 54 and 73.1% in pre-
dicting treatment failure, and 54.5 and 68.7% in 
predicting death. They concluded that pretrans-
plant 18F-FDG PET cannot be recommended in 
aggressive NHL, because available studies suffer 
from major methodological flaws, and reported 
prognostic estimates are low.
Zhu et al. [21] aimed to determine the prog-
nostic value of interim and final 18F-FDG PET in 
NHL patients treated with rituximab-containing 
chemotherapy. The combined HRs of interim 
PET for PFS and OS in DLBCL were 4.4 
(p = 0.11) and 3.99 (p = 0.46), respectively. The 
combined HRs of final PET for PFS and OS in 
DLBCL were 5.91 (p = 0.39) and 6.75 (p = 0.92), 
respectively. Regarding non-DLBCL with final 
PET, the combined HRs of final PET for PFS and 
OS were 4.05 (p  =  0.79) and 5.1 (p  =  0.51), 
respectively. In conclusion, in DLBCL, both 
interim and final PET can be performed for sur-
vival and progression analysis. But in other NHL, 
it would be necessary to perform final PET for 
predictive purposes.
Adams et  al. [22] aimed to systematically 
review and meta-analyse the value of interim 18F- 
FDG PET in predicting treatment failure in 
HL. The area under the summary ROC curve was 
0.877. Pooled sensitivity and specificity were 
70.8% (95%CI: 64.7–76.4%) and 89.9% (95%CI: 
88–91.6%). The overall prognostic value of 
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interim PET appeared to be moderate for exclud-
ing and relatively high for identifying treatment 
failure in HL. However, they stated that interim 
PET cannot yet be implemented in routine clini-
cal practice due to moderate-quality evidence and 
inter-study heterogeneity that cannot be fully 
explained yet.
Sickinger et al. [23, 24] assessed the effects of 
interim 18F-FDG PET treatment modification in 
individuals with HL. PFS was shorter in partici-
pants with PET-adapted therapy (without radio-
therapy) than in those receiving standard 
treatment with radiotherapy (HR: 2.38; 95%CI: 
1.62–3.5). This difference was also apparent in 
comparisons of participants receiving no addi-
tional radiotherapy (PET-adapted therapy) versus 
radiotherapy (HR: 1.86 (95%CI: 1.07–3.23) and 
in those receiving chemotherapy but no radio-
therapy (PET-adapted therapy) versus standard 
radiotherapy (HR: 3.0; 95%CI: 1.75–5.14). 
Overall, this systematic review found moderate- 
quality evidence that PFS was shorter in individ-
uals with early-stage HL and a negative PET 
receiving chemotherapy only (PET-adapted ther-
apy) than in those receiving additional radiother-
apy (standard therapy). It was still uncertain 
whether PET-positive individuals benefit from 
PET-based treatment adaptation and the effect of 
such an approach in those with advanced HL.
Adams et  al. [25] aimed to systematically 
review the prognostic value of pretransplant 18F- 
FDG PET in refractory/relapsed HL treated with 
autologous stem cell transplantation (SCT). 
Pooled sensitivity and specificity of pretransplant 
18F-FDG PET in predicting treatment failure (i.e. 
either progressive, residual, or relapsed disease) 
were 67.2% (95%CI: 58.2–75.3%) and 70.7% 
(95%CI: 64.2–76.5%), respectively. Pooled sen-
sitivity and specificity of pretransplant 18F-FDG 
PET in predicting death during follow-up were 
74.4% (95%CI: 58.8–86.5%) and 58% (95%CI: 
49.3–66.3%), respectively. In conclusion, the 
moderate quality of evidence suggested pretrans-
plant 18F-FDG-PET to have value in predicting 
outcome in refractory/relapsed HL patients 
treated with autologous SCT.  Nevertheless, a 
considerable proportion of pretransplant 18F- 
FDG PET-positive patients remained disease free 
and a considerable proportion of pretransplant 
18F-FDG PET-negative patients developed dis-
ease relapse after autologous SCT.
Adams et al. [26] systematically reviewed and 
meta-analysed the outcome of HL patients with a 
post-treatment 18F-FDG PET-negative residual 
mass. The disease relapse rate in HL patients 
with a 18F-FDG PET-negative residual mass after 
first-line therapy was approximately 6.8%. They 
concluded that the presence of a non-18F-FDG- 
avid residual mass has not been proven yet to be 
associated with a worse outcome than a post- 
treatment 18F-FDG-PET-based complete remis-
sion status without a residual mass.
The same group [27] analysed the prognostic 
value of complete remission status at 18F-FDG 
PET in HL after completion of first-line therapy. 
The pooled disease relapse rate during follow-up 
among all patients with complete remission sta-
tus at end-of-treatment 18F-FDG-PET was 7.5% 
(95%CI: 3.9–13.8%). They concluded that, 
although the disease relapse rate in HL patients 
who achieve an 18F-FDG PET-based complete 
remission after first-line therapy is low, it is actu-
ally high when considering the generally favour-
able outcome of HL.
9.4.2  Multiple Myeloma
Caldarella et al. [28] aimed to evaluate the use-
fulness of 18F-FDG PET or PET/CT in monitor-
ing response to treatment in patients with 
MM. Based on the findings from the literature, 
18F-FDG PET or PET/CT appeared to be useful 
in the assessment of treatment response in 
patients with MM. In particular, PET or PET/CT 
could detect the response to treatment earlier 
than other imaging. Negative findings on post- 
treatment 18F-FDG PET or PET/CT were mostly 
correlated with complete clinical and histological 
remission or, at least, low risk of recurrences or 
disease progression. Persistence of metabolically 
active lesions was related to shorter overall and 
event-free survival. Therefore, post-treatment 
18F-FDG PET findings could be of higher prog-
nostic significance than standard response moni-
toring methods. In the near future, 18F-FDG PET 
F. Bertagna et al.
85
or PET/CT will be used even more in the assess-
ment of metabolic response after treatment in 
patients with MM, as a guidance for clinical deci-
sion and to eventually decide for alternative ther-
apies in non-responding patients.
9.5  Prognostic Role of Semi- 
quantitative PET Parameters
Guo et  al. [29] have analysed whether baseline 
metabolic tumour volume (MTV) and total lesion 
glycolysis (TLG) measured by 18F-FDG PET/CT 
affect prognosis of patients with lymphoma. 
Patients with high baseline MTV showed a worse 
prognosis considering PFS and OS as well as 
patients with high baseline TLG. A high baseline 
MTV was significantly associated with worse 
survival in DLBCL patients treated with R-CHOP 
as well as a high baseline TLG.  The negative 
effect of high baseline MTV on PFS was demon-
strated in HL. A high baseline MTV was signifi-
cantly associated with worse survival in ENKTL 
patients. A high baseline TLG was significantly 
associated with worse survival in ENKL patients. 
The authors concluded that high baseline MTV 
or TLG predict significantly worse PFS and OS 
in patients with lymphoma.
Wang et  al. [30] evaluated the prognostic 
value of maximum standardized uptake value 
(SUVmax), MTV, and TLG of baseline, interim 
and end-of-treatment 18F-FDG PET/CT parame-
ters in ENKTL.  SUVmax, MTV and TLG on 
baseline PET/CT were significantly associated 
with PFS and with OS. For the delta SUV (DS) 
on interim PET/CT, the HRs for PFS and OS 
were 5.15 (95%CI 2.71–9.80) and 5.8 (95%CI 
2.28–14.73), respectively. Similarly, the DS on 
end-of-treatment PET/CT was a significant pre-
dictor of PFS and OS with HRs of 3.65 (95%CI: 
2.13–6.26) and 3.32 (95%CI: 1.79–6.15), respec-
tively. They suggested that SUVmax, MTV, TLG 
on baseline PET/CT, DS on interim PET/CT and 
DS on end-of-treatment PET/CT may be signifi-
cant prognostic indicators for PFS and OS in 
ENKTL patients. Moreover, TLG tended to be 
superior to SUVmax and MTV on baseline PET/
CT for predicting survival of ENKTL patients. 
Therefore, response monitoring and prognostica-
tion assessments based on multiple PET/CT 
parameters should be considered in the manage-
ment of ENKTL patients.
Xie et  al. [31] analysed whether SUVmax, 
MTV and TLG acquired from 18F-FDG PET/CT 
are predictors of prognosis of DLBCL. Combined 
results suggested a strong link between the high 
SUVmax, MTV and TLG values and the poor 
3-year PFS with ORs of 2.59, 3.69 and 2.29, 
respectively. Similarly, high MTV and TLG val-
ues unfavourably influenced the 3-year OS with 
ORs of 5.40 and 2.19, respectively. The pooled 
results also showed that high SUVmax and MTV 
were negative predictors of PFS. The TLG value 
was not predictive of PFS. And for OS, only high 
MTV was a strong predictor of poor prognosis in 
DLBCL.  Their results suggested that SUVmax 
and MTV may be significant prognostic markers 
for PFS and MTV may be the only predictor for 
OS in DLBCL.




Wang et  al. [32] aimed to compare the perfor-
mance of whole-body magnetic resonance imag-
ing (WB-MRI) with that of 18F-FDG PET/CT for 
lesion detection and initial staging in patients 
with aggressive or indolent lymphoma. In terms 
of staging, the pooled accuracy of WB-MRI and 
18F-FDG PET/CT for HL and aggressive NHL 
were 98% (95%CI: 94–100%) and 98% (95%CI: 
94–100%), respectively. The pooled accuracy of 
18F-FDG PET/CT dropped to 87% (95%CI: 
72–97%) for staging in patients with indolent 
lymphoma, whereas that of WB-MRI remained 
96% (95%CI: 91–100%). Subgroup analysis 
indicated an even lower accuracy of 18F-FDG 
PET/CT for staging of less 18F-FDG-avid indo-
lent NHLs (60%; 95%CI: 23–92%), in contrast to 
the superior performance of WB-MRI (98%; 
95%CI: 88–100%). The authors concluded that 
WB-MRI is a promising radiation-free imaging 
technique that may serve as a viable alternative to 
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18F-FDG PET/CT for staging of 18F-FDG-avid 
lymphomas, where 18F-FDG PET/CT remains 
the standard of care. Additionally, WB-MRI 
seemed a less histology-dependent functional 
imaging test than 18F-FDG PET/CT and may be 
the imaging test of choice for staging of indolent 
NHLs with low 18F-FDG avidity.
Regacini et al. [33] aimed to compare WB-MRI 
with 18F-FDG PET/CT for lymphoma staging. 
WB-MRI and 18F-FDG-PET/CT agreed in 90.5% 
of the cases. In most of the studies, when there 
was disagreement between the methods, WB-MRI 
overstaged in relation to 18F-FDG PET/CT.  The 
sensitivity of WB-MRI and 18F- FDG PET/CT, in 
comparison with the clinical- radiological stan-
dard, ranged from 59 to 100% and from 63 to 
100%, respectively. The authors concluded that 
WB-MRI has excellent agreement with 18F-FDG-
PET/CT and is a great alternative for managing 
lymphoma patients, without using ionizing radia-
tion or an intravenous contrast agent.
Gariani et  al. [34] evaluated the diagnostic 
performance of WB-MRI including diffusion 
weighted sequences (DWI) compared to whole- 
body CT or 18F-FDG PET/CT in patients with 
MM.  WB-MRI detected more lesions than 18F- 
FDG PET/CT (sensitivity 68–100% versus 
47–100%) but was less specific (specificity 
37–83% versus 62–85.7%). Despite these 
insights the authors concluded that, because of 
the heterogeneity of the studies, future prospec-
tive trials should assess the impact of WB-MRI 
on management of MM.
Weng et  al. [35] conducted a systematic 
review of the published literature to evaluate the 
diagnostic accuracy of 18F-FDG PET, 18F-FDG 
PET/CT, MRI and scintigraphy for MM-related 
bone disease. For 18F-FDG PET and PET/CT, 
pooled sensitivity and specificity were 91% and 
69%, respectively. Statistically significant differ-
ences were not found in the sensitivity and speci-
ficity between MRI, scintigraphy, 18F-FDG-PET 
and PET/CT.  In conclusion, the authors sug-
gested that 18F-FDG-PET, PET/CT, MRI and 
scintigraphy are all associated with high detec-
tion rate of bone disease in patients with 
MM. Thus, in clinical practice, it is recommended 
that we could choose these tests according to the 
condition of the patient.
9.7  Conclusions
Overall, 18F-FDG PET or PET/CT appears to be a 
useful and accurate diagnostic tool for haemato-
logical malignancies in clinical practice from an 
“evidence-based” point of view. Some topics and 
results need further investigations in order to 
overcome methodological limits and clarify the 
real diagnostic role of this tool and its more 
appropriate position in the diagnostic flow chart.
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Endocrine tumours have a wide range of clinical 
presentations and can be found anywhere from 
the neck to the pelvis. Diagnostic imaging is cru-
cial to predict the exact tumour extent, foremost 
in metastatic disease. Anatomical imaging as 
computed tomography (CT) and magnetic reso-
nance imaging (MRI) serves as the first-line 
modality in the locoregional staging of these 
tumours. Compared with anatomical imaging, 
PET shows both high sensitivity and specificity. 
Several meta-analyses have described the diag-
nostic performance of positron emission tomog-
raphy (PET) and hybrid imaging (PET/CT) in 
endocrine tumours and disorders.
10.2  Adrenal Tumours 
and Paragangliomas
10.2.1  Characterization of Adrenal 
Masses
Dinnes and colleagues reviewed the evidence on 
the accuracy of imaging tests for differentiating 
malignant from benign adrenal masses. They 
concluded that CT density >10 Hounsfield Unit 
(HU) offers high sensitivity for detection of adre-
nal malignancy in participants with no prior indi-
cation for adrenal imaging. With respect to a 
limited database and heterogeneity and low qual-
ity of included studies for meta-analysis, the 
authors concluded that there is insufficient evi-
dence for the diagnostic value of individual imag-
ing tests in distinguishing benign from malignant 
adrenal masses [1].
Kim and colleagues explored the role of the 
diagnostic accuracy of 18F-FDG PET or PET/CT 
for characterization of adrenal lesions [2]. The 
pooled sensitivity for 18F-FDG PET or PET/CT 
was 91% (95% confidence interval (95%CI): 
88–94%) and the pooled specificity was 91% 
(95%CI: 87–93%). Although, at present, the lit-
erature regarding the use of 18F-FDG PET or 
PET/CT for the characterization of adrenal 
masses remains limited, 18F-FDG PET or PET/
CT demonstrated good sensitivity and specificity 
for the characterization of adrenal masses.
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Rufini and co-authors compared the diagnostic 
performance of metaiodobenzylguanidine 
(MIBG scintigraphy) and PET with different 
radiopharmaceuticals in patients with paragan-
glioma (PGL). The authors concluded that the 
diagnostic performance of PET with different 
radiopharmaceuticals is clearly superior to that 
of MIBG scintigraphy in patients with PGL, 
mainly for familial, extra-adrenal and metastatic 
diseases [3].
A review article by Treglia and co-authors 
investigated the diagnostic performance of 
18F-DOPA PET in patients with paraganglioma 
(PGL). The pooled sensitivity of 18F-DOPA 
PET and PET/CT in detecting PGL was 91% 
(95%CI: 87–94%) on a per-patient-based anal-
ysis and 79% (95%CI 76–81%) on a per-lesion-
based analysis. The pooled specificity of 
18F-DOPA PET and PET/CT in detecting PGL 
was 95% (95%CI: 86–99%) on a per-patient-
based analysis and 95% (95%CI: 84–99%) on a 
per-lesion- based analysis. The area under the 
receiver operating characteristic (ROC) curve 
was 0.95 on a per-patient- and 0.94 on a per-
lesion-based analysis. The authors described 
the possible risk of false-negative 18F-DOPA 
PET results in metastatic PGL, besides the fact 
that succinate dehydrogenase subunit B 
(SDHB) gene mutations could influence the 
diagnostic performance of 18F-DOPA PET or 
PET/CT [4].
Kan and colleagues performed a meta- analysis 
on the localization of metastatic pheochromocy-
toma (PHEO) and PGL with germline mutations, 
comparing 68Ga-somatostatin analogues and 18F- 
FDG PET/CT.  The pooled sensitivity of 68Ga 
peptides and 18F-FDG PET were 95% 
(95%CI: 92–97) and 85% (95%CI: 78–91%), 
respectively. The pooled specificity of 68Ga pep-
tides and 18F-FDG PET were 87% 
(95%CI: 63–96%) and 55% (95%CI: 37–73%), 
respectively. The authors concluded that 
68Ga-somatostatin analogues PET/CT demon-
strated good performance in the localization of 
metastatic PGL, especially those with germline 
mutations, compared to 18F-FDG PET/CT [5].
Han and colleagues performed a systematic 
review and meta-analysis on the performance of 
68Ga-somatostatin analogues PET in the detec-
tion of PGL. The pooled detection rate was 93% 
(95%CI: 91–95%), which was significantly 
higher than that of 18F-DOPA PET (80%; 95%CI: 
69–88%), 18F-FDG PET (74%; 95%CI: 46–91%) 
and MIBG scintigraphy (38%; 95%CI: 20–59%). 
A greater prevalence of head and neck PGL was 
associated with higher detection rates of 
68Ga-somatostatin analogues PET.  The authors 
suggest the use of 68Ga-somatostatin analogues 
PET as a first-line imaging modality for the pri-
mary staging or restaging of PGL with unknown 
genetic status [6].
10.3  Neuroblastoma
Bleeker and colleagues described the role of 
MIBG scintigraphy and 18F-FDG PET for diag-
nosing neuroblastoma (NB). In one study, the 
sensitivity of 18F-FDG PET/CT compared to 
MIBG scintigraphy was 100% and 92%, respec-
tively. Specificity could not be calculated for both 
modalities. The diagnostic accuracy of 18F-FDG 
PET/CT imaging in case of a negative 123I-MIBG 
scintigraphy could not be calculated because of 
very limited data. It has to be mentioned that in 
about 10% of the patients with histologically 
proven NB the tumour does not accumulate 
123I-MIBG which underlines the importance of 
additional functional/anatomical imaging (e.g. 
18F-FDG PET/CT) [7].
A review article by Xia and co-authors dem-
onstrated a summary sensitivity for MIBG scin-
tigraphy and 18F-FDG PET(/CT) of 79% and 
89%, respectively. The summary specificity for 
MIBG scintigraphy and 18F-FDG PET(/CT) was 
84% and 71%, respectively. The authors con-
cluded that 18F-FDG PET(/CT) showed higher 
per-lesion accuracy than MIBG scintigraphy 
and might be the preferred modality for the 
staging of NB [8].
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10.4  Merkel Cell Carcinoma
Treglia and co-authors investigated the diagnos-
tic performance of 18F-FDG PET and PET/CT in 
patients with Merkel cell carcinoma (MCC). The 
meta-analysis provided the following pooled 
results on a per-examination-based analysis: sen-
sitivity was 90% (95%CI: 80–96%) and specific-
ity was 98% (95%CI: 90–100%). The area under 
the summary ROC curve was 0.96. No significant 
statistical heterogeneity between the studies was 
found. The authors concluded that 18F-FDG PET 
or PET/CT demonstrated high sensitivity and 
specificity, being accurate methods in the detec-
tion of MCC taking into account that literature in 
MCC remains limited [9].
10.5  Gastroenteropancreatic 
and Pulmonary 
Neuroendocrine Tumours
Singh and co-authors evaluated the diagnostic 
performance of 68Ga-somatostatin analogues 
PET or PET/CT on neuroendocrine tumours 
(NETs). For the initial diagnosis of NETs, 
68Ga-somatostatin analogues PET or PET/CT had 
a pooled sensitivity of 91% (95%CI: 85–94%) 
and a pooled specificity of 94% (95%CI: 
86–98%). In the setting of staging and restaging, 
the sensitivity of 68Ga-somatostatin analogues 
PET or PET/CT for detecting primary and/or 
metastatic lesions ranged from 78.3 to 100%, 
whereas specificity ranged from 83 to 100%. 
Change in management occurred in 45% (95%CI: 
36–55%) of the cases, with majority of the 
changes involving surgical planning and patient 
selection for peptide receptor radionuclide ther-
apy [10].
This is in line with a systematic review by 
Barrio and colleagues who investigated the 
impact of 68Ga-somatostatin analogues PET/CT 
in patients with NETs. A change of management 
occurred in 44% of cases after 68Ga-somatostatin 
analogues PET/CT (range: 16–71%). In some 
studies, 68Ga-somatostatin analogues PET/CT 
was performed after conventional scintigraphy 
(111In-Octreotide). In this subgroup, additional 
information led to a change in management in 
39% of cases (range: 16–71%). The authors con-
cluded that the management was changed in 
more than one-third of patients undergoing 
68Ga-somatostatin analogues PET/CT even when 
performed after an 111In-Octreotide scintigraphy 
[11].
In this line, another meta-analysis was pub-
lished by Deppen and co-authors who compared 
conventional 111In-Octreotide imaging with 
68Ga-DOTATATE PET/CT in pulmonary and gas-
troenteropancreatic NETs, with estimated pooled 
sensitivity of 90.9% (95%CI: 81.4–96.4%) and 
pooled specificity of 90.6% (95%CI: 77.8–
96.1%) for 68Ga-DOTATATE PET/CT [12].
The high diagnostic performance of 
68Ga-somatostatin analogues PET or PET/CT for 
thoracic and gastroenteropancreatic NETs was 
showed by the meta-analysis of Treglia et  al. 
reporting a pooled sensitivity and specificity of 
93% (95%CI: 91–95%) and 91% (95%CI: 
82–97%), respectively. 68Ga-somatostatin ana-
logues PET/CT should be considered as first-line 
diagnostic imaging method for these tumours 
[13].
An updated meta-analysis on this regard 
reported a pooled sensitivity of 93% (95%CI: 
91–94%) and a pooled specificity of 96% 
(95%CI: 95–98%) for 68Ga-somatostatin ana-
logues PET or PET/CT. The area under the sum-
mary ROC curve was 0.98, confirming the good 
diagnostic performance of 68Ga-somatostatin 
analogues PET or PET/CT compared to diagnos-
tic CT and conventional scintigraphy (e.g. 
111In-Octreotide) [14].
An evidence-based article compared 
68Ga-DOTATOC and 68Ga-DOTATATE PET in 
NETs, reporting no statistically significant differ-
ences of diagnostic performance among these 
imaging methods on a per-patient-based analysis 
[15].
10.6  Congenital Hyperinsulinism
Paediatric patients with congenital hyperinsulin-
ism (CHI) due to pancreatic disease can be evalu-
ated by PET or PET/CT, in particular by using 
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18F-DOPA.  A systematic review and meta- 
analysis by Blomberg and co-authors aimed to 
quantify the diagnostic performance of pancre-
atic venous sampling (PVS), selective pancreatic 
arterial calcium stimulation with hepatic venous 
sampling (ASVS) and 18F-DOPA PET in diag-
nosing and localizing focal form of CHI. 
18F-DOPA PET was superior in distinguishing 
focal from diffuse CHI compared to PVS and 
ASVS. Furthermore, it localized focal CHI in the 
pancreas more accurately than PVS and ASVS 
(pooled accuracy: 82% vs. 76% and 64%, respec-
tively) [16].
Yang and colleagues performed a meta- 
analysis of published data on the diagnostic role 
of 18F-DOPA PET in patients with CHI.  The 
pooled sensitivity of 18F-DOPA PET and PET/CT 
in detecting CHI was 88%. The pooled specific-
ity of 18F-DOPA PET and PET/CT in demonstrat-
ing CHI was 79%. The area under the ROC curve 
was 0.92. The authors concluded that 18F-DOPA 
PET or PET/CT demonstrated high sensitivity 
and specificity in patients with CHI [17].
These findings are in line with another meta- 
analysis by Treglia and co-authors: the pooled 
sensitivity and specificity of 18F-DOPA PET or 
PET/CT in differentiating between focal and dif-
fuse CHI were 89% (95%CI: 81–95%) and 98% 
(95%CI: 89–100%), respectively. The area under 
the ROC curve was 0.95. The pooled accuracy of 
these functional imaging methods in  localizing 
focal CHI was 80% (95%CI: 71–88%). Although 
possible sources of false-negative results for 
focal CHI should be kept in mind, the authors 
concluded that 18F-DOPA PET or PET/CT are 
accurate methods for localizing focal CHI [18].
10.7  Thyroid Diseases
10.7.1  Thyroid Incidentalomas
Nayan and colleagues evaluated through a sys-
tematic review and meta-analysis the malignancy 
rates of thyroid incidentalomas identified in 
adults by 18FDG PET/CT. The pooled proportion 
of malignancy was 19.8% (95%CI: 15.3–24.7%) 
with most of cases being papillary thyroid cancer. 
The authors stated that thyroid incidentalomas 
identified through 18FDG PET require thorough 
investigation [19].
In this context, a review article by Qu and co- 
authors was focused on focal thyroid incidentalo-
mas (FTI) identified on 18F-FDG PET or PET/
CT.  A meta-analysis was performed to investi-
gate whether the maximum standardized uptake 
value (SUVmax) could discriminate between 
benign and malignant FTI and to explore the cut-
off value of SUVmax for the diagnosis of malig-
nancy. The results of this article indicated that 
there was no statistically significant difference in 
the size between benign and malignant FTI, 
while a significantly higher SUVmax was 
observed in the malignant group. The authors 
concluded that a higher SUVmax in FTI was 
associated with a higher risk of thyroid malig-
nancy, especially at a threshold of 3.3 or more 
[20].
Treglia and co-authors described the preva-
lence and malignancy risk of FTI detected by 18F- 
FDG PET or PET/CT. Pooled prevalence of FTI 
was 1.92% (95%CI: 1.87–1.99%). Considering 
FTI which underwent histopathology evaluation, 
the pooled risk of malignancy was 36.2% 
(95%CI: 33.8–38.6%), without significant differ-
ences among various geographic areas. The 
authors concluded that FTI are observed in about 
2% of 18F-FDG-PET or PET/CT and they should 
be further investigated due to a significant risk of 
malignancy [21].
10.7.2  Indeterminate Thyroid 
Nodules
A meta-analysis by Wang and colleagues evalu-
ated the diagnostic accuracy of 18F-FDG PET or 
PET/CT in discriminating between malignant 
and benign lesions in thyroid nodules with inde-
terminate fine needle aspiration biopsy (FNAB). 
The prevalence of malignant lesions in these 
patients was 26.2% (ranging from 19.6 to 40%). 
The pooled sensitivity and specificity of 18F-FDG 
PET or PET/CT for the detection of cancer were 
89.0% (95%CI: 79.0–95%) and 55% (95%CI: 
48–62%), respectively. Although SUVmax was 
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higher in malignant lesions, there was still a great 
overlap with benign lesions. In conclusion, 18F- 
FDG PET or PET/CT showed a high sensitivity 
in detecting thyroid cancers in patients with inde-
terminate FNAB results [22].
10.7.3  Recurrence of Differentiated 
Thyroid Cancer
A meta-analysis by Haslerud and co-authors 
described the role of 18F-FDG PET in recurrent 
differentiated thyroid cancer (DTC) after total 
thyroidectomy and radioiodine ablative therapy. 
Pooled sensitivity and specificity of this method 
in detecting recurrent DTC were 79.4% (95%CI: 
73.9–84.1%) and 79.4% (95%CI: 71.2–85.4%), 
respectively, with an area under the ROC curve of 
0.858. The authors concluded that this method 
can be useful for detecting recurrent DTC in 
patients having undergone radioiodine ablative 
therapy [23].
A meta-analysis by Caetano and co-authors 
aimed to evaluate the accuracy of 18F-FDG PET 
and PET/CT for detecting recurrence of DTC, 
not identified by 131I whole-body scintigraphy 
(I-WBS). The combined sensitivity, specificity 
and accuracy for 18F-FDG PET were 84%, 84% 
and 91%, respectively; for 18F-FDG PET/CT, the 
combined sensitivity, specificity and accuracy 
were 93%, 81% and 93% respectively [24].
Another meta-analysis by Schütz and co- 
authors about the use of 18F-FDG PET and PET/
CT for detecting recurrent DTC demonstrated 
that 18F-FDG PET and PET/CT showed higher 
sensitivity (89.7% for PET and 94.3% for PET/
CT) compared with conventional imaging 
(65.4%) and comparable results for specificity 
[25].
Kim and colleagues investigated the diagnos-
tic accuracy of 18F-FDG PET/CT for the detec-
tion of recurrent and/or metastatic diseases in 
DTC patients with progressively and/or persis-
tently elevated thyroglobulin antibodies (TgAb) 
levels and negative I-WBS through a systematic 
review and meta-analysis. The pooled sensitivity 
for 18F-FDG PET or PET/CT was 84% (95%CI: 
77–89%), the pooled specificity 78% (95%CI: 
67–86%). The area under the ROC curve was 
0.88 (95%CI: 0.85–0.90). The authors concluded 
that 18F-FDG PET or PET/CT demonstrated 
moderate sensitivity and specificity for the detec-
tion of recurrent and/or metastatic diseases in 
DTC patients with progressively and/or persis-
tently elevated TgAb levels and negative I-WBS 
[26].
A meta-analysis by Santhanam and co-authors 
investigated the accuracy of 18F-FDG PET/CT in 
the detection of residual disease in patients with 
BRAFV600E mutated thyroid cancer. The authors 
demonstrated that presence of BRAFV600E muta-
tion in DTC confers a higher likelihood of 18F- 
FDG avidity and is associated with higher 
SUVmax values compared to BRAFV600E- 
mutation negative status [27].
The role of 124I-PET/CT in detecting lesions of 
DTC amenable to 131I-therapy was recently 
described. The pooled sensitivity of 124I-PET/CT 
in detecting DTC lesions amenable to 131I-therapy 
was 94.2% (95%CI: 91.3–96.4%), and the pooled 
specificity was 49.0% (95%CI: 34.8–63.4%). 
The authors concluded that 124I-PET/CT is a sen-
sitive tool to diagnose radioiodine-avid DTC 
lesions, but also detects some new lesions that are 
not visualized on the post-treatment I-WBS [28].
10.7.4  Recurrence of Medullary 
Thyroid Cancer
Treglia and co-authors described the role of 18F- 
FDG PET or PET/CT in patients with suspected 
recurrent medullary thyroid cancer (MTC). A 
sub-analysis considering PET device used, serum 
calcitonin, carcino-embryonic antigen (CEA), 
calcitonin doubling time (CTDT) and CEA dou-
bling time (CEADT) values was also performed. 
Detection rate (DR) of 18F-FDG PET or PET/CT 
in suspected recurrent MTC on a per-patient- 
based analysis was 59% (95%CI: 54–63%). DR 
increased in patients with serum calcitonin 
≥1000  ng/L (75%), CEA ≥5  ng/mL (69%), 
CTDT <12  months (76%) and CEADT 
<24  months (91%). The authors reported that 
about 40% of suspected recurrent MTC remain 
usually unidentified by 18F-FDG PET or  PET/
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CT. However, 18F-FDG PET and PET/CT could 
modify the patient management in a certain num-
ber of recurrent MTC because these methods are 
often performed after negative conventional 
imaging studies [29].
In another meta-analysis evaluating the diag-
nostic performance of 18F-FDG and PET/CT for 
detection of recurrent or metastatic MTC, the 
pooled sensitivities of 18F-FDG-PET and PET/
CT were 68% (95%CI: 64–72%) and 69% 
(95%CI: 64–74%), respectively [30].
Other PET radiotracers beyond 18F-FDG were 
evaluated for detecting recurrent MTC. In a meta- 
analysis evaluating the DR of 18F-DOPA PET or 
PET/CT for recurrent MTC, the DR of 18F-DOPA 
PET and PET/CT on a per-patient- and a per- 
lesion- based analysis was 66% and 71%, respec-
tively. The DR significantly increased in patients 
with serum calcitonin ≥1000  ng/L (86%) and 
CTDT <24 months (86%). Therefore, 18F-DOPA 
PET/CT may be a very useful functional imaging 
method in detecting recurrent MTC [31].
Another meta-analysis assessed the DR of 
68Ga-somatostatin analogues PET or PET/CT in 
patients with recurrent MTC. The DR on a per- 
patient- based analysis was 63.5% (95%CI: 
49–77%). DR of 68Ga-somatostatin analogues 
PET or PET/CT increased in patients with higher 
serum calcitonin levels (83% for calcitonin 
>500 ng/L). The authors concluded that the diag-
nostic performance of 68Ga-somatostatin ana-
logues PET or PET/CT in recurrent MTC was 
lower compared to that of the same imaging 
method in the majority of NETs [32].
10.8  Parathyroid Diseases
Different PET tracers may be used to detect 
hyperfunctioning parathyroid glands in patients 
with hyperparathyroidism (HPT), including 
11C-methionine (11C-MET) and radiolabelled 
choline. 11C-MET PET has an overall good sensi-
tivity (69%) and positive predictive value (98%) 
in detecting hyperfunctioning parathyroid glands 
in patients with HPT and it may be considered a 
reliable second-line imaging method to enable 
minimally invasive parathyroidectomy [33].
Yuan and co-authors published a meta- 
analysis on the diagnostic value of 11C-MET PET 
in detecting hyperfunctioning parathyroid glands 
in patients with HPT and negative 99mTc-MIBI 
scan. Pooled sensitivity and specificity of 11C- 
MET PET in patients with HPT with negative or 
inconclusive 99mTc-MIBI scan were 86% and 
86%, respectively. The authors concluded that 
11C-MET PET can be a useful functional imaging 
modality in patients with negative or inconclu-
sive 99mTc-MIBI scan [34].
Caldarella and co-authors investigated the 
diagnostic performance of 11C-MET PET in 
patients with suspected parathyroid adenoma. 
Pooled sensitivity and DR values of 11C-MET 
PET in patients with suspected parathyroid ade-
noma were 81% (95%CI: 74–86%) and 70% 
(95%CI: 62–77%), respectively, on a per-patient- 
based analysis. The authors also concluded that 
11C-MET PET could be helpful when conven-
tional imaging techniques are negative or incon-
clusive in localizing parathyroid adenoma [35].
An evidence-based article by Kim and col-
leagues investigated the diagnostic performance 
of radiolabelled choline for localization of hyper-
functioning parathyroid gland in patients with 
HPT.  The pooled sensitivity for radiolabelled 
choline PET/CT was 90% (95% CI: 86–94%) 
and the pooled specificity 94% (95%CI: 90–96%) 
[36].
These findings are in line with a recent meta- 
analysis on the diagnostic performance of radiola-
belled choline PET for detecting hyperfunctioning 
parathyroid glands: on a per- patient analysis, the 
sensitivity was 95% (95%CI: 92–97%) and the 
positive predictive value was 97% (95%CI: 
95–98%); on a per-lesion analysis, pooled sensi-
tivity and PPV were 92% (95%CI: 88–96) and 
92% (95% CI: 89–95%), respectively [37].
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11.1  Introduction
This chapter summarizes 15 meta-analyses pub-
lished in the literature on the use of PET for car-
diac diseases, with the majority (n = 8) concerning 
the diagnosis of coronary artery disease (CAD) 
using myocardial perfusion imaging (MPI) in 
comparison to other modalities. Second in the 
number of published meta-analyses, three studies 
concentrated on the prognostic value of MPI for 
adverse cardiovascular events. Finally, one meta- 
analysis was published on the use of PET for four 
indications among myocardial viability assess-
ment, the presence of microvascular disease 
(impaired coronary vascular function in absence 
of obstructive, epicardial CAD), the use of car-
diac hybrid imaging and the diagnostic of cardiac 
amyloidosis.
11.2  Myocardial Blood Flow 
Perfusion




Myocardial Perfusion Imaging 
Modalities
Since the years 1950s, the technology of image 
acquisition in nuclear cardiology has progres-
sively evolved from initial planar to more recent 
rapid hybrid cadmium-zinc-telluride (CZT) 
single- photon emission computed tomography/
computed tomography (SPECT/CT) and digi-
talized 3-dimensional (3D) positron emission 
tomography/computed tomography (PET/CT). 
Contemporary to this evolution, advances in the 
computation of acquired quantitative data using 
more performant software have led to a more 
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objective, digital-based assessment of the patho-
physiological processes underlying cardiovascu-
lar diseases, from the stenosis of epicardial 
coronary artery to microvascular dysfunction, 
including coronary vasomotor as well as endo-
thelial dysfunction. In the meantime, new radio-
tracers for perfusion imaging have been 
developed, from potassium-43 (43K) to thallium-
 201 (201Tl) and technetium-99 metastable- 
labelled (99mTc) radiotracers for SPECT/CT; 
rubidium-82 (82Rb), oxygen-15-labelled water 
([15O]-H2O), nitrogen-13-labelled ammonia 
([13N]-NH3), and still under development F-18 
fluorine-labelled radiotracers for PET/CT.
Apart from nuclear techniques using SPECT/
CT and PET/CT, numerous non-invasive modali-
ties have been developed to assess the myocardial 
perfusion, including dobutamine stress echocar-
diography (DSE), cardiac magnetic resonance 
(CMR), computed tomographic myocardial per-
fusion imaging (CT-MPI), fractional flow reserve 
derived from computed tomography (FFR-CT), 
with different diagnostic performances [1–4]. 
The development of these non-invasive modali-
ties aims to contribute to counteract the burden of 
coronary artery disease (CAD), as the latest rep-
resents one of the leading causes of death and 
disability in developing countries [5]. In the field 
of nuclear imaging, especially PET/CT, there are 
accumulating evidences on the importance of 
flow quantification to guide management of sta-
ble CAD [6, 7], suggesting the potential role of 
PET/CT as gatekeeper for invasive coronary 
angiography (ICA). Therefore, following this 
paradigm change in the treatment of patients with 
CAD, it is of great importance to accurately 
select the right non-invasive imaging test evaluat-
ing the hemodynamic significance of a coronary 
stenosis for the right patient.
Jaarsma et al. [3] performed for the first time a 
meta-analysis on direct comparison of the diag-
nostic accuracy of three imaging modalities, 
PET/CT, CMR and SPECT/CT, for the diagnosis 
of significant CAD, using ICA as reference stan-
dard. In this meta-analysis, PET/CT performed 
better than CMR and SPECT/CT.
Dai et  al. [1] have also assessed in a meta- 
analysis the diagnostic performance of six different 
cardiac imaging modalities, including PET/CT, 
for the evaluation of altered myocardial perfu-
sion, using fractional flow reserve (FFR) derived 
from ICA as the reference standard. Among these 
imaging modalities, PET/CT as well as CMR and 
CT-MPI demonstrate high accuracy to detect 
hemodynamically significant CAD, as compared 
with SPECT/CT, DSE and FFR-CT on a patient 
and coronary territory basis. From these three 
best performing modalities, CMR and CT-MPI 
perform better than PET/CT in the evaluation of 
perfusion deficit. However, with the advent of 3D 
digital PET/CT, it is expected that the improve-
ment in the spatial resolution would add an incre-
mental value in the evaluation of perfusion deficit 
[8]. One of the strengths of PET/CT and CMR 
over other perfusion imaging modalities is the 
ability to absolutely quantify myocardial blood 
flow, as this has been well demonstrated to be a 
strong predictor of coronary artery disease [9]. In 
this field, PET/CT performs better than CMR 
according to these data. Using PET/CT, different 
parameters are generated for the quantitative 
assessment of myocardial blood flow: hyperemic 
MBF (hMBF) defined as the myocardial blood 
flow during hyperemic stress test; resting MBF 
(rMBF) defined as the myocardial blood flow in 
resting conditions; relative myocardial blood 
flow (RBF) defined as the ratio from hMBF in the 
stenosed coronary territory to hMBF of a refer-
ence non- stenotic territory; and myocardial flow 
reserve (MFR) defined as the ratio from hMBF 
and rMBF [10]. Evidences have demonstrated a 
discrepancy in the diagnostic accuracy of differ-
ent MBF parameters [1, 10]. Indeed, hMBF has 
been found to be more accurate than CFR and 
FFR in the detection of significant coronary 
artery disease using either FFR derived from ICA 
or visual evaluation of the severity of the stenosis 
during ICA, as well as both as reference standard. 
The limited performance of CFR regarding sensi-
bility and specificity as compared to the two 
other parameters is linked to the clinically rele-
vant coronary pathophysiology, as MFR evalu-
ates the global vascular response to hyperemia 
[9]. Thus, epicardial coronary stenosis (from 
mild diffuse to focal severe) and microvascular 
dysfunction (from vasomotor tone to endothelial 
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function) are determinants for the assessment of 
MFR. Alterations of one of these parameters in 
resting conditions can already lead to an activa-
tion of compensatory vasodilation of the resis-
tance vessels in the microcirculation, resulting in 
an alteration of rMBF [11]. Thus, MFR could be 
limited in the detection of epicardial coronary 
stenosis in the presence of diffuse atherosclero-
sis. However, in contrary to hMBF, MFR has the 
best prediction value for major adverse cardio-
vascular events (MACE) when comparing both 
parameters [9]. FFR showed the best specificity 
from all three parameters. However, unlike the 
two other parameters, it requires a coronary terri-
tory free from relevant coronary stenosis, what 
can be problematic in patients with coronary 
3-vessels disease. And this explains the limited 
sensibility of this parameter. The results of this 
meta-analysis are in line with the previous pub-
lished meta-analysis from Takx et al. [2], with all 
patients presenting an intermediate epicardial 
coronary stenosis in ICA, further evaluated by 
FFR.  Interestingly, in this meta-analysis, post- 
test probabilities following a negative respec-
tively a positive test result in PET/CT and CMR 
was calculated (derived from pre-test probability 
and likelihood ratio), with high accuracy, ranging 
from 9% to 11% respectively from 84% to 85%. 
Indeed, over sensitivity and specificity, the clini-
cal performance of a non-invasive perfusion 
modality can be best assessed by the ability of 
post-test probability to confidently rule-in (post- 
test probability ≥85%) or rule-out (post-test 
probability ≤15%) relevant CAD. In this line, a 
recent meta-analysis has investigated the ranges 
of pre-test probability of significant CAD, in 
which five imaging modalities, including PET/
CT, can highlight an accurate post-test probabil-
ity [12]. For this purpose, anatomic and func-
tional reference standard were used, derived from 
ICA and FFR respectively with cut-off values for 
determining significant CAD for a stenosis >50% 
on ICA or a FFR ≤0.80. Depending on the refer-
ence standard used, PET/CT as well as the other 
functional imaging techniques (SPECT/CT, 
CMR) performed different. Indeed, using ana-
tomic reference standard, they all showed only 
moderate accuracy, whereas there was a signifi-
cant improvement of their performance when 
using functional reference standard.
When comparing nuclear cardiology modali-
ties together, PET/CT appears more advanta-
geous than SPECT/CT in many aspects in two 
meta-analyses [13, 14]. PET/CT has a higher 
spatial resolution resulting from better count sen-
sitivity and higher energy of their radiotracers. 
Moreover, PET/CT has a better image quality 
due to short half-life of their radiotracers leading 
to higher signal-to-noise ratio. This short half-life 
of the radiotracers enables lower patient radiation 
exposure as compared to SPECT, with up to 
tenth, respectively, half of a standard dose for 
201Tl and 99mTc as compared to 82Rb. And when 
evaluating the efficacy of transmyocardial laser 
revascularization (TMR) in patients with refrac-
tory angina not amenable to conventional percu-
taneous or surgery revascularization, PET/CT, in 
contrary to SPECT/CT, demonstrates an improve-
ment of the subendocardial to subepicardial ratio 
in the follow-up, where SPECT/CT showed no 
changes in a meta-analysis [15]. Thus, PET/CT, 
as compared to SPECT/CT, did have better reso-
lution to assess the subendocardial and subepi-
cardial perfusion, which is a relevant factor for 
the detection and follow-up of patients with 
CAD.
There are some limitations who have to be 
taken into consideration when interpreting the 
results of the most discussed meta-analysis. In 
the last decade, evidences from randomized con-
trolled trials highlighted the importance of con-
sidering the hemodynamic significance of 
epicardial coronary lesion using fractional flow 
reserve (FFR) than just the traditional visual 
assessment of the severity of the epicardial coro-
nary lesion in the decision of revascularization 
[16]. Indeed, these evidences demonstrate a dis-
crepancy between the visual assessment of the 
severity and the functional significance of the 
lesion, with impact on the outcome when revas-
cularizing or not. Moreover, in many patients 
with stable CAD and epicardial coronary steno-
sis, the non-inferiority of optimal medical treat-
ment (OMT) over percutaneous coronary 
intervention (PCI) on top of OMT has been well 
demonstrated [17]. Therefore, using visual 
11 Evidence-Based PET for Cardiac Diseases
102
assessment of the severity of coronary stenosis as 
reference could have introduced significant bias 
of the present results.
FFR is a surrogate of the coronary perfusion, 
derived from measurement of the coronary pres-
sure before and after the stenosis. Thereby, it 
would ideally represent the proportion of blood 
flow available to the myocardium distally from 
the stenosis, as compared to the one in the 
absence of coronary stenosis [18]. Using FFR as 
reference standard to evaluate the accuracy of 
coronary perfusion, PET/CT is largely question-
able for many reasons. First, early evidences 
from the 1980s have demonstrated the predomi-
nant role of coronary flow over coronary perfu-
sion pressure for the maintenance of an adequate 
myocardial function. In this animal experimental 
study, the significant reduction of coronary perfu-
sion pressure to values equivalent to an FFR 
around 0.4 did not lead to alteration of the myo-
cardial function as long as the coronary flow was 
maintained [19]. Second, perfusion imaging 
modalities were used to validate FFR [20], mak-
ing it less suitable as reference standard to deter-
mine the accuracy of perfusion PET/CT. Third, 
recent data from large, multicenter, prospective 
randomized trial demonstrate that a significant 
proportion of patients (60% of the study popula-
tion) with epicardial stenosis showing FFR ≤0.8 
did not require coronary revascularization [21]. 
Following all these evidences, the results of these 
meta-analyses should be interpreted with care. It 
is not excluded that one of these imaging modali-
ties is more accurate than what it was found, but 
it could not be demonstrated due to the use of 
FFR as reference standard. Other bias could also 
have an impact on the results of these different 
meta-analyses, such as the use of different PET/
CT scans and different PET/CT scan protocols, 
the difference in the prevalence of CAD in the 
different studies, the difference in the threshold 
of FFR and visual assessing of the severity of the 
coronary stenosis. Moreover, most of the meta- 
analyses have evaluated the imaging modalities 
as a stand-alone technique, without integrating 
other clinical parameters such as age and gender 
as well as other para-clinical parameters such as 
ventricular function, which could have increased 
the accuracy of the imaging modality. Finally, 
even if considerable efforts have been made to 
reduce the radiation exposure of patients under-
going a PET/CT, it remains a matter of concern 
when comparing to other imaging modalities 
such as CMR with no radiation exposure.
Despite the significant advances in the assess-
ment of patients with CAD, further investigations 
are still needed to overcome these limitations, 
thus bringing a new step of comprehension in the 
art of performing the right exam to the right 
patient.
11.2.2  Prognostic Value 
of Myocardial PET
PET MPI is increasingly being used for an accu-
rate assessment of myocardial ischemia in 
patients with known or suspected coronary artery 
disease (CAD). It has been proposed by the 
American Heart Association that PET MPI may 
play a role as a novel cardiovascular biomarker, 
allowing better risk stratification of patients with 
CAD.
A first meta-analysis by Siontis et al. [22] spe-
cifically evaluated the incremental prognostic 
value that PET MPI added to standard risk fac-
tors in patients with known or suspected 
CAD.  They selected 20 studies (with possible 
overlap in 5) totaling 22,203 patients, during a 
long span of 20 years, with only seven prospec-
tive studies. There was considerable heterogene-
ity among studies as MPI acquisition protocols, 
image analysis and selected radiotracer were not 
standardized among the studies. Only five studies 
reported changes in model classification, dis-
crimination and risk stratification. PET MPI 
improved risk classification in four out of these 
five studies Despite the limitations of the meta- 
analysis, the authors were able to show that there 
is a strong association between abnormal perfu-
sion (both by quantitative and qualitative analy-
sis) and patient’s outcome. They concluded that 
the limited data suggest that PET MPI may 
improve risk stratification, but this should be 
 confirmed by data from larger and standardized 
prospective randomized controlled trials.
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The second systematic review and meta- 
analysis by Chen et al. [23] focused on evaluating 
the prognostic value of normal PET MPI in 
patients with suspected or known CAD.  They 
selected 11 studies with a total of 20,471 patients 
in whom PET MPI was performed for the diag-
nosis of coronary artery disease and with evalua-
tion of cardiovascular death, all-cause death and 
major cardiovascular events (MACE) at a follow-
 up ≥3  months. They found highly significant 
negative predictive values for cardiac death 
(98.8%; 95% confidence interval (CI), 97.64–
99.39%), all-cause death (94.8%; 95% CI: 
92.99–96.30%) and MACE (90.2%; 95% CI: 
78.01–96.03%), with a reasonable follow-up 
period of 36.9  months, 26.8  months and 
35.7 months, respectively. In a subgroup analy-
sis, there was no significant difference in negative 
predictive value in studies with a normal PET 
MPI determined by absence of perfusion abnor-
malities compared to those using coronary flow 
reserve. An important limitation is that the 
authors were not able to differentiate patients 
with known coronary artery disease from patients 
with only clinical suspicion.
The third wide meta-analysis carried by 
Smulders et  al. [24] compared several non- 
invasive tests for depiction of coronary artery dis-
ease. The aim was to evaluate the prognostic 
value of negative non-invasive cardiac investiga-
tions in patients with suspected or known 
CAD.  They compared CT angiography, stress 
echocardiography, cardiac magnetic resonance, 
exercise electrocardiographic testing, SPECT 
and PET.  The evaluated outcome was annual 
event rate for cardiac death and myocardial 
infarction. They included 165 studies with a total 
of 122,721 patients. Annual event rates (AER) 
after a negative test varied among the imaging 
modalities (between 0.32 for CT angiography 
and 1.36 for stress echocardiography). Some 
modalities are preferred in populations at higher 
event risk or known CAD. The authors supposed 
the different patient population among studies 
could explain the differences between modali-
ties. Indeed, when adjusting for the population 
risk, the AER was similar between modalities. 
This meta-analysis supports that a negative 
non- invasive cardiac study provides predictive 
information with good accuracy, which should 
influence the clinical practice by reducing the 
need of further cardiac investigations.
In the last years, there is growing scientific 
evidence describing the value of non-invasive 
cardiac investigations, not only as a diagnostic 
tool but also as a predictive prognosis biomarker. 
Specifically, a negative test has an excellent prog-
nosis, which should reasonably reassure the 
patient.
11.3  Assessment of Myocardial 
Viability
The concept of hibernating myocardium has been 
adopted in the early 1980s following the cumu-
lating evidences of an improvement of the myo-
cardial regional contractile function after an 
aorto-coronary bypass surgery [25]. It described 
a condition of altered left ventricular contractile 
function as a consequence of prolonged reduced 
coronary blood supply at rest, with improving 
potential following coronary revascularization. 
Different non-invasive imaging modalities, such 
as dobutamine stress echocardiography, cardiac 
magnetic resonance imaging and nuclear imag-
ing, focusing on different aspects of the viable 
myocardium, have been proposed to identify 
viability in dysfunctional myocardial segments, 
with different diagnostic accuracy [26]. Among 
all these modalities, PET is considered as the 
gold standard [27].
In the meta-analysis of Tsai et  al. [28], the 
authors investigated the accuracy of SPECT for 
the diagnosis of myocardial viability in patients 
with CAD and left ventricular dysfunction as 
compared to 18F-FDG PET. Although this meta- 
analysis was not centred on PET, which was only 
used as the gold-standard comparator for SPECT, 
it is the only one published about viability involv-
ing PET/CT. The authors found eight prospective 
studies totaling 320 patients (3580 segments ana-
lysed). The criteria used for SPECT viability 
were diverse in these eight studies, but most 
 frequently involved the presence of myocardial 
rest perfusion visible (e.g. >50% or >55%), while 
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two studies also involved 18F-FDG in the criteria 
for SPECT viability (usually with SPECT vs. 
PET mismatch indicating viability).
SPECT as compared to PET resulted in the 
following pooled values: pooled sensitivity 82% 
(95%CI 81–84%), pooled specificity 88% 
(95%CI 86–90%), diagnostic odd ratio 62.6 
(95%CI 19.3–203) and the area under the receiv-
ing operating characteristic curve was 
0.945 ± 0.026. There was a significant heteroge-
neity among studies especially in the definition 
of myocardial viability and the largest study 
included 58 patients, but the QUADAS quality 
assessment was of excellent quality and the fun-
nel plot indicated no publication bias.
Thus, this meta-analysis showed that SPECT 
can be used adequately to assess myocardial via-
bility in patients with CAD and left ventricular 
dysfunction. However, nowadays SPECT appears 
to be an outdated modality for assessing myocar-
dial viability, and cardiac PET would be pre-
ferred for this diagnosis.
11.4  Microvascular Disease
Coronary artery disease (CAD) has often been 
exclusively associated to epicardial coronary 
abnormalities, as visualized during invasive coro-
nary angiography (ICA). Nowadays, there are 
more evidences on the involvement of the entire 
coronary circulation, including the microcircula-
tion, in the development of symptoms related to 
CAD [29]. This issue has been highlighted in a 
large cohort of symptomatic patients undergoing 
a diagnostic ICA for suspected obstructive epi-
cardial CAD, where about 60% of the patients 
did not have a significant obstructive CAD (ste-
nosis ≤50%) [30]. Microvascular dysfunction 
may encounter for a significant number of symp-
tomatic patients without relevant obstructive 
CAD [29, 31]. Coronary microvascular disease 
(CMD) englobes a group of disorders affecting 
the structure and function of the coronary micro-
circulation in relation with endothelial dysfunc-
tion or a dysregulation of the vascular smooth 
muscle. Numerous non-invasive techniques have 
been proposed to assess the coronary microvas-
cular function, such as PET/CT, dynamic CT-MPI 
and CMR [32]. Among these, PET/CT is the 
most validated modality with good reproducibil-
ity and accuracy.
In a systematic review and meta-analysis, 
Brainin et  al. investigated the consequences of 
impaired coronary vascular function in the 
absence of obstructive coronary arterial disease 
[33]. In six studies (n = 1192 patients) endothe-
lial dependent epicardial dysfunction was 
assessed, five of them measured coronary flow 
reserve (CFR) during angiography using cold- 
pressure test or acetylcholine stimulation. In one 
study, CFR was measured using cold-pressure 
testing during PET. In a pooled analysis, the rela-
tive risk (RR) of 2.49 for cardiovascular events 
was significantly increased. In another group of 
ten studies (n  =  5134), non-endothelial depen-
dent epicardial dysfunction was assessed measur-
ing coronary flow velocity reserve using 
echocardiography. These studies showed an 
increased RR of 4.58. In the last group including 
ten studies (n = 3687 patients) measuring CFR by 
PET, non- endothelial dysfunction was associated 
with an increased RR of 2.44.
These results underline that coronary vascular 
dysfunction as assessed by PET/CT has a prog-
nostic value on cardiovascular events in a group 
of patients without obstructive coronary arterial 
disease. RR remained significantly elevated when 
excluding patients with diabetes or angina, as it 
remained elevated when including only patients 
with one specific stressor. Even if the number of 
studies remained small with different methods 
applied, impaired coronary vascular function in 
the absence of obstructive coronary disease 
should be reported for its prognostic value and 
considered as a potential therapeutic target.
11.5  Cardiac Hybrid Imaging
Cardiac multimodality (hybrid) imaging is a 
technique relying on the combination (on a side- 
by- side or fusion mode) of imaging modalities 
providing in one hand cardiac morphological 
data, such as CT, echocardiography or CMR, and 
in the other hand imaging modalities providing 
myocardial functional data, such as PET/CT. The 
goal of this combination is to gain information of 
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these different imaging modalities in a comple-
mentary fashion in order to better guide coronary 
revascularization [34].
Coronary CT angiography (CCTA) has high 
negative predictive value and sensitivity for diag-
nosing obstructive CAD; however, its positive 
predictive value and specificity are lower. In par-
ticular, CCTA may overestimate coronary artery 
stenosis. Therefore, a hybrid approach combin-
ing CCTA with MPI modalities—including PET, 
SPECT and CMR—may help diminish the false- 
positive rate of CCTA by fusing anatomic data 
derived from CCTA with functional data obtained 
through MPI, thus potentially overcoming CCTA 
limitations. To evaluate the clinical utility of this 
approach, Rezvi et al. [35] conducted a system-
atic literature review and meta-analysis compar-
ing the diagnostic performance of hybrid cardiac 
imaging modalities with stand-alone CCTA for 
assessing obstructive CAD, using as a reference 
standard invasive coronary angiography (ICA).
The results of the meta-analysis showed that, 
at the per-patient level, CCTA and MPI demon-
strated comparable sensitivity (p  =  0.35), but 
CCTA displayed lower specificity (66%) com-
pared to MPI (83%) for predicting obstructive 
CAD; at the per-vessel level, specificity of CCTA 
and MPI was similar (p = 0.02), and sensitivity 
was higher for CCTA (89%) than for MPI alone 
(78%) (p < 0.001).
When the diagnostic performance of hybrid 
versus CCTA imaging method was examined on 
a per-patient basis, sensitivity, negative likeli-
hood ratio (LR–) and diagnostic odds ratio 
(DOR) of hybrid imaging techniques compared 
to CCTA to detect obstructive CAD were, respec-
tively, 91%, 0.11 and 159.00, versus 90%, 0.06 
and 53.80 (p > 0.05, for all). Specificity and posi-
tive likelihood ratio (LR+) were higher for hybrid 
imaging compared to stand-alone CCTA (93% 
and 12.80 versus 66% and 3.39, respectively). At 
the per-vessel level, summary receiver-operator 
curves (sROC) demonstrated a statistically sig-
nificant and higher area under the curve (AUC) 
value for hybrid imaging than for CCTA (0.97 
versus 0.93, respectively; p = 0.047).
In conclusion, hybrid imaging techniques out-
performed stand-alone CCTA for detecting 
obstructive CAD in patients undergoing both 
anatomic and functional testing, demonstrating 
higher specificity and LR+ on a per-patient 
basis. In addition, at the per-vessel level, 
hybrid imaging could better identify CAD 
based on sROC curves; however, sensitivity 
was comparable for hybrid versus stand-alone 
CCTA imaging.
11.6  Cardiac Amyloidosis
Amyloidosis encompasses a group of infiltrative 
disorders characterized by extracellular accumu-
lation of fibrillary proteins, leading to functional 
impairment of different tissues and organs, 
including the heart. In patients with systemic 
amyloidosis, cardiac involvement could lead to 
significantly increased morbidity and mortality. 
The most common types of cardiac amyloidosis 
are systemic light chain (AL) and transthyretin 
(ATTR) amyloidosis. This differentiation is of 
importance as it differs in treatment and progno-
sis, untreated patients with AL amyloidosis hav-
ing the poorest prognosis [36]. ATTR has been 
long time considered as a rare disease because of 
the lack of disease awareness, its quiescent nature 
at the beginning and the heterogeneity of symp-
toms when clinical manifest. Nowadays, accu-
mulating evidences showed that it may be more 
prevalent than thought, especially in certain 
groups of patients such as older people or patients 
with aortic stenosis [37]. Moreover, with the 
emergence of new treatment options, early diag-
nosis is critical because of the better effectiveness 
of the treatment in the earlier course of the dis-
ease [38]. In line with this, bone scintigraphy as a 
non-invasive tool in the flowchart to accurately 
differentiate between AL and ATTR amyloidosis 
is well established [39]. Moreover, recent devel-
opment in amyloid tracers for positron emission 
tomography (PET) could lead to an early diagno-
sis and potentially improve the prognosis of those 
patients. In that setting, we shortly present the 
results of the first systematic review and 
 meta- analysis on the diagnostic performance of 
amyloid PET imaging in cardiac amyloidosis by 
Kim et  al. [40]. The authors also reported the 
potential additional value of using semi-quan-
titative parameters for the diagnosis of cardiac 
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amyloidosis and for distinguishing between AL 
and ATTR amyloidosis.
Six retrospective studies with a total of 98 
patients (69 patients with systemic amyloidosis 
and 29 control patients) were included in this 
meta-analysis. Among amyloid radiotracers, 11C- 
PIB was the most commonly used in four studies, 
whereas 18F-Florbetapir and 18F-Florbetaben 
were each used in one study.
In the whole cohort (six studies), the pooled 
sensitivity was 0.95 (95% CI 0.87–0.99), and 
pooled specificity was 0.98 (95% CI 0.87–1.00). 
Positive likelihood ratio (LR) was 10.130 (95% 
CI 3.749–27.376), negative LR was 0.100 (95% 
CI 0.045–0.221), and diagnostic odds ratio was 
148.83 (95% CI  =  34.026–650.98). Summary 
receiver operating characteristic curve showed 
high performance with an area under curve of 
0.9731 with a standard error of 0.0156. Looking 
only at the four 11C-PIB studies, similar results 
were found with a diagnostic odds ratio of 134.19 
(95% CI 24.039–749.03).
The use of semi-quantitative parameters was 
reported in four studies (three with 11C-PIB and 
one with 18F-Florbetaben) and consisted of reten-
tion index (RI) and/or target-to-background ratio 
(TBR). RI derived from dynamic acquisitions 
(RI = mean myocardial SUV/integral of the arte-
rial time–activity curve). By contrast, TBR was 
extracted from static acquisitions (TBR = max or 
mean myocardial SUV/mean SUV of the 
descending thoracic aorta). Patients with cardiac 
amyloidosis had significantly higher RI and TBR 
values in comparison to control patients. Using 
both, pooled standardized mean difference 
(SMD) was of 1.42 (95% CI 0.83–2.01; 
p < 0.001). The performance of RI and TBR for 
discriminating between AL and ATTR amyloido-
sis was assessed in three studies (two with 11C- 
PIB and one with 18F-Florbetaben) and showed 
significantly higher uptake in the former (pooled 
SMD = 0.96; 95% CI 0.13–1.79; p < 0.001).
To resume, amyloid PET imaging presents 
with strong performance to diagnose cardiac 
amyloidosis with high sensitivity and specificity 
(≥95%). The addition of semi-quantitative 
parameters, such as RI and TBR, could help 
improve the diagnosis and accurately differenti-
ate between AL and ATTR amyloidosis.
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Nuclear medicine techniques are non-invasive 
tools that can early detect pathophysiological 
changes in affected tissues in patients with 
inflammatory or infectious diseases. These 
changes usually occur before clinical onset of 
symptoms and before the development of ana-
tomical changes detected by radiological tech-
niques [1, 2]. Currently, hybrid imaging 
techniques as positron emission tomography/
computed tomography (PET/CT) may provide 
functional and morphological information for 
early diagnosis of infectious and inflammatory 
diseases [1, 2].
The ability of Fluorine-18 fluorodeoxyglucose 
(18F-FDG) PET/CT to identify sites of inflamma-
tion and infection is mainly related to the glyco-
lytic activity of the cells involved in the 
inflammatory response [3, 4]. Enough evidence 
in the literature already exists about the diagnos-
tic performance of 18F-FDG PET/CT in the diag-
nosis and management of several infectious and 
inflammatory diseases [5]. The results of the 
selected articles, including pooled values and 
95% confidence interval (95%CI), are presented 
in Table 12.1 and summarized here below.
12.2  Fever of Unknown Origin 
(FUO)
Fever of unknown origin (FUO) is commonly 
defined as temperature ≥38.3 °C on at least two 
occasions, duration of illness ≥3 weeks or mul-
tiple febrile episodes in ≥3 weeks, not immuno-
compromised patient, and uncertain diagnosis 
despite thorough history-taking, physical exami-
nation, and obligatory investigations [6]. The 
diagnosis in patients with FUO is a challenging 
medical problem; the cause of FUO may be 
infectious diseases, non-infectious inflammatory 
diseases, or tumors, and 18F-FDG PET/CT detect-
ing foci of increased glucose metabolism may be 
used for revealing the source of fever [6]. Several 
meta-analyses have estimated the diagnostic per-
formance of 18F-FDG PET/CT in the assessment 
of FUO unidentified by conventional workup 
[7–13].
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Table 12.1 Characteristics and main findings of included meta-analyses on the diagnostic performance of 18F-FDG 
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Dong et al. firstly reported that the pooled sen-
sitivity and specificity of 18F-FDG PET/CT for 
the detection of FUO were 98.2% (95%CI: 93.6–
99.8) and 85.9% (95%CI: 75–93.4), respectively. 
Therefore, this method should be considered 
among the first diagnostic tools for patients with 
FUO in whom conventional diagnostics have 
been unsuccessful [7].
Hao et  al. confirmed the high sensitivity of 
18F-FDG PET/CT for the diagnosis of patients 
with FUO (pooled value: 88%; 95%CI: 81–88), 
but the possibility of false positive results should 
be kept in mind [8].
Another meta-analysis demonstrated that 
abnormal 18F-FDG PET/CT findings are associ-
ated with a substantially increased final diagnos-
tic rate in FUO (pooled odds ratio: 8.94; 95%CI: 
4.18–19.12, p  <  0.00001). Consequently, 18F- 
FDG PET/CT could be considered for inclusion 
in the first-line diagnostic workup of FUO [9].
Tateuchi et al. reported that 18F-FDG PET/CT 
can be useful in identifying the source of fever in 
patients with classic FUO (immunocompetent 
patients). The summary sensitivity and specific-
ity were 86% (95%CI: 81–90) and 52% (95%CI: 
36–67), respectively. The contribution of 18F- 
FDG PET/CT may be limited in clinical settings 
in which infectious and neoplastic causes are less 
common. Indirect comparisons of test perfor-
mance suggested that 18F-FDG PET/CT outper-
formed standalone 18F-FDG PET, Gallium-67 
scintigraphy, and radiolabelled leukocyte scintig-
raphy in detecting causes of FUO. Studies using 
standardized diagnostic algorithms are needed to 
determine the optimal timing for testing and to 
assess the impact of tests on management deci-
sions and patient-relevant outcomes [10].
Recently, Bharucha et al. reported an overall 
diagnostic contribution of 56% (95%CI: 50–61) 
of 18F-FDG PET/CT in all patients with FUO. In 
a subgroup analysis taking into account previous 
investigations the diagnostic yield/added contri-
bution of 18F-FDG PET/CT over CT was 32% 
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abnormal 18F-FDG-PET/CT in patients with 
FUO was 69% (95%CI: 63–75); the higher pro-
portion of abnormal scans was accounted for by a 
proportion of false positive abnormal scans with 
no contribution to the final diagnosis, with an 
overall result of 9% (95%CI: 5–14). The authors 
concluded that there is insufficient evidence to 
support the value of 18F-FDG PET/CT in investi-
gative algorithms of FUO [11].
Conversely, in an updated meta-analysis on 
patients with FUO or inflammation of unknown 
origin (IUO), 18F-FDG PET/CT was demon-
strated to be very helpful for recognizing and 
excluding diseases, directing further diagnostic 
decisions, and avoiding unnecessary invasive 
examinations. The pooled sensitivity and speci-
ficity were 84% (95%CI: 79–89) and 63% 
(95%CI: 49–75), respectively. Based on these 
findings, the authors recommended 18F-FDG 
PET/CT among the first-line diagnostic tools for 
patients with FUO and IUO [12].
Lastly, it has been recently demonstrated that 
patients with negative 18F-FDG PET/CT results 
were significantly more likely to present with 
spontaneous fever regression than those with 
positive 18F-FDG PET/CT results (summary rela-
tive risk = 5.6: 95%CI: 3.4–9.2; p < 0.001) [13].
Overall, there is not agreement among the 
selected meta-analyses about the added value of 
18F-FDG PET/CT in patients with FUO.  The 
main drawback of the meta-analyses evaluating 
the diagnostic performance of 18F-FDG PET/CT 
for this specific indication is that they include 
articles without real FUO patients or with highly 
variable definitions of FUO; therefore, related 
meta-analyses could be not accurate in this regard 
[14].
12.3  Large Vessel Vasculitis (LVV)
Large vessel vasculitis (LVV) is defined as an 
inflammatory disease mainly affecting the large 
arteries, with two major variants, Takayasu arte-
ritis (TA) and giant cell arteritis (GCA). GCA 
often coexists with polymyalgia rheumatica 
(PMR) in the same patient, since both belong to 
the same disease spectrum [15]. 18F-FDG PET/
CT may demonstrate increased radiopharmaceu-
tical uptake in the vascular wall of large vessels 
in patients with LVV; therefore, this method may 
be used for diagnosis, monitoring of disease 
activity, and evaluating disease progression in 
LVV [15–18], and several meta-analyses have 
assessed the role of this imaging method in this 
setting [19–25].
First meta-analyses including both 18F-FDG 
PET and PET/CT studies reported a valuable 
diagnostic performance of these methods in 
patients with GCA with a pooled sensitivity and 
specificity of 80% (95%CI: 63–91) and 89% 
(95%CI: 78–94), respectively [19], and a moder-
ate value of these methods in assessing TA activ-
ity, with a pooled sensitivity and specificity of 
70.1% (95%CI: 58.6–80) and 77.2% (95%CI: 
64.2–87.3), respectively [20].
In a meta-analysis of Soussan et al. including 
both 18F-FDG PET and PET/CT studies, these 
imaging methods showed good performances in 
the diagnosis of LVV, with higher accuracy in 
GCA patients than in TA patients. A vascular 
uptake equal to or higher than the liver uptake 
appeared to be a good criterion for the diagnosis 
of vascular inflammation. 18F-FDG PET or PET/
CT showed high sensitivity and specificity for the 
diagnosis of LVV in GCA patients in comparison 
to controls, with pooled values of 90% (95%CI: 
79–93) and 98% (95%CI: 94–99), respectively. 
18F-FDG PET or PET/CT had a pooled sensitivity 
of 87% (95%CI: 78–93) and specificity of 73% 
(95%CI: 63–81) for the assessment of disease 
activity in TA, with up to 84% of specificity in 
studies using National Institutes of Health crite-
ria as the disease activity assessment scale [21].
Another meta-analysis by Lee et al. confirmed 
that 18F-FDG PET/CT has good diagnostic accu-
racy for LVV with a pooled sensitivity and speci-
ficity of 83.9% (95%CI: 71.7–92.4) and 87.2% 
(95%CI: 72.6–95.7), respectively [22].
In a recent meta-analysis, the pooled sensitiv-
ity and specificity of 18F-FDG PET or PET/CT 
for detecting active disease in TA compared to 
clinical assessment were 81% (95%CI: 69–89) 
and 74% (95%CI: 55–86), respectively. Active 
disease by 18F-FDG PET or PET/CT was also 
associated with elevations of acute phase reac-
tants, as C-reactive protein (CRP) and erythro-
cyte sedimentation rate (ESR) [23]. Conversely, 
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in another meta-analysis by Gomez et al. about 
the association between the CRP value and 18F- 
FDG PET or PET/CT vascular positivity in TA, 
CRP concentration only moderately reflected the 
18F-FDG PET vascular positivity in TA, suggest-
ing dissociated information [24]. More prospec-
tive studies are needed to assess the value of 
18F-FDG PET/CT as an independent biomarker 
for subtle vascular wall inflammation detection in 
patients with TA [24].
Lastly, an updated meta-analysis confirmed 
that 18F-FDG PET or PET/CT has a good perfor-
mance for the detection of active disease in 
patients with LVV with a pooled sensitivity and 
specificity of 88% (95%CI: 79–93) and 81% 
(95%CI: 64–91), respectively. Therefore, 18F- 
FDG PET/CT could be suggested as a surrogate 
biomarker for assessment of disease activity of 
LVV during or after immunosuppressive therapy, 
but further studies are warranted to determine if 
PET-based treatment of LVV can improve out-
comes [25].
Several factors may significantly influence the 
diagnostic performance of 18F-FDG PET/CT in 
LVV including different PET interpretation crite-
ria, atherosclerotic vascular 18F-FDG uptake (a 
possible source of false positive findings), and 
immunosuppressive therapy (a possible source of 
false findings) [15].
Overall, based on the available evidence, 18F- 
FDG PET/CT has demonstrated high diagnostic 
performance for the detection of LVV.  Further 
studies are needed to select the most clinically 
relevant and reproducible criteria for defining the 
presence of LVV with 18F-FDG PET/CT, as well 
as to test the clinical impact of 18F-FDG PET/CT 
on the management of patients with suspected 
LVV [15].




Infectious endocarditis (IE) is a serious and 
potentially life-threatening condition. The cur-
rent diagnosis of IE is based on the modified 
Duke criteria, which has approximately 80% sen-
sitivity for the diagnosis of native valve endocar-
ditis (NVE), with lower sensitivity for the 
diagnosis of prosthetic valve endocarditis (PVE) 
and culture-negative endocarditis [26, 27]. Non- 
invasive imaging modalities may improve diag-
nosis of infective endocarditis (IE) [26, 27]. In 
particular, 18F-FDG PET/CT is currently included 
as diagnostic tool in the diagnostic flow chart for 
IE [26–29] and some meta-analyses have evalu-
ated the diagnostic performance of this method in 
patients with IE or CIED infections [30–34].
A first meta-analysis published in 2016 dem-
onstrated that the overall diagnostic perfor-
mance of 18F-FDG PET/CT for the diagnosis of 
IE was not high due to the low sensitivity: 
pooled sensitivity and specificity were 61% 
(95%CI: 52–88) and 88% (95%CI: 80–93), 
respectively. However, the diagnostic perfor-
mance of 18F-FDG PET/CT increased in the 
subgroup of patients with PVE [30].
Mahmood et  al. demonstrated that 18F-FDG 
PET/CT may be a useful adjunctive diagnostic 
tool in the evaluation of diagnostically challeng-
ing cases of IE, particularly in PVE. The pooled 
sensitivity and specificity of 18F-FDG PET/CT 
for diagnosis of IE were 76.8% (95%CI: 71.8–
81.4) and 77.9% (95%CI: 71.9–83.2), respec-
tively. Diagnostic accuracy was improved for 
PVE with pooled sensitivity of 80.5% (95%CI: 
74.1–86) and pooled specificity of 73.1% 
(95%CI: 63.8–81.2). More recent studies pub-
lished from 2015 to 2017 reported a higher 
pooled sensitivity of 81.3% (95%CI: 74.3–87) 
and specificity of 79% (95%CI: 71.2–85.5). The 
majority of the recent studies were prospective 
and used a specific protocol (i.e., a low- 
carbohydrate fat-allowed diet for at least 24  h 
prior to imaging, a prolonged fasting prior to 
imaging, and/or an intravenous heparin bolus 
prior to 18F-FDG administration). 18F-FDG PET/
CT also has the potential to detect clinically rel-
evant extra-cardiac foci of infection, malignancy, 
and other sources of inflammation, leading to 
more appropriate treatment regimens and surgi-
cal intervention. Additional extra-cardiac foci of 
infection were found on 17% of patients in this 
meta-analysis [31].
In another meta-analysis, Juneau et al. demon-
strated that 18F-FDG PET/CT has a good diag-
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nostic accuracy for the diagnosis of IE if adequate 
patient preparation for suppression of physiologi-
cal myocardial 18F-FDG uptake was performed, 
including prolonged fasting at least 12 h and/or 
heparin injection before 18F-FDG administration, 
and/or high-fat carbohydrate-restricted protein- 
permitted diet (minimum two meals for 24  h). 
Pooled sensitivity of 18F-FDG PET/CT per-
formed with adequate cardiac preparation for the 
diagnosis of IE was 81% (95%CI: 73–86) and 
pooled specificity was 85% (95%CI: 78–91). In 
the subgroup of patients with PVE, the pooled 
sensitivity was 85% (95%CI: 77–91) but speci-
ficity was 81% (95%CI: 72–88). Therefore, 18F- 
FDG PET/CT may be useful in the investigation 
of IE, and should be considered in cases where 
the diagnosis is uncertain [32].
18F-FDG PET/CT may be helpful in the diag-
nosis of cardiovascular implantable electronic 
device (CIED) infections, particularly in patients 
with the absence of localizing signs or definitive 
echocardiographic findings. In a recent meta- 
analysis, Mahmood et al. reported a pooled sensi-
tivity and specificity of 18F-FDG PET/CT in the 
diagnosis of CIED infections of 85% (95%CI: 
80–89) and 90% (95%CI: 84–94), respectively. 
18F-FDG PET/CT demonstrated a higher sensi-
tivity of 96% (95%CI: 86–99) and specificity of 
97% (95%CI: 86–99) for diagnosis of pocket 
infections. Diagnostic accuracy for lead infec-
tions or CIED-IE was lower with pooled sensitiv-
ity of 76% (95%CI: 65–85) and specificity of 
83% (95%CI: 72–90). In the subgroup of studies 
that described the use of any myocardial suppres-
sion protocol, the pooled sensitivity was 92% 
(95%CI: 85–96) and the pooled specificity was 
81% (95%CI: 71–89) [33].
Another recent meta-analysis confirmed the 
high diagnostic performance of 18F-FDG PET/
CT for the diagnosis of CIED infections with a 
pooled sensitivity of 87% (95%CI: 82–91) and a 
pooled specificity of 94% (95%CI: 88–98). 
Pooled sensitivity and specificity for diagnosis of 
pocket/generator related CIED infections were 
93% (95%CI: 84–98) and 98% (95%CI: 88–100), 
respectively. Pooled sensitivity and specificity 
for diagnosis of lead or IE-related CIED infec-
tion were 65% (95%CI: 53–76) and 88% (95%CI: 
77–94), respectively [34].
Overall, 18F-FDG PET/CT demonstrated a 
good diagnostic performance in patients with IE 
and CIED infections with higher diagnostic accu-
racy if adequate patient preparation for suppres-
sion of physiological myocardial 18F-FDG uptake 
was performed.
12.5  Vascular Graft Infections
Vascular graft infection (VGI), a serious compli-
cation in vascular surgery, has a high morbidity 
and mortality rate. The diagnosis is complicated 
by non-specific symptoms and challenged by the 
variable accuracy of different imaging techniques 
[35, 36]. A recent meta-analysis demonstrated a 
good diagnostic performance of 18F-FDG PET/
CT in patients with VGI with a pooled sensitivity 
and specificity of 95% (95%CI: 87–99) and 80% 
(95%CI: 69–89), respectively [36].
Another recent meta-analysis investigating the 
diagnostic accuracy of 18F-FDG PET/CT in VGI 
reported a pooled sensitivity and specificity for 
focal 18F-FDG uptake of 97% (95%CI: 89–99) 
and 89% (95%CI: 70–96), respectively [37].
Factors influencing the diagnostic perfor-
mance of 18F-FDG PET/CT in VGI include the 
time at which 18F-FDG PET/CT is performed 
after surgery (if 18F-FDG PET/CT is performed 
in cases of recently implanted grafts, false posi-
tive 18F-FDG PET/CT findings for VGI are pos-
sible), the use of antibiotics prior to 18F-FDG 
PET/CT (causing possible false negative findings 
for VGI), and the PET interpretation criteria used 
[37].
12.6  Sarcoidosis
Sarcoidosis is a multisystem chronic inflamma-
tory disease of unknown etiology characterized 
by widespread growth of non-caseating granulo-
mas. The diagnosis of sarcoidosis is based on 
clinical and imaging presentation, histological 
confirmation, and the absence of alternative dis-
eases. Imaging techniques may play a role in the 
diagnostic workup of patients with sarcoidosis to 
assess disease extent and activity, and treatment 
response evaluation [38]. The role of 18F-FDG 
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PET/CT in patients with sarcoidosis is well 
established [39, 40]. Based on evidence-based 
data, the recommendations for use of 18F-FDG 
PET/CT in patients with sarcoidosis could be the 
following: evaluation of inflammatory active dis-
ease in patients with persistent symptoms and 
negative serologic markers; assessment of inflam-
mation in radiologic stage IV sarcoidosis with 
lung fibrosis; evaluation of inflammatory active 
extrathoracic sites of sarcoidosis or assessment 
of cardiac sarcoidosis (especially in patients with 
implanted pacemakers); identification of active 
sites for diagnostic biopsy not revealed by other 
methods; evaluation of treatment response in 
refractory sarcoidosis [39].
The role of 18F-FDG PET/CT in cardiac sar-
coidosis is currently under active investigation 
[41] and some meta-analyses have addressed the 
diagnostic performance of 18F-FDG PET/CT in 
this setting [42–44].
In the meta-analysis of Youssef et  al., the 
pooled sensitivity and specificity of 18F-FDG 
PET or PET/CT for diagnosis of cardiac sarcoid-
osis were 89% (95%CI: 79–96) and 78% (95%CI: 
68–86), respectively [42].
Tang et  al. demonstrated that the diagnostic 
accuracy of 18F-FDG PET/CT for cardiac sar-
coidosis depends on adequate suppression of 
physiological cardiac glucose uptake. Overall, 
18F-FDG PET/CT had a pooled sensitivity of 
75% (95%CI: 69–80) and a pooled specificity of 
81% (95%CI: 76–85) for the diagnosis of cardiac 
sarcoidosis. This modest diagnostic accuracy was 
attributed to the inclusion of studies in which a 
short fasting duration before scanning likely 
influenced its sensitivity. Excluding studies with-
out adequate myocardial suppression resulted in 
a pooled sensitivity of 81% (95%CI: 76–86) and 
a pooled specificity of 82% (95%CI: 77–86). 
Fasting for at least 12  h before scanning or a 
high-fat low-carbohydrate diet given at 3–6  h 
before imaging or heparin infusion before imag-
ing has shown to improve the diagnostic accuracy 
of 18F-FDG PET/CT in cardiac sarcoidosis [43].
Lastly, an updated meta-analysis on the diag-
nostic performance of 18F-FDG PET or PET/CT 
in cardiac sarcoidosis demonstrated a pooled sen-
sitivity and specificity of 84% (95%CI: 71–91) 
and 83% (95%CI: 74–89), respectively. The pres-
ence of combined myocardial perfusion imaging 
improved the diagnostic accuracy of 18F-FDG 
PET/CT for diagnosis of cardiac sarcoidosis. 
Nevertheless further large multicenter studies in 
this setting are needed [44].
12.7  Musculoskeletal Infections
Timely identification and precise localization of 
musculoskeletal infections by imaging tech-
niques are critical for early initiation of treatment 
and can have a significant impact on patient out-
come. In this setting, nuclear medicine and radio-
logical imaging are complementary techniques 
[45]. In particular, several meta-analyses have 
investigated the diagnostic performance of 18F- 
FDG PET/CT in patients with suspicious muscu-
loskeletal infections [46–54].
Wang et  al. calculated the diagnostic perfor-
mance of 18F-FDG PET or PET/CT in patients 
with suspicious osteomyelitis reporting a high 
pooled sensitivity and specificity in this setting: 
pooled values were 92.3% (95%CI: 86.7–96.1) 
and 92% (95%CI: 87–95.6), respectively [46].
A first meta-analysis focused on the diagnos-
tic performance of 18F-FDG PET or PET/CT in 
osteomyelitis related to diabetic foot reported a 
pooled sensitivity and specificity of 74% (95%CI: 
60–85) and 91% (95%CI: 85–96), respectively 
[47]. An updated meta-analysis on the same topic 
demonstrated a pooled sensitivity of 89% 
(95%CI: 68–97) and a pooled specificity of 92% 
(95%CI: 85–96) [48].
Jin et  al. calculated the diagnostic perfor-
mance of 18F-FDG PET or PET/CT in detecting 
prosthetic infection after arthroplasty. They 
found a pooled sensitivity and specificity of 86% 
(95%CI: 82–90) and 86% (95%CI: 83–89), 
respectively. The pooled sensitivity of 18F-FDG 
PET or PET/CT in demonstrating hip and knee 
prosthetic infection was 88% (95%CI: 83–92) 
and 72% (95%CI: 58–84), respectively. The 
pooled specificity of 18F-FDG PET or PET/CT in 
demonstrating hip and knee prosthetic infection 
was 88% (95%CI: 84–91) and 80% (95%CI: 
71–88), respectively [49].
A meta-analysis focused on periprosthetic hip 
infection confirmed the good diagnostic accuracy 
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of 18F-FDG PET or PET/CT in this setting with 
pooled sensitivity and specificity of 86% (95%CI: 
80–90) and 93% (95%CI: 90–95), respectively, 
using increased 18F-FDG uptake in the bone- 
prosthesis interface as the criterion for infection 
for the index test [50].
A meta-analysis focused on periprosthetic 
knee infection demonstrated a nonoptimal diag-
nostic accuracy of 18F-FDG PET or PET/CT in 
this setting with pooled sensitivity and specificity 
of 70% (95%CI: 56–81) and 84% (95%CI: 
76–90) [51].
Some factors influencing the diagnostic per-
formance of 18F-FDG PET/CT in patients with 
osteomyelitis should be underlined: first of all, 
several interpretation criteria of 18F-FDG PET 
have been used in the literature, by using visual 
and/or semi-quantitative criteria, leading to dif-
ferent diagnostic accuracy values [46–51]. 
Furthermore, continuous physiologic 18F-FDG 
activity around the prostheses may be cause of 
false positive 18F-FDG PET/CT findings for peri-
prosthetic infection [49–51].
18F-FDG PET or PET/CT has an excellent 
diagnostic performance in detecting infectious 
spondylodiscitis [55]. A first meta-analysis on 
18F-FDG PET or PET/CT in patients with suspi-
cious spondylodiscitis reported a pooled sensitiv-
ity and specificity of 97% (95%CI: 83–100) and 
88% (95%CI: 74–95), respectively [52]. In this 
setting, the diagnostic performance of 18F-FDG 
PET or PET/CT was higher compared with mag-
netic resonance imaging (MRI). Considering 
studies comparing 18F-FDG PET or PET/CT and 
MRI, pooled sensitivity and specificity of 18F- 
FDG PET or PET/CT were 96% (95%CI: 84–99) 
and 90% (95%CI: 79–96), whereas the pooled 
sensitivity and specificity of MRI were 76% 
(95%CI: 65–84) and 62% (95%CI: 45–77) [53]. 
Another recent meta-analysis confirmed the bet-
ter diagnostic accuracy of 18F-FDG PET or PET/
CT compared to MRI for the detection of 
 spondylodiscitis: for 18F-FDG PET or PET/CT, 
pooled sensitivity and specificity were 95% 
(95%CI: 87–98) and 88% (95%CI: 73–95), 
respectively; for MRI, pooled sensitivity and 
specificity were 85% (95%CI: 65–95) and 66% 
(95%CI: 48–80), respectively [54].
Overall, based on the available evidence, 
18F- FDG PET/CT has demonstrated a good 
diagnostic performance for the detection of 
musculoskeletal infections.
12.8  Inflammatory Rheumatic 
Diseases
Molecular imaging methods, including 18F-FDG 
PET/CT, have been proposed for a better assess-
ment of inflammatory rheumatic diseases [56]. 
18F-FDG uptake in the shoulders or hips was 
often reported in PMR (pooled prevalence: 76%), 
especially in periarticular sites (pooled preva-
lence: 84%). Furthermore, interspinous 18F-FDG 
uptake, demonstrating interspinous bursitis, is 
common in PMR (pooled prevalence: 67%). 
However, these findings are not very specific for 
PMR [57].
Patients with rheumatoid arthritis (RA) may 
also have interspinous 18F-FDG uptake (pooled 
prevalence: 34%) or articular 18F-FDG uptake in 
shoulders or hips (pooled prevalence: 66%) or in 
other articular regions (pooled prevalence: 78%). 
Articular 18F-FDG uptake is not specific for PMR 
or RA, as it is common in other connective tissue 
diseases (pooled prevalence: 70%). Overall, 18F- 
FDG PET/CT is helpful in diagnostic research, 
but the interpretation of 18F-FDG uptake at each 
site is not characteristic of a specific inflamma-
tory rheumatic disease [57].
12.9  Inflammatory Bowel 
Diseases
18F-FDG PET/CT may also be used to image 
areas of active inflammation, such as those 
occurring in patients with active inflammatory 
bowel disease (IBD) as Crohn’s disease and 
ulcerative colitis [58]. In this setting, 18F-FDG 
PET or PET/CT showed a good accuracy with a 
pooled sensitivity and specificity of 85% 
(95%CI: 81–88) and 87% (95%CI 84–90), 
respectively [59]. These findings were confirmed 
by another meta- analysis including prospective 
studies only [60]. Nevertheless, more prospec-
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tive studies evaluating the role of 18F-FDG PET/
CT for this indication are needed. Specific chal-
lenges for the use of 18F-FDG PET/CT in IBD 
are the physiological 18F-FDG uptake in the 
bowel and the movement of the bowel that may 
influence a correct co- registration of 18F-FDG 
PET and CT images [59].
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Over the past two decades, one of the major 
breakthroughs for the approach to neurological 
diseases both in the clinical and research settings 
has been represented by the validation of diag-
nostic biomarkers able to demonstrate the pres-
ence of pathological mechanisms, alteration in 
neurotransmission as well as to predict disease 
progression [1, 2]. The use of PET with different 
tracers as well as other imaging biomarkers sup-
port the etiological diagnosis of neurological dis-
orders in  vivo. This approach is particularly 
relevant in the field of neurodegenerative dis-
eases. In fact, neurodegenerative diseases are 
characterized by the progressive degeneration 
and death of neurons. They represent a heteroge-
neous group of conditions characterized by dif-
ferent etiologies, different neuropathological and 
neurochemical alterations leading to different 
clinical pictures and courses [3]. Indeed, an early 
accurate diagnosis allows to tackle the disease 
with available or experimental intervention, life-
style changes, or logistical arrangements, before 
disability has developed. Early intervention is 
expected to have greater clinical impact, extend 
independent and active life, improve its quality, 
and decrease the burden and costs of the disease 
[4]. However, the validation of PET tracers in 
neurological disease is still ongoing, and evi-
dence on its comparative and combined diagnos-
tic value with respect to other biomarkers is 
incomplete [4, 5]. As a matter of fact, the increas-
ing pressure for cost-effectiveness requires sys-
tematic assessment and validation of all 
biomarker performance in the clinical settings. 
Similarly only an evidence-based approach to 
new PET tracers can allow to select the most 
promising tracers for PET imaging in the research 
field both for pathophysiological investigations 
and for upcoming diagnostic approaches.
13.2  Evidence-Based PET 
in Neurodegenerative 
Dementia
Although the use of PET tracers for neurotrans-
mission is also actively investigated, the vast 
majority of PET tracers recently developed for 
the clinical and pathophysiological evaluation 
of neurodegenerative dementia aim to evaluate 
the presence of specific pathological proteins 
deposition or mechanisms underlying neurode-
generation [3]. Tracers targeting neuroinflam-
mation are also under investigation in this field 
but their use is still very far from the clinical 
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setting [6]. Alzheimer’s disease (AD) is by far 
the most relevant target for brain PET clinical 
imaging in neurodegenerative diseases [5]. The 
2011 World Alzheimer Report has underlined 
that only a relatively small percentage of demen-
tia cases (ranging between 20 and 50%) are 
identified and correctly diagnosed in the early 
stages. This evidence means that at least half of 
the population of dementia patients does not 
receive a complete diagnostic workup at disease 
onset. This diagnostic delay gives rise to a so-
called “treatment gap” between early stages of 
the disease and formal diagnosis, thus delaying 
correct care and preventing organized support 
which ameliorates patient’s quality of life (and 
positively impacting also on caregivers and 
family members). In the field of AD, two main 
categories of biomarkers have been proposed to 
identify the prodromal stage of disease [2, 7]. 
On the one side, amyloidosis biomarkers are 
able to identify the molecular/neuropathological 
feature of AD and include cerebrospinal fluid 
(CSF) amyloid-β1-42 reduction and brain amy-
loid accumulation as imaged through PET tech-
nology using radiopharmaceuticals that 
selectively bind to the fibrillar aggregates of 
amyloid-β plaques (AMY-PET) [2]. On the 
other side, neurodegeneration biomarkers reflect 
neuronal injury and downstream neurodegener-
ation, which can be measured by the increase of 
tau protein in the CSF, regional atrophy on MRI 
or synaptic metabolic dysfunction on fluo-
rine-18 fluorodeoxyglucose PET (18F- FDG 
PET) [2]. As a matter of fact, the progressive 
dysfunction and loss of neurons lead to distinct 
involvement of functional systems and major 
clinical symptoms are mainly determined by the 
anatomical regions showing neuronal and syn-
aptic dysfunction (which however do not neces-
sarily reflect the molecular changes in the 
background) [8]. In this framework, MRI has 
both an exclusionary and inclusionary role for 
the early assessment of MCI. In fact on one side 
it can exclude secondary etiology of cognitive 
symptoms (i.e., vascular damage or normal 
pressure hydrocephalus) and it can increase the 
likelihood of a neurodegenerative dementia by 
highlighting the presence of atrophy in specific 
cortical regions [9]. Similarly, 18F-FDG PET is a 
well-founded method for evaluation of brain 
function and it is useful for the early diagnosis 
of AD and other dementias in people with mild 
cognitive impairment (MCI). 18F-FDG PET is a 
sensitive and specific imaging modality avail-
able to support the etiological diagnosis of the 
underlying neurodegenerative dementia in 
demented patients. In particular, hypometabo-
lism in the temporoparietal lobe, assessed by 
qualitative visual interpretation of the scans, 
represents the typical pattern found in AD [10]. 
However, despite its widespread use and the 
well- established role in the clinical settings, the 
quality of the available studies and thus the role 
of 18F-FDG PET in identifying patients affected 
by AD who are still at the stage of MCI are less 
validated. As a matter of fact, discriminating 
between patients who will and will not progress 
to dementia due to AD is critical in the context 
of care and it must be pursued before patients 
have crossed the threshold into dementia. One 
of the background reasons associated with this 
surprising lack of evidence is related to evolving 
definition of MCI in the last decade. 
Unfortunately, the characteristics of the MCI 
patients recruited in the available published 
studies are quite diverse across the literature of 
the last 10 years and this heterogeneity is largely 
reflected but the lack of a reproducible value of 
sensitivity and specificity of 18F-FDG PET for 
the identification of MCI due to AD. Moreover, 
the sensitivity and specificity of 18F-FDG PET 
(as well as of all AD biomarkers) depend largely 
on the method of interpretation. It is, nowadays, 
advisable to use a combination of visual qualita-
tive and semiquantitative analysis. In fact, the 
actual general sensitivity and specificity values, 
although still variable, are higher than 80% for 
both in the centers where it is utilized computer 
aided visual read approach such as Statistical 
Parametric Mapping (SPM), three-dimensional 
Stereotactic Surface Projection (3-D-SSP) sta-
tistics (Neurostat) or AD t-sum implemented in 
other software [11, 12]. Software able to com-
bine information from MRI and 18F-FDG PET 
(even in the multicenter settings) have also been 
developed and have been demonstrated to 
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improve detection and differentiation of AD 
and FTD (with 88–100% accuracy for AD 
detection) [13].
In more recent years, the availability of PET 
biomarkers of amyloid deposition such as 11C- 
PiB and 18F-labeled tracers (18F-Flutemetamol, 
18F-Florbetaben, and 18F-Florbetapir) has gained 
great attention [14]. These tracers exhibit high 
affinity binding for fibrillary amyloid that is a 
hallmark of AD and can be found in moderate to 
high number in cortical gray matter in all cases of 
AD developing many years before the onset of 
dementia. The vast majority of preliminary stud-
ies with amyloid PET has been carried out with 
11C-PIB. It has been reported by measuring 11C- 
PiB distribution in MCI and control subjects, that 
MCI patients who converted to AD, at an esti-
mated rate of 25% per year, had greater 11C-PiB 
retention in several brain area with a 93.5% sen-
sitivity and 56% specificity [15]. Moreover, none 
of the 11C-PiB negative MCI patients demon-
strated to be converted to AD indicating that 11C- 
PiB negativity had a 100% negative predictive 
value for progression to AD [7, 16]. However, 
due to the 20-min half-life of 11C, 11C-PiB can 
only be used in PET centers with on-site cyclo-
tron and radiopharmacy facilities while 18F is a 
more suitable radioisotope for widespread clini-
cal use. Accordingly, the availability of fluori-
nated amyloid PET tracers has favored a greater 
impact of this tool also in the clinical settings 
[17]. In particular, a sensitivity of amyloid 
18F-labeled tracers ranging from 89 to 97%, with 
a specificity ranging from 63 to 93% has been 
reported both for visual and semiquantitative 
analysis and no significant differences have been 
highlighted among the different agents [18].
The overall impacts of AMY-PET from the 
reported literature are a change of diagnosis and 
management in 35.2% and 59.6% of cases, 
respectively, leading to reduction in unnecessary 
investigations, treatments, relief of distress of 
caregivers, and potential involvement in clinical 
trials [19].
In particular, AMY-PET (as well as CSF data) 
are relevant for the differential diagnosis of eti-
ologies underlying primary progressive aphasia 
(PPA). In fact, it has been suggested that the cur-
rent clinical classification system for PPA should 
aim to predict underlying pathology across dif-
ferent cohorts and clinical settings which has a 
greater specificity with respect to neurodegener-
ation biomarkers (MRI and 18F-FDG PET) [20]. 
In fact, although patients’ characteristics includ-
ing age and ApoE genotype should be consid-
ered when interpreting AMY-PET, it has been 
highlighted that AMY-PET positivity is signifi-
cantly more prevalent in logopenic variant of 
PPA, which belongs to the AD spectrum, (86%) 
than in non-fluent variant of PPA (20%) or 
semantic variant of PPA (16%) which should be 
part of the spectrum of fronto-temporal degen-
eration [21]. It should be noted however that 
cognitive normal older people has a high burden 
of amyloid defined as incidental amyloidosis. 
Indeed, the presence of amyloid deposition is not 
sufficient to define the presence of pathophysio-
logic processes associated with AD which has to 
include the concomitant tau deposition [22]. 
Analyses in AMY-PET positive cognitive normal 
subjects have shown that the episodic memory 
and global cognitive function consistently had 
the largest, albeit still modest, effect sizes 
between performance and amyloid burden, 
whereas executive function, working memory, 
processing speed, visuospatial function, and 
semantic memory exhibited relatively smaller 
effect sizes [23]. Moreover, the incidence of 
brain amyloidosis increases with aging in all 
non-AD populations and has been repeatedly 
reported in other neurological conditions such as 
in dementia with Lewy bodies (DLB) and 
Parkinson’s disease (PD). Similarly, all amyloid 
PET tracers have affinity to amyloid in vessel 
walls, and can thus result in positive scans in 
case of cerebral amyloid angiopathy (CAA) [7]. 
In this framework, it has been demonstrated that 
the ratio between the occipital and the whole 
brain uptake is higher in patients with CAA than 
in patients with AD, possibly suggesting a more 
limited regional amyloid deposition on CAA 
[24]. Accordingly, AMY- PET has a moderate to 
good diagnostic accuracy for the identification of 
patients with CAA; especially as a negative scan 
it is useful to rule out CAA in the appropriate 
clinical setting [25]. Finally, it should be noted 
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that soluble Aβ oligomers and neurofibrillary 
tangles (NFTs), the other histopathologic cores 
of Alzheimer’s disease are not detected by this 
method, possibly producing false negative results 
[26].
13.3  Evidence-Based PET 
for Movement Disorders
Movement disorders are a group of neurologic 
syndromes characterized by an excess of move-
ment or a scarcity of voluntary and automatic 
movements [27] related to different neurodegen-
erative or acquired central nervous system dis-
eases affecting structures involved in movement 
control and modulation such as basal ganglia, 
cerebellum, cortex, and different thalamic nuclei. 
Parkinson’s disease (PD) represents the second 
most common neurodegenerative disorder after 
AD and is typically characterized by motor and 
non-motor manifestations. Motor dysfunctions 
include bradykinesia, resting tremor, and muscu-
lar rigidity [28] as the result of dopaminergic 
deficit due to degeneration of the dopaminergic 
nigrostriatal system [29]. On the other hand, non- 
motor features usually associated with the dam-
age in non-dopaminergic pathways may include 
depression, olfactory and autonomic dysfunc-
tion, sleep disorders, psychiatric symptoms, pain, 
fatigue, and cognitive impairment [30] and can, 
in some case, even precede the motor phase by 
several years [31]. Besides the most prevalent 
PD, there are other related atypical parkinsonian 
syndromes (APS) also known as Parkinson-plus 
syndromes. From the neuropathological point of 
view, on the basis of the predominant multisys-
temic progressive accumulation of misfolded 
proteins, parkinsonian disorders could be classi-
fied into α synucleinopathies (PD with and with-
out cognitive impairment/dementia, dementia 
with Lewy bodies—DLB, and multiple system 
atrophy—MSA) and tauopathies (corticobasal 
degeneration—CBD and progressive supranu-
clear palsy—PSP). All the aforementioned con-
ditions must be distinguished from 
non-degenerative causes of parkinsonism (e.g., 
toxic/drug-induced, psychogenic, or vascular eti-
ologies) in which presynaptic nigrostriatal path-
ways are preserved. Molecular imaging has 
proven to be a powerful tool for improving our 
understanding of the pathophysiology underlying 
parkinsonian disorders. In particular, PET and 
single photon emission computed tomography 
(SPECT) imaging are used as surrogate of unique 
in vivo functional measurement of monoaminer-
gic pathways impairment in neurodegenerative 
diseases since the early 1980s [32]. Actually, 
these techniques are able to evaluate and detect 
nigrostriatal degeneration from different points 
of view. The analogue of levodopa 18F-fluorodopa 
(18F-DOPA) is a PET tracer that estimates the 
activity of aromatic amino acid decarboxylase 
enzyme (AADC), which converts levodopa into 
dopamine in striatal cells, thus reflecting dopa-
mine synthesis. After its conversion in 
18F-fluorodopamine, it follows the same fate of 
endogenous dopamine and is thus transported to 
intraneuronal storage vesicles by vesicular mono-
amine transporter 2 (VMAT2) [33] to then be 
released into the synaptic cleft and interact with 
postsynaptic dopamine receptors.
On the other hand, presynaptic dopamine 
transporter (DAT) density, responsible for reup-
take of dopamine (DA) from the synaptic cleft 
and typically reduced in PD [34], can be mea-
sured through 123I-FP-CIT (123I-ioflupane), one of 
the most used radiotracers for SPECT imaging, 
or with specific PET tracers (18F-PE2I; N-(3- 
iodoprop- 2Eenyl)-2β-carbomethoxy-3β-(4- 
methyl- phenyl)nortropane). Finally, specific 
radiolabeled ligands for VMAT2 also exist and 
can be used in PET imaging for research pur-
poses (11C- and 18F-dihydrotetrabenazine). The 
applicability of functional imaging in the evalua-
tion of striatal dopaminergic degeneration in con-
trol subjects and PD patients is well documented. 
Actually, PET and SPECT studies with AADC, 
VMAT2, and DAT tracers are able to monitor 
nigrostriatal deficit over time demonstrating the 
negative effects of age on DA transporters and 
receptors. According to Karrer et al. [35], age has 
a significantly larger effect on D1- than D2-like 
receptors with an average age reduction across 
the DA system of about 3.7–14.0% per decade. 
On the contrary, DA synthesis capacity seems to 
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be spared from this detrimental effect. This find-
ing nicely fit with the results of a contemporary 
meta-analysis of Kaasinen et al. [36] including 
PD patients submitted to PET and SPECT studies 
for the evaluation of striatal presynaptic dopa-
mine function. In this meta- analysis, it was dem-
onstrated a higher defect in DAT and VMAT2 
function compared to AADC defect in PD 
patients. This difference is possibly due to the 
effect of a compensatory upregulation in AADC 
function, confirming vesicular monoamine trans-
porter 2 and dopamine transporter as the most 
sensitive targets to assess. In the same study, a 
linear correlation between disease severity and 
dopamine loss was demonstrated and a mean 
motor disease duration of 4–7 years was needed 
to overcome the general compensatory changes 
in the terminal area of the nigrostriatal tract in PD 
and induce a detectable loss of about 50% of 
putaminal presynaptic dopamine function. It 
should be noted, however, that 18F-DOPA PET 
is a valid alternative to 123I-FP-CIT 
SPECT.  Similarly, PET VMAT2 tracers as 11C- 
and 18F-labeled dihydrotetrabenazine are very 
sensitive in detecting presynaptic dysfunction in 
PD without significant influence by compensa-
tory changes [37] but are less available than other 
tracers. Besides dopaminergic dysfunction, sero-
tonergic system exerts an important role in PD 
pathophysiology. Among PET ligands that have 
been developed for the evaluation of serotonergic 
receptors and serotonin transporter (SERT), 
11C-DASB is a second-generation PET ligand 
with the best selectivity for the SERT [38]. In 
their systematic review examining the in  vivo 
SERT changes in PD measured by 11C-DASB 
PET, Pagano et al. [39] demonstrated that SERT 
dysfunction is associated with the development 
of several motor (tremor and dyskinesias) and 
non-motor symptoms (depression, fatigue, apa-
thy, and weight changes). In particular, they 
observe a highest decrease in SERT binding in 
the rostral raphe and caudate followed by puta-
men, thalamus, ventral striatum, caudal raphe, 
and hypothalamus, according to succession of 
pathological events in serotonergic neurons 
described by Braak’s PD staging [29]. 
Furthermore, reduced SERT binding in putamen 
is associated with longer duration of the disease, 
whereas lower 11C-DASB binding in caudate is 
associated with worse cognitive function and 
older age. Interestingly, although SERT binding 
in putamen decreased with the progression of the 
disease, PD patients with dyskinesias have rela-
tively preserved putaminal serotonergic function 
with mechanisms not fully clarified.
Moreover, PET and SPECT are able to detect 
pathologic changes from the earliest phase of the 
disease, improving diagnostic accuracy in the 
early stages [40]. REM sleep behavior disorder 
(RBD) confirmed by polysomnography is a para-
somnia occurring during REM sleep character-
ized by the loss of physiological muscle atonia 
and associated with dream-enacted behaviors. It 
is defined “idiopathic” when appears isolated, 
without any other clinical sign of a neurological 
disorder. However, more than 80% of idiopathic 
RBD patients will develop a definite neurodegen-
erative disease, mostly a synucleinopathy. 
Furthermore, the presence of abnormal presynap-
tic dopaminergic PET or SPECT scan is consid-
ered the second most relevant risk factor for 
prodromal PD [41] predicting a high risk for 
short-term conversion into a synucleinopathy in 
idiopathic RBD patients [42]. A recent meta- 
analysis about the role of presynaptic dopaminer-
gic imaging in RBD shows that idiopathic RBD 
patients exhibit decreased nigrostriatal dopami-
nergic functioning in comparison with healthy 
controls, especially at the putamen level. 
Furthermore, patients with idiopathic RBD and 
patients with PD without RBD exhibit a similar 
degree of nigro-caudate dopaminergic deafferen-
tation [43].
Molecular imaging can also facilitate the dif-
ferential diagnosis among PD, atypical parkinso-
nian syndromes (APS), essential tremors, and 
other degenerative conditions that represent a 
group of complex and heterogeneous diseases 
with overlapping symptomatology and variable 
response to dopaminergic medications. 123I-FP- 
CIT SPECT can distinguish degenerative forms 
of parkinsonism from essential tremor [44], drug- 
induced parkinsonism [45] and could also differ-
entiate DLB from AD. Subjects with PD and APS 
show indeed an early reduction of striatal 
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 dopaminergic binding [46] usually before the 
appearance of motor symptoms. On the contrary, 
patients with essential tremor, drug-induced par-
kinsonism, and AD are characterized by normal 
dopamine transporter uptake [47]. Although a 
differential pattern has been described at the 
group level, a real distinction between the various 
degenerative forms of parkinsonism is not possi-
ble by means of SPECT assessment only. To this 
purpose, 18F-FDG PET has demonstrated to be 
more promising. As suggested by Albrecht et al. 
[48], glucose hypometabolism at 18F-FDG PET 
can identify consistent functional brain abnor-
malities in PD, outperforming structural MRI. In 
particular, while MRI showed only focal and 
inconsistent alterations, in PD patients the 
authors found an extensive glucose hypometabo-
lism in bilateral inferior parietal cortex and left 
caudate nucleus that is related to cognitive defi-
cits (inferior parietal cortex) and motor symp-
toms (caudate nucleus). Disease-specific patterns 
of regional glucose metabolism in patients with 
parkinsonism are well documented [49, 50]. 
However, the valuable capability of 18F-FDG 
PET for accurate differentiation between PD and 
APS has been unanimously accepted only in 
recent years. In a preliminary meta-analysis, 
Meyer et al. well described the different 18F-FDG 
uptake pattern in PD and APS [51]. PD is charac-
terized by a posterior temporoparietal, occipital, 
and sometimes frontal hypometabolism with a 
relative hypermetabolism of the putamen, palli-
dum, thalamus sensorimotor cortex, pons, and 
cerebellum.
MSA patients show instead a marked hypo-
metabolism of the putamen (mainly in its poste-
rior portion), pons, and cerebellum, which may 
be more pronounced in the striatum or in the pons 
and cerebellum, on the basis of the clinical pre-
sentation. Conversely, PSP is characterized by a 
regional hypometabolism preferentially involv-
ing the medial, dorsal, and ventrolateral frontal 
areas (i.e., the anterior cingulate gyrus, supple-
mentary motor area, precentral gyrus, and 
premotor- to-posterior prefrontal areas); caudate, 
thalamus, and upper brain stem. Finally, CBD 
patients have a typically highly asymmetric 
hypometabolism of the frontoparietal areas, 
striatum, and thalamus contralateral to the most 
affected body side. A concomitant cortical hypo-
metabolism may be mainly found in the parietal 
cortex and usually extends across the sensorimo-
tor cortex into the cingulate gyrus and premotor- 
to- posterior prefrontal areas.
18F-FDG PET has proved to be particularly 
relevant also for the diagnosis of DLB and is 
actually listed among the supportive biomarkers 
for its identification [52]. DLB is characterized 
by a more prominent hypometabolism affecting 
the primary visual cortex and occipital cortex 
with relative preservation of subcortical struc-
tures and primary somatomotor cortex and with 
a concomitant hypometabolism in posterior 
associative cortex. In particular, the presence of 
a hypometabolism in the precuneus with a rela-
tive sparing of glucose uptake in posterior cingu-
late gyrus is known as “cingulate island sign” 
and has proved to significantly increase 18F-FDG 
PET specificity for the differential diagnosis 
with respect to AD, although lower than DAT 
SPECT [53].
18F-FDG PET evidence is also available for 
Huntington’s disease gene expression carriers 
(HDGECs). Actually, several PET imaging stud-
ies investigating the glucose metabolism in 
HDGECs have shown specific metabolic patterns 
mainly characterized by a progressive reduction 
of subcortical and cortical glucose metabolism in 
the striatum, thalamus, insula, posterior cingulate 
gyrus, and prefrontal and occipital cortex associ-
ated to a relative hypermetabolism in the cerebel-
lum and pons [54]. In particular, reduction in 
striatal metabolism seems to be an early feature 
of the disease, preceding neuronal loss and thus 
motor onset of the disease. However, glucose 
metabolism deficits are only one of the many 
factors involved in Huntington’s disease and 
18F-FDG PET is not indicated for the diagnosis 
of this disease. Besides 18F-FDG, other striatal 
PET radioligands have been used in this con-
text. In particular, a meta-analysis aiming to 
investigate striatal molecular changes in 158 
premanifest and 191 manifest HDGECs patients 
[10] demonstrates a significant decrease not 
only in glucose metabolism in caudate and 
putamen but also in dopamine D2 receptors and 
in striatal phosphodiesterase 10A binding. 
This findings well reflect the different 
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neuropathological mechanisms underlying the 
development of the disease.
Finally, PET and SPECT could guide the cli-
nician in the choice of the different therapeutic 
modalities and in monitoring therapy response. 
PET has proved to be able to determine drug 
dosage for optimal efficacy in movement disor-
ders as in the case of PD patients under deprenyl 
treatment evaluated with 11C-deprenyl PET [55]. 
18F-DOPA PET has been used in several studies 
to evaluate the effects of potential neuroprotec-
tive agents on dopaminergic function [56]. 
11C-raclopride PET was used to evaluate striatal 
D2 receptor status in PD patients showing a nor-
mal or raised striatal D2 binding potential in 
untreated patients with PD but reduced in 
patients with PD and a fluctuating response to 
L-dopa [57].
Finally, PET and SPECT studies have proved 
the existence of a link between impulse control 
disorders (ICD) and dopamine activity dysfunc-
tion across ventral and dorsal striatum in PD 
patients [58]. ICD are a class of psychiatric disor-
ders including pathological gambling, hypersex-
uality, binge-eating, and compulsive shopping 
that could appear in around 30% of PD patients 
as a complication of D2/3 dopamine agonist 
treatment and, to a lesser extent, levodopa. A 
recent meta-analysis demonstrated the PET/
SPECT dopaminergic striatal correlates of ICD 
in PD. In particular, in ICD patients authors find 
lower DAT levels in the dorsal striatum and in its 
subdivisions (i.e., putamen, caudate) and reduced 
binding (i.e., increased dopamine release) in the 
ventral striatum in response to reward-related 
stimuli or gambling task. These lines of evidence 
highlight the importance of PET pharmacoki-
netic and pharmacodynamic studies in our under-
standing of the mechanisms of action, efficacy, 
and complications of medical interventions in 
patients with neurological diseases.
13.4  Evidence-Based PET 
for Psychiatric Disorders
While in the clinical settings either 18F-FDG or 
AMY-PET can be used to support the differential 
diagnosis between neurodegenerative dementia 
and depressive pseudodementia, in the specific 
field of psychiatric disorders, PET technology 
has more extensively been used for research pur-
poses to determine pathophysiology of diseases 
and response to intervention [59]. In particular, 
the availability of tracers for imaging of neuro-
transmission allows the investigation of different 
systems (i.e., serotonin, dopamine GABA path-
ways) and to investigate a wide range of psychi-
atric diseases. Similarly, brain PET with different 
tracers (i.e., tracers for neuroinflammation) has 
been used to explore new hypotheses related to 
the onset of psychiatric diseases. The vast major-
ity of PET studies carried out in the last 20 years 
in psychiatric patients have aimed to map func-
tional alterations and mechanism underlying 
major depressive disorder (MDD), a common 
mental illness with high lifetime prevalence 
(close to 20%.). Indeed, although the presence of 
aberrant brain activation during cognitive and 
emotional processing has been extensively evalu-
ated in MDD patients, results of available studies 
vary considerably. Muller and colleagues sum-
marized the evidence derived from neuroimaging 
experiments (using fMRI or PET) of group com-
parisons between adults with unipolar depression 
and healthy controls and reporting significant 
activation differences between patients and con-
trols during emotional or cognitive tasks [60]. 
Several inconsistencies across available studies 
emerged from this systematic review. Brain 
metabolism in MDD was also specifically 
addressed in several voxel-based PET studies 
which were submitted to a meta-analytical 
approach by Su et al. [61]. Again while decreased 
prefrontal, insular, and limbic cerebral glucose 
metabolism was repeatedly highlighted in 
depressed patients with respect to healthy con-
trols, available literature has not always been 
consistent. In this framework, the involvement of 
specific regions such as insula, limbic system, 
basal ganglia, thalamus, and cerebellum was 
more frequently reported, suggesting that these 
regions are likely to play a key role in the patho-
physiology of depression. In keeping with these 
results, convergent change in the limbic-cortical 
brain circuit in depression compared to controls 
was also found in multi-modal imaging studies 
involving both PET and MRI data. Reported 
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 specific changes include lower gray matter vol-
umes in amygdala, dorsal frontomedian cortex, 
and the right paracingulate cortex, as well as rela-
tive hypermetabolism in the right subgenual and 
pregenual anterior cingulate cortices. Building a 
strong and evidence-based mapping of these 
alterations in MDD is relevant as these regions 
could serve as a specific region-of-interest-for-
disease template for both in vivo imaging in indi-
vidual patients and postmortem histopathologic 
exploration [62]. Other PET studies investigated 
altered function related to different pathways 
including 5-HT receptor and transporter dysfunc-
tion in neuropsychiatric disorders. Indeed, 
impairment of serotonin receptor and transporter 
function is increasingly recognized to play a 
major role in the pathophysiology of neuropsy-
chiatric diseases including anxiety disorder, 
major depressive disorder, bipolar disorder, and 
schizophrenia. In particular, a retrospective anal-
ysis revealed that these psychiatric disorders dif-
fered in affected brain regions, affected synaptic 
constituents as well as direction of dysfunction in 
terms of either sensitization or desensitization of 
transporter and receptor binding sites [63].
Striatal presynaptic dopamine pathway has 
been the most frequent target for PET and SPECT 
imaging in schizophrenia [64]. As a matter of 
fact, the role of striatal dopaminergic neurotrans-
mission in the onset of symptoms of schizophre-
nia (including psychotic symptoms) is currently 
targeted by dopaminergic drugs. A specific 
marker of the integrity of presynaptic dopamine 
neurons in the striatum, the density of striatal 
dopamine terminals, can be quantified through 
molecular neuroimaging of DAT. A meta- analysis 
of DAT density in the striatum of schizophrenic 
patients demonstrated that striatal DAT density 
was not significantly different between patients 
and controls [64]. Similar negative findings were 
regionally confirmed in putamen and caudate. 
There was no moderating effect for external fac-
tors such as antipsychotic medication or illness 
duration. Accordingly, the authors concluded that 
loss of integrity of striatal dopaminergic synapses 
is not critical for the emergence of schizophrenia 
and these findings are relevant for further refining 
dopaminergic hypotheses of schizophrenia (with 
possible repercussion on interventional studies 
aiming to identify new treatment options). By 
contrast, a different window on presynaptic dopa-
minergic function was opened by studies explor-
ing this pathway through 11C-/18F-DOPA PET 
[65]. Available studies were summarized in the 
meta-analysis by Fusar-Poli and Meyer- 
Lindenberg [65]: patients with schizophrenia 
showed increased striatal uptake as compared 
with controls and this finding was regionally con-
firmed in both caudate and putamen. Finally, no 
significant effect of age, illness duration, gender, 
psychotic symptoms, and exposure to antipsy-
chotics was highlighted. Of note, sensitivity anal-
ysis confirmed robustness of meta-analytic 
findings. Finally, data from animal models and 
from postmortem studies suggest that schizo-
phrenia is associated with brain GABAergic dys-
function. However, it is still unclear the extent of 
this effect in vivo studies of GABA function in 
patients with schizophrenia [66].
PET and SPECT studies with several tracers 
have been used on other neuropsychiatric dis-
eases including obsessive compulsive disorders, 
Tourette’s syndrome (TS), and attention deficit 
hyperactivity disorder (ADHD) as well as to test 
brain function in specific conditions such as in 
case of ecstasy/polydrug use and disorders of 
consciousness. In particular, dopaminergic imag-
ing with PET and SPECT was able to demon-
strate dopaminergic alterations in TS and 
pathophysiology and psychostimulant treatment 
of attention deficit in ADHD. In fact, dopaminer-
gic alterations in TS are in line with the current 
pathophysiological hypotheses of a tonic-phasic 
dysfunction in the dopamine system although 
available studies are characterized by low effect 
sizes due to the heterogeneity of the disease [67]. 
Similarly, although dopaminergic studies in 
ADHD yielded inconsistent results often demon-
strating either high and low striatal dopamine 
transporter levels across different studies, a sys-
tematic review of the available evidence high-
lighted that striatal dopamine transporter density 
in ADHD is depended on previous psychostimu-
lant exposure, with lower density in drug-naive 
subjects and higher density in previously medi-
cated patients [68]. More general approaches on 
brain perfusion and metabolism by means of 
SPECT and PET allowed to demonstrate that 
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pharmacological and psychological treatments 
reduce resting cortico-striato-thalamo-cortical 
circuit activity in obsessive compulsive disorder. 
Similarly markedly reduced activity within mid-
line cortical and subcortical sites (anatomical 
structures linked to the default-mode network) 
are present in patients with disorders of con-
sciousness [69, 70]. Finally, PET studies on post-
synaptic 5HT2A receptor imaging allowed to 
highlight that serotonin axons with the longest 
projections from the raphe nuclei might be more 
markedly affected by ecstasy/MDMA use.
13.5  Conclusions
In conclusion, a huge body of literature has high-
lighted an ongoing and promising role of PET 
with different tracers in neurodegenerative 
dementia, movement and psychiatric disorders. 
In some clinical settings such as in case patients 
with mild cognitive impairment and dementia, 
for the differential diagnosis of underlying etiol-
ogy as well as for the early and accurate identifi-
cation of patients with neurodegenerative 
parkinsonian syndromes, PET has gained an 
increasing relevant clinical role. By contrast the 
possibility to accurately quantify neurotransmis-
sion with different tracers is increasingly sup-
porting the use of PET technology for 
pathophysiological and interventional studies in 
patients with psychiatric disorders. In both cases 
(clinical use of PET in neurodegenerative demen-
tia and parkinsonian syndromes and research use 
of PET in psychiatric disorders), it is crucial to 
proceed with robust methodology which starts 
with the systematic evaluation of evidence-based 
results of previous studies. Only this approach 
will allow to balance costs and clinical advance-
ment, thus meeting the needs of both patients and 
health-care systems.
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In literature, there are few meta-analyses that 
have addressed technical and methodological 
issues concerning positron emission tomography 
(PET) imaging despite their important role in 
determining the quality of the diagnostic results 
[1–19].
14.2  Factors Affecting 18F-FDG 
Uptake
The factors that may affect fluorine-18 fluorode-
oxyglucose (18F-FDG) uptake of normal tissues/
organs and tumour lesions have been explored by 
three studies.
Wang et al. [1] demonstrated that the impact 
of time interval on standardized uptake value 
(SUV) in liver and mediastinal blood pool was 
relatively medium but clinically noticeable. Due 
to the rare studies, this relationship remains to be 
verified for other organs (cerebellum, spleen, 
bone marrow, muscle, bowel and adipose tissue). 
Nevertheless, other factors such as body mass 
index and blood glucose level (BGL) appeared to 
be important in determining 18F-FDG uptake in 
normal organs.
The effect of BGL on 18F-FDG uptake and 
SUV has been more extensively explored by 
Eskian et al. [2] who demonstrated a correlation 
between increased BGLs and increased SUVmax 
and SUVmean values in liver and blood pool. 
Conversely, an increase of BGL is significantly 
associated to lower SUVmax and SUVmean in 
brain and muscle while both SUV values in 
tumours seemed to be affected, with significant 
reduction, only by BGL >200 mg/dl. The authors 
concluded suggesting that in patients with BGL 
lower than 200 mg/dl no interventions are needed 
for lowering BGL, unless the liver is the organ of 
interest. Nevertheless, new studies are warranted 
to evaluate sensitivity and specificity of 18F-FDG 
PET for diagnosis of malignant lesions in patients 
with hyperglycaemia.
The uptake of 18F-FDG in brown adipose tis-
sue (BAT) is another finding that may affect the 
detection of tumour lesions. Hou et al. [3] dem-
onstrated that gender, season and age are risk fac-
tors for 18F-FDG uptake in BAT. In particular, the 
18F-FDG uptake rate was 2.16 times in females as 
that in males, 8.67 times in the minors as that in 
the adults and 1.94 times in winter as that in 
summer.
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14.3  Repeatability 
of the Quantitative 
Measurements
PET is widely used in oncology for the response 
assessment to treatment by the quantitative mea-
surements of tracer uptake of the tumour lesions. 
For this purpose, the repeatability of these mea-
surements in metabolic imaging is pivotal and 
needs to be established. Two studies dealt with 
the repeatability of the SUV estimation in tumour 
lesions [4, 5].
De Langen et al. [4] demonstrated that in 18F- 
FDG PET imaging SUVmean had better repeat-
ability performance than SUVmax. For serial 
PET scans, a combination of 20% as well as 1.2 
SUVmean units was most appropriate threshold 
to identify a significant metabolic change in 
tumoural lesions. Nevertheless, both measures 
showed poor repeatability for lesions with low 
18F-FDG uptake since test-retest variability is 
affected by the level of 18F-FDG uptake while 
tumour volume had minimal influence on repeat-
ability. The authors recommend to report the 
evaluation of biologic effects in PET by using a 
combination of minimal relative and absolute 
changes of SUV.
The same group also analysed the response 
evaluation using 18F-Fluorothymidine (18F-FLT) 
[5]. In this case, the best repeatability was 
obtained using SUVpeak. Differences ≥25% in 
18F-FLT SUV measurements likely represented a 
true change in tumour uptake. Nevertheless, 
larger differences are required for FLT metrics 
comprising volume estimates when no lesion 
selection criteria are applied.
The partial volume effect is another factor that 
may hamper accurate quantification of radiophar-
maceutical uptake by tumour lesions leading to 
underestimations of SUV values and possibly 
compromising the lesion detection. A meta- 
analysis [6] investigated the clinical impact of the 
partial volume effect correction factor in onco-
logical PET studies and in particular the potential 
benefit in its application for diagnosis, staging, 
prognostication and response assessment con-
cluding that the accumulated evidence does not 
support routine application of partial volume cor-
rection in standard clinical PET practice.
14.4  Dual-Time-Point Imaging
A second late acquisition after conventional 18F- 
FDG PET/CT imaging (dual-time-point tech-
nique) has been suggested to discriminate 
between inflammatory and neoplastic lesions. 
This approach is based on the evidence that in 
inflammatory lesions the 18F-FDG uptake is char-
acterized by a progressive washout after an initial 
trapping, while in tumour tissues, in particular 
before treatment, the uptake of the tracer 
increases over time. Two meta-analyses addressed 
this issue: both showed comparable performance 
between standard single-time-point and dual- 
time- point 18F-FDG PET imaging in diagnosing 
pulmonary nodules [7] and in detecting lymph 
nodal metastases [8]. The results of the studies do 
not support the routine use of an additional late 
acquisition for these two clinical purposes.
14.5  Correlation Between 
Proliferation Markers (Ki-67) 
and Tracer Uptake 
in Tumours
Although 18F-FDG is not a tumour-specific agent, 
several studies showed that 18F-FDG uptake may 
be an index of biological aggressiveness of the 
disease. Nevertheless, whether 18F-FDG PET 
imaging can be a marker of tumour cell prolifera-
tion remains controversial. Deng et al. [9] anal-
ysed pooled data from clinical studies focused on 
this issue. The results demonstrated a moderate 
positive correlation between 18F-FDG uptake and 
tumour cell proliferation marker Ki-67 (com-
bined correlation coefficient  =  0.44) and sug-
gested that 18F-FDG SUV may be used as an 
indicator of the tumour proliferation and inva-
siveness. A subgroup analysis based on different 
tumour types showed varied degrees of correla-
tion. The correlation was highly significant in 
thymic epithelial tumours; significant in gastro- 
intestinal stromal tumours (GIST); moderate in 
lung, breast, bone and soft tissue, pancreatic, 
oral, thoracic, uterine and ovary cancers; average 
in brain, oesophageal and colorectal cancers; and 




The correlation between 18F-FLT uptake and 
Ki-67 was also investigated. Chalkidou A et al. 
[10] found sufficient data to support a strong 18F- 
FLT/Ki-67 correlation only for brain, lung and 
breast cancer. The authors highlighted the impor-
tance of the methodology used to measure Ki-67 
expression: the correlation was significant and 
independent of cancer type only when using 
Ki-67 average measurements, or measuring 
Ki-67 maximum expression on whole surgical 
samples.
14.6  Correlation Between 18F-FDG 
SUVmax and ADC Values 
in Tumour Tissues
Apparent diffusion coefficient (ADC) is a param-
eter obtained by diffusion-weighted magnetic 
resonance imaging (MRI), reflecting the brown-
ian movement of water molecules. The ADC 
value has been shown to link with the cell den-
sity, microvascular circulation and membrane 
integrity of a tumour tissue. Two meta-analyses 
[10, 11] examined the potential relationship 
between 18F-FDG SUV that characterize the met-
abolic activity of tumour cells and ADC.  Both 
studies found inverse correlation between ADC 
and SUV in patients with cancer. This inverse 
correlation, which was generally weak, appeared 
higher in the brain tumour, cervix carcinoma and 
pancreas cancer. However, larger prospective 
studies are warranted to validate these prelimi-
nary findings in different cancer types.
14.7  Diagnostic Performance 
of Hybrid Imaging 
in Oncology
After the introduction in the last years of hybrid 
scanners, many experiences indicated that the 
integration of functional and morphological 
imaging (hybrid imaging) provides additional 
diagnostic information useful in different clinical 
settings and particularly in oncology.
In a meta-analysis published by Gao et al. in 
2013 [13], pooled data from comparative studies 
revealed that integrated PET/CT has higher sen-
sitivity (0.95 vs 0.85) and similar specificity 
(0.96 vs 0.95) with respect to PET alone in the 
detection of distant metastases. Analogous results 
were obtained comparing integrated PET/CT 
with CT alone (sensitivity 0.97 vs 0.80 and speci-
ficity 0.97 vs 0.94, respectively), confirming the 
additional value of the PET/CT hybrid imaging 
in tumour staging.
More recently published data suggested a 
complementary role of 18F-FDG PET/CT and 
MRI in oncological patients. Miles et  al. [14] 
compared these two imaging modalities in 
patients with suspected residual disease or recur-
rent tumours. PET demonstrated greater sensitiv-
ity for detecting lymph nodal recurrence, whereas 
MRI was more effective than PET/CT in the 
detection of skeletal and hepatic recurrence. A 
review of studies assessing therapeutic impact of 
PET/MRI suggested a greater likelihood for 
change in clinical management when PET/MRI 
was used for assessment of suspected residual or 
recurrent disease rather than tumour staging. 
Supplementing the evidence-base data for 18F- 
FDG PET/MRI with studies that compared the 
components of this hybrid technology separately, 
18F-FDG PET/MRI is likely to be clinically effec-
tive for the investigation of patients with sus-
pected residual or recurrent cancers.
Xu et  al. [15] demonstrated that 18F-FDG 
PET/CT has similar patient-based sensitivity 
(0.85 versus 0.85) and specificity (0.96 versus 
0.97) to MRI in the detection of distant metasta-
ses. Similar lesion-based performance was also 
estimated (PET/CT sensitivity and specificity: 
0.85 and 0.90 and MRI sensitivity and specific-
ity: 0.88 and 0.89). The analysis of a small num-
ber of studies indicated that the combined use of 
these two modalities may have higher patient- 
based sensitivity (0.89) than PET/CT (0.82) and 
whole body MRI (0.81) alone, suggesting that 
the combined use of these two modalities may 
provide more benefit than PET/CT and MRI 
alone.
Finally, Shen et  al. [16] after analysing the 
results of 38 studies that involved 753 patients 
and 4234 lesions concluded that PET/MRI has 
excellent diagnostic potential for the overall 
detection of malignancies in cancer patients. On 
a per-patient level, the pooled sensitivity and 
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specificity were 0.93 and 0.92, respectively. On a 
per-lesion level, the corresponding estimates 
were 0.90 and 0.95, respectively.
14.8  Varia
The 18F-FDG PET/CT imaging has been defined 
by several authors as more accurate than standard 
radiological imaging in evaluating the response to 
treatment in oncological patients, in particular 
when a residual mass is still detectable. Kim et al. 
[17] compared the tumour response assessment 
according to the metabolic criteria developed by 
the European Organization for Research and 
Treatment of Cancer (EORTC) and morphologic 
criteria (RECIST1.1.) in patients with malignant 
solid tumours. The pooled analysis of 181 patients 
recruited from seven studies demonstrated a mod-
erate agreement of tumour responses between the 
RECIST and EORTC criteria (k  =  0.493). The 
level of agreement was not affected by the anti-
cancer treatments (chemotherapy or targeted ther-
apy). A disagreement was found in 66 of 181 
patients (36.5%). Tumour response was upgraded 
in 54 patients and downgraded in 12 when adopt-
ing the EORTC criteria. The estimated overall 
response rates were significantly different 
between the two criteria (52.5% by the EORTC 
vs. 29.8% by the RECIST, p < 0.0001). The con-
clusions confirmed that the metabolic findings are 
more sensitive than the morphologic criteria to 
detect tumour response to the treatment.
The PET/CT imaging with radiolabelled cho-
line is a reliable tool for the detection and local-
ization of recurrent disease in patients with 
prostate carcinoma. A meta-analysis by von 
Eyben et al. [18] investigated whether the use of 
different tracers, 11C-choline (11C-Cho) and 
18F-fluorocholine (18F-FCH), may provide differ-
ent diagnostic performance. The detection rates 
of metastatic sites in studies with 11C-Cho and 
18F-FCH did not differ significantly. The radia-
tion activity of 11C-Cho and 18F-FCH injected 
was not significantly associated with the detec-
tion rate of extra-prostatic lesions. The authors 
concluded that the detection of metastatic lesions 
in patients with biochemical recurrence (PSA 
levels of 1–10 g/ml) was clinically relevant when 
performed by PET/CT with radiolabelled choline 
regardless of the radiotracer injected.
The introduction of hybrid medical imaging 
technology has transformed the practice of diag-
nostic nuclear medicine and nowadays PET/CT 
and single photon emission computed tomogra-
phy/computed tomography (SPECT/CT) have 
wide acceptance for many clinical investigations. 
A concern with PET/CT and SPECT/CT imaging 
is the combined radiation doses from both radio-
pharmaceutical and X-ray CT components. 
Therefore, it is imperative to implement a radia-
tion dose optimization process to protect patients 
from unwarranted high radiation burdens. 
Alkhybari et  al. [19] systematically reviewed 
data published in literature to determine the vari-
ations in reported national diagnostic reference 
levels (NDRL) methodology and values for adult 
PET/CT and SPECT/CT procedures. 
Discrepancies were found between the method-
ologies applied to establish and report both PET/
CT and SPECT/CT NDRLs. In particular, the 
authors remarked the opportunity for hybrid 
imaging to report both radiation doses from the 
radioactivity injected and the CT dose rather than 
a separate NDRL.  They concluded that further 
researches should be focused on reporting more 
NDRLs for hybrid examinations to collect 
enough data to establish a robust NDRL standard 
for the CT portion in PET/CT and SPECT/CT 
examinations.
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